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1.1 Managed competition reforms in the Dutch health care system
In developed countries typically three waves of health care reform are observed (Cutler, 
2002). The Netherlands is no exception to this (Van de Ven and Schut, 2008). First, from 
about 1940 to 1970, the focus was on ensuring universal coverage. When the Dutch 
government became worried about the seemingly uncontrollable growth of health care 
spending, the focus from about 1970 to 2000 shifted to cost containment by introducing 
controls, rationing, and expenditure caps. Since the strict reliance on cost containment 
resulted in long waiting lists and a lack of incentives for efficiency and innovation, the 
focus since about 2000 is on incentive-based reforms. 
Already in 1987 a market-oriented health care reform was advised by the Dekker Com-
mittee. Some minor reforms were indeed implemented during the 1990s, but it lasted 
until 2006 before a major step was taken in the gradual transition from supply-side 
government regulation towards managed competition. January 1, 2006 marks the start-
ing point of a health care system in which competing insurers are expected to become 
the prudent buyers of health care on behalf of their enrolees. With the implementation 
of the Health Insurance Act, a universal mandatory basic health insurance scheme is 
established with open enrollment and community rating (Enthoven and Van de Ven, 
2007; Van de Ven and Schut, 2008). Individual consumers have an annual choice among 
private insurers, who can negotiate differentiated contracts, selectively contract, or 
vertically integrate with health care providers. Premium subsidies make basic health 
insurance affordable for everyone and a risk-equalization system compensates insurers 
for enrolees with predictably high medical expenses. 
In addition to the implementation of the Health Insurance Act, market-based reforms in 
the Dutch health care system also include a gradual liberalisation of provider markets. 
Since February 2005, hospitals and insurers are able to negotiate prices per Diagnosis 
Treatment Combination (DBC) for a number of routine hospital services, such as cataract 
surgery and hip replacement.1 From 2005 to 2009 the proportion of freely negotiable 
hospital production, called B-segment, has been increased from about 10 percent to 
about 34 percent of total hospital expenditure. For the remainder of hospital produc-
tion, called A-segment, prices per DBC are determined by the Dutch Healthcare Author-
ity (NZa).
1 Each patient admitted to a Dutch hospital or visiting a hospital’s outpatient clinic is categorised into 
a DBC. Each DBC includes all hospital activities and services (both inpatient and outpatient) associated 
with the patient’s demand for care, from his initial consultation or examination to the final check-up.
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The ultimate goal of the market-based health care reform is to increase the efficiency 
of health care provision by stimulating provider competition in two different ways. 
First, health insurers are encouraged to act as prudent buyers of care on behalf of their 
enrolees by increasing the incentives and freedom to negotiate contracts with indi-
vidual providers about prices and/or quality. Though insurers gradually have started to 
take-up their new role, this transition is still work-in-progress (Van de Ven and Schut, 
2009; Boonen, 2009). For several reasons insurers until now have been quite reluctant 
to selectively contract with providers and to offer preferred provider contracts to their 
customers: (i) supply and prices of most health care services are still heavily regulated; 
(ii) insurers often lack the quality information required for selective contracting; (iii) in-
surers fear a loss of reputation if they would restrict patient choice; and (iv) insurers run 
only limited financial risk on the costs of hospital care. Second, by providing consumer 
information patients are encouraged to make an active choice between alternative 
providers. From the opening up of markets such as the supply of domestic energy and 
telecommunications to competition, it can be learned that the behaviour of consumers 
is crucially important for the degree of competition (Waterson, 2003). How much do 
they search and how many firms do they search amongst? And how do they respond to 
observed differences between firms in the market?
This thesis focuses on the feasibility of hospital competition in the Netherlands. Though 
hospital markets are characterised by multiple imperfections, in large part deriving from 
the uncertainty and asymmetry of information between buyers (individual patients, 
insurers) and sellers (hospitals),2 empirical evidence suggests that competition among 
providers can be socially beneficial by resulting in lower prices and/or higher quality 
(e.g. Kessler and McClellan, 2000; Gaynor, 2006).3 For hospital competition to be effec-
tive, at least two necessary conditions need to be met: (i) insurers and patients must 
be able to choose from a sufficient number of hospital substitutes; and (ii) information 
about hospital quality must be reliable, comprehensive, and publicly available. 
The remainder of this chapter is structured as follows. First, a brief description of the 
development of hospital market structure in the Netherlands is provided. Next, the role 
of merger control in Dutch hospital markets is discussed. Then the importance of public 
2 Excellent discussions of how the health care industry differs from other industries can be found in 
Gaynor and Vogt (2000) and Dranove and Satterthwaite (2000).
3 Studies examining the consequences of competition in markets for health care almost exclusively deal 
with hospital markets in the US. In the Netherlands the data required for such analyses is not easily acces-
sible for academic researchers, which seriously hampers the development of empirical work in this area.
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reporting about hospital quality in competitive markets and recent Dutch initiatives in 
this area are highlighted. Finally, the central research questions of this thesis are outlined.
1.2 Changes in Dutch hospital market structure
When making choices, how many hospital substitutes are available for Dutch patients? 
In the past two decades hospital mergers have substantially reduced the number of 
hospitals in the Netherlands (e.g. Varkevisser et al., 2004). As a result of consolidation, 
the total number of organisations providing general inpatient hospital services has 
steadily declined from 162 in 1985 to 93 in 2009 (Table 1.1). 
From 1978 to 2009 the total number of hospital mergers in the Netherlands equals 92. 
As shown by Figure 1.1, merger activity was most intense in the mid-1980s and early-
1990s. When analysing the reduction of independent hospital organisations in more 
detail, several reasons for hospital consolidation can be distinguished. Initially hospital 
consolidation involved mergers among small-scale hospitals. Since the early 1970s the 
Dutch government induced hospitals with less than 150-200 beds to merge in order 
to (i) reduce excess capacity caused by a substantial decrease in the average length of 
stay and (ii) safeguard public goals such as quality and continuity of care. In later years 
hospital consolidation most often involved mergers among medium- and large-scale 
hospitals. For a considerable period of time the global budgeting system for hospitals, 
replacing an open-ended budgeting system in 1983, included higher payments for 
bigger hospitals. That is, for the parameters in the variable part of the budget (e.g. ad-
missions, nursing days) bigger hospitals received a higher payment per parameter than 
smaller hospitals to compensate them for higher costs associated with the provision 
of more sophisticated hospital services and differences in their case-mix. This “merger 
bonus” provided all hospitals with a financial incentive to consolidate in order to in-
crease in scale. Consequently, during the 1980s and early-1990s the nature of the Dutch 
Table 1.1: Number of independent hospital organisations in the Netherlands
1985 1995 2004 2005 2006 2007 2008 2009
General hospitals 155 110 90 89 88 87 87 85
Academic hospitals 7 9 8 8 8 8 8 8
Total 162 119 98 97 96 95 95 93
Sources: statline.cbs.nl and NZa (2009)
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hospital industry changed substantially. From the late-1990s, merging hospitals seem to 
anticipate the gradual introduction of managed competition in the health care system.4
At two different moments in time, the Dutch government attempted to stop hospital 
consolidation. First, in 1992 the State Secretary of Health at the time (Hans Simons) 
announced he would be reserved about new hospital mergers and therefore invited 
hospitals to consider alternatives. His legal instruments to prohibit hospitals from merg-
ing, however, were very limited (Section 1.3). Second, in 2002 the Minister of Health at 
the time (Els Borst) asked for a voluntary standstill agreement, in which all hospitals 
would agree to temporarily stop merging until a study by the Netherlands Board for 
Health Facilities (CBZ) on the spatial distribution of hospital services was completed. 
The Dutch Hospital Association (NVZ) complied with this request and urged its members 
not to merge. After the publication of the study (CBZ, 2002), concluding that hospital 
merger activity was not (yet) threatening the accessibility of hospital services, the NVZ 
argued there was no reason to continue the standstill agreement. 
4 When discussing consolidation in US hospital markets, Gaynor and Haas-Wilson (1999, pp.148/149) 
argue that in a changing health care system many mergers “can be understood as jockeying for position 
to make sure not to be the one left standing when the music stops, or as an attempt by providers to 
improve their bargaining positions relative to insurers.”
Figure 1.1: Hospital mergers in the Netherlands 1978-2009
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Table 2.1: Hospital merger cases litigated in t e US 1991-2008a 
Case Year Winner in court Primary reason(s) for court decisio  
Augusta, Georgia 1991 Hospitals Not-for-profit organisatio  
Ukiah, California 1994 Hospitals Geographic market definition 
Joplin, Missouri 1995 Hospitals Geographic market definition, not-for-profit organisation 
Dubuque, Iowa 1995 Hospitals Geographic market definition 
Grand Rapids, Michigan 1996 Hospitals Not-for-profit organisation, efficiencies 
Long Island, New York 1997 Hospitals Product market definition 
Popular Bluff, Montana 1999 Hospitals Geographic market definition 
Evanston, Illinois 2007 FTC  
Falls Church, Virginia 2008 -b  
a. This overview is an update of the list of cases presented in Gaynor and Vogt (2000, p.1422). 
b. There is no court decision since the merging hospitals decided to abandon the transaction after the FTC 
sought to stop it. 
 
 
Source: en artog (2004) and Za (2009)
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1.3 Merger control in Dutch hospital markets
For many years mergers were not made the subject of competition policy in the Nether-
lands. The Economic Competition Act (WEM) of 1956 did not include preventive merger 
control. Under this act, cartels, other restrictive practices, and abuses of a dominant 
position were tolerated unless they were found to be contrary to the public interest.5 
In only a handful cases restrictive arrangements were found to be against the public 
interest so that for good reason the Netherlands was referred to as a “cartel paradise”. 
For the hospital industry, the Hospital Facilities Act (WZV) of 1971 regulated entry and 
curbed investments. But this act provided the Minister of Health with very limited legal 
instruments to prohibit hospital mergers. If the merger plan would include the building 
of a new hospital, a license for this investment was required under the WZV. Hence, the 
government was only able to block a proposed hospital merger in case of development 
of new facilities.
In 1998 the Competition Act (Mw) has replaced the WEM. The Mw is modelled after 
the competition rules in the EC Treaty and subsequent legislation and includes (i) a 
prohibition on cartels; (ii) a prohibition on the abuse of a dominant position; and (iii) 
a preventive merger control regime. It is enforced by the Netherlands Competition 
Authority (NMa), an independent administrative body. Under the Mw, mergers between 
any firms (including hospitals) whose combined and individual turnovers exceed the 
thresholds that are in force are subject to notification and prior approval by the NMa. 
According to Section 41.2 of the Mw, the NMa will prohibit a merger “if, as a result of the 
proposed concentration, effective competition on the Dutch market or a part thereof 
would be appreciably impeded, specifically as a result of the creation or strengthening 
of a dominant economic position.”6 
Until 2004 the NMa did not assess proposed hospital mergers since it was argued that 
hospitals were not able to compete due to strict supply and price regulation. In January 
2004, the NMa issued a position document in which it stated that as a result of institu-
tional and regulatory changes in the Dutch health care system the economic and legal 
context now offers scope for competition among hospitals. This implied that from then 
5 That is, if firms informed the Minister of Economic Affairs about their cartel agreement. Reported agree-
ments were registered in the Dutch “cartel register”.
6 A dominant position is defined as a position of one or more undertakings which enables them to 
prevent effective competition being maintained on the Dutch market or a part thereof, by giving them 
the power to behave to an appreciable extent independently of their competitors, their suppliers, their 
customers or end-users.
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the anticompetitive effects of proposed hospital mergers needed to be assessed.7 From 
2004 to 2009 the NMa has permitted all eight proposed hospital mergers.8 Since the 
implementation of the Healthcare Market Regulation Act (WMG) in October 2006, the 
Dutch Healthcare Authority (NZa) advices the NMa on proposed hospital mergers. In 
addition to the preventive merger control procedure, other than the former WZV the 
new Healthcare Providers Entry Act (WTZi) of 2006 allows the government to take action 
if a hospital merger would endanger the accessibility of emergency care.9 Until now, this 
legal instrument has not been used.
1.4 Information about hospital quality
In addition to a sufficient number of hospital substitutes to choose from, public disclo-
sure of reliable and comprehensive information about quality is also a necessary condi-
tion for effective hospital competition. In the absence of adequate sources of quality 
information about individual providers, patients (and/or their health insurers) can not 
choose a hospital with confidence that it is indeed the most preferred combination of 
quality and travel time without incurring prohibitive search costs (Dranove and Satter-
thwaite, 2000). Patients are then unable to give providers clear signals as to what they 
value implying that hospitals are not encouraged to meet their preferences and improve 
performances. Unclear signals may, for example, encourage hospitals to systematically 
underproduce unobserved clinical quality and overproduce patient convenience. Public 
disclosure of hospital quality indicators is therefore an important, but not sufficient, 
precondition for effective hospital competition. 
There are, however, many problems in measuring quality of hospital care. Most impor-
tantly, hospital quality is multidimensional. When only a few outcomes are measured, 
hospitals may devote too much attention to these areas and may neglect unmeasured 
aspects of their performance. As can be learned from the effects of competitive reforms 
in the UK National Health Service during the 1990s, increased competition in combina-
7 One might argue that because Dutch hospitals are not-for-profit-firms, the ability to benefit from the 
exercise of market power and the incentives for it are reduced. However, though not under shareholder 
pressure, empirical evidence suggests that not-for-profit hospitals do not behave differently from for-
profit hospitals in regard to exercising market power (Gaynor and Vogt, 2000; Vita and Sacher, 2001). 
Hence, the degree and type of competition rather than hospital ownership per se seem to determine 
hospital behaviour (Varkevisser, 2008).
8 In two cases, the proposed merger was allowed by the NMa but not consummated.
9 By law, in case of an emergency each inhabitant should be able to reach an emergency department by 
ambulance within 45 minutes of travel time.
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tion with a limited set of quality indicators may induce hospitals to reduce unmeasured 
and unobserved quality in order to improve measured and observed performances 
(Propper et al., 2004 and 2008). 
Despite these difficulties, public reporting of comparative quality information has be-
come an accepted way of improving hospital quality in many countries. For instance, 
quality report cards have been prominent in the US for almost two decades and since 
the late 1990s they are also a central feature of UK health care reform. After examining 
the experiences in these two countries, Marshall et al. (2003) make a series of recom-
mendations on how to maximise the effectiveness of public quality reporting. First, if 
it is to be effective, public reporting needs to be mandatory. When it is not, hospitals 
may withdraw from a reporting scheme when they perceive that participation is not 
in their self-interest. Second, report cards should be tailored to the needs of users 
rather than rely on readily available data that is difficult to interpret. Third, to secure 
meaningful comparability hospital performance reporting requires at least some sort 
of risk-adjustment. The public disclosure of hospital performance indicators without ad-
equate risk-adjustment may lead to risk selection by providers thereby decreasing social 
welfare rather than increasing it (Dranove et al., 2003). Fourth, increasing the public’s 
interest and confidence in hospital quality reports is important for their effectiveness. 
When making consumer information about hospital quality publicly available without 
providing further support, patients may not search it out, not understand it, distrust it, 
and fail to make use of it.
Though in the past years several promising initiatives have been employed to improve 
transparency, public reporting on quality in Dutch hospital markets is currently still in its 
infancy. In addition to the information made public by individual hospitals and hospital 
rankings provided by the media, some hospital quality information has become available 
for patients on a government sponsored patient-oriented health care portal. Patients 
can use this portal for comparing hospitals on different sets of performance indicators,10 
developed by the Dutch Healthcare Inspectorate (IGZ) in cooperation with stakeholders 
(hospitals and medical specialists). An unresolved question is whether patients respond 
to this information and how this may impact hospital competition in the Netherlands.
10 This portal, www.KiesBeter.nl (literally: “make better choices”), also allows consumers to compare 
health plans on prices, services, consumer satisfaction, and supplementary health insurance schemes.
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1.5 Research questions and structure of this thesis
As discussed above, effective hospital competition first requires the availability of a suf-
ficient number of hospital substitutes. Since hospital consolidation reduces the number 
of alternative choices, preventive merger control is of crucial importance. Antitrust 
agencies like the NMa, however, are struggling with the assessment of proposed hospital 
mergers. Most importantly, geographic market definition is rather complicated:11 which 
hospitals are feasible substitutes from the patient’s perspective? Due to the presence of 
third party payers (health insurers), price regulation, and the general unobservability of 
negotiated prices in deregulated hospital markets, the standard Small but Significant 
Non-transitory Increase in Price (SSNIP or “hypothetical monopolist”) test is not ap-
plicable. Unfortunately, traditional alternative methods for defining hospital markets 
(Elzinga/Hogarty approach, critical loss analysis) suffer from serious methodological 
shortcomings and have proven to be inaccurate. Hence, the NMa and NZa are in need of 
new approaches for hospital market definition. Both international experiences and new 
approaches to hospital market definition that are suggested in the recent economic 
literature may provide useful starting points. The appropriate approach to defining 
geographic hospital markets, however, depends crucially on the prevailing institutions 
and market structure implying that antitrust enforcement practices in other countries 
and novel methodologies are not directly applicable in the Dutch context. Research is 
therefore needed to examine their applicability to hospital markets in the Netherlands.
Since the availability of a sufficient number of hospital substitutes is a necessary con-
dition for successful market-based health care reforms in the Netherlands, effective 
antitrust enforcement is crucially important. However, it is not a sufficient condition. 
Effective hospital competition at least also requires market transparency and patient 
responsiveness to observed quality differences. Unfortunately, studies on patient choice 
are almost exclusively performed in the context of US hospital markets. Little is therefore 
known about patients’ willingness to travel for higher quality in the Dutch setting where 
their choices are not affected by prices and hospitals directly compete for patients on 
non-price dimensions. Also in this area research is needed, taking patient heterogeneity 
and hospital differentiation explicitly into account.
11 Assessing market power in hospital merger cases typically involves two steps: definition of the product 
market and definition of the geographic market. The first, however, has not nearly been as contentious 
as the latter.
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This thesis aims to improve the understanding of patient choice, competition, and an-
titrust enforcement in Dutch hospital markets by addressing the following four central 
research questions:
1.  What lessons can be learned from experiences with hospital merger control in coun-
tries with a competitive hospital sector?
2.  What is the appropriate approach for defining geographic hospital markets in the 
Netherlands?
3.  How to assess the substitutability of Dutch hospitals taking both patient and hospital 
heterogeneity into account?
4.  Do patients respond to publicly available information about hospital quality and how 
may this affect competition in Dutch hospital markets?
The remainder of the thesis is structured as follows. To learn from international experi-
ences with hospital merger control, Chapter 2 focuses on antitrust agencies’ practices 
toward hospital mergers in three different countries with competitive hospital markets 
and preventive hospital merger control: the United States, Germany, and the Nether-
lands. Since geographic market definition is the Achilles’ heel of hospital merger control, 
Chapter 3 discusses the strengths and weaknesses of both the methods historically 
employed as well as three new approaches to defining hospital markets (time-elasticity 
approach, competitor-share approach, and option demand approach). Particularly their 
applicability to Dutch hospital markets is discussed. Chapter 4, which is the first empiri-
cal analysis of actual hospital visits in the Netherlands (revealed preferences), assesses 
what patient characteristics and hospital attributes affect patients’ decisions to bypass 
the nearest hospital for their first visit to the hospital’s outpatient clinic. To take the 
heterogeneity of hospital care into account, bypass decisions for two different medi-
cal specialties are analysed: orthopaedic care, reflecting a regular type of hospital care, 
and the more sophisticated medical specialty of neurosurgery. Chapter 5 empirically 
analyses hospital substitutability in the market for neurosurgery by estimating hospitals’ 
time-elasticities. In the Dutch context, time-elasticities provide relevant information 
about patients’ propensity to consider alternative hospitals if a particular hospital 
would become more “costly”. Chapter 6 examines whether in the market for angioplasty 
patients respond to publicly available information about hospital quality and what 
implications their choice behaviour may have for hospital competition. The market for 
angioplasty in the Netherlands provides a unique opportunity to empirically assess the 
impact of consumer information on quality competition in a regulated hospital market: 
Chapter 118
patient choice is affected by observed quality and geographic location only, hospital 
prices are fixed, and entry is restricted. To conclude the thesis, chapter 7 summarises the 
main conclusions and policy recommendations obtained from the preceding chapters. 
Note to the reader
Because the chapters 2, 3, 4, 5, and 6 of this thesis are written as separate articles for 
publication in international journals, they can be read independently.
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Abstract
When relying on markets to allocate health care resources, strict enforcement of the 
antitrust laws in health care markets becomes essential. Hospital merger control is 
particularly important, since often only a small number of hospitals compete within a 
geographically limited market. To learn from international experiences with hospital 
merger control, in this paper the antitrust enforcement practices in three different coun-
tries with a competitive hospital sector are examined: the United States, Germany, and 
the Netherlands. In addition to a general comparison, for each of these countries one 
recent landmark case is analysed. From the findings of this international comparison 
two important lessons are formulated. First, geographic market definition is the Achilles’ 
heel of hospital merger control but European antitrust enforcement agencies do not 
necessarily have to struggle with this issue as much as their US counterparts. Second, 
recent court decisions confirm that geographic hospital markets are rather small. Based 
on our observations we further conclude it is better for antitrust enforcement agencies 
to be too restrictive when assessing proposed hospital mergers rather than too permis-
sive. In particular since hospital mergers may have serious anticompetitive effects and 
post-merger antitrust enforcement is not likely to offer an effective safety net.
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2.1 Introduction
Traditionally, competition and antitrust enforcement has been important in the US 
health care system only. In recent years, however, more countries have started to turn 
away from reliance on strict supply rationing and price controls in health care (Cutler, 
2002). Particularly in Germany and the Netherlands strict enforcement of the antitrust 
laws in health care markets is becoming more important as a result of recent market-
oriented reforms (Stock et al., 2007; Van de Ven and Schut, 2008). However, from US 
experiences it follows that this is all but straightforward. Due to the unique attributes 
of health care markets (e.g. the presence of third party payers) the definition of relevant 
markets, which is a necessary step towards the objective of assessing providers’ market 
power, is particularly challenging.
The focus of this paper is on hospital merger control since competitive pressures in 
hospital markets generally provoke horizontal consolidation (Gaynor and Haas-Wilson, 
1999). Consolidation may add to efficiency by eliminating excess capacity and utilising 
economies of scale and/or scope. However, research indicates that mergers only pro-
duce significant cost savings when hospitals consolidate their services more fully while 
in fact most mergers do not (e.g. Dranove and Lindrooth, 2004; Kjekshus and Hagen, 
2007). Since unambiguous cost advantages are absent, antitrust enforcement agencies 
have all the more reason to be suspicious when assessing proposed hospital mergers. In 
general, mergers may allow hospitals to exercise market power by raising prices and/or 
lowering quality. Studies on the effects of hospital mergers on prices, costs and quality 
provide clear evidence that hospital mergers in the US have actually deteriorated mar-
ket outcomes. From the extensive survey of the empirical literature offered by Vogt and 
Town (2006), it follows that hospital consolidation in the 1990s raised prices by at least 5 
percent and likely significantly more. When merging hospitals are closely located, prices 
even seem to increase by 40 percent or more. Hospital mergers also seem to reduce 
quality, though empirical evidence in this area is limited and mixed.1 
1 Even when consolidation is likely to improve health outcomes, the reduction in hospital price competi-
tion may very well erase these gains in consumer welfare (Ho et al., 2007). 
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Concerning the overall effect, Town et al. (2006) estimate that from 1990 to 2001 the 
primary impact of hospital mergers in the US appeared to be a transfer of consumers’ 
surplus to hospitals’ surplus. That is, the loss of total welfare was quite modest but hos-
pital consolidation substantially reduced consumer welfare.2
To prevent anticompetitive effects from occurring and to safeguard effective competi-
tion in health care markets, preventive merger control is of crucial importance. Given 
the fact that in the US competition has always played an important role in allocating 
health care resources, it is not surprising to find that analyses of the likely effects of 
hospital mergers there have been an important part of antitrust enforcement since the 
early 1980s. However, enforcement of the antitrust laws in hospital markets has proven 
to be particularly difficult. Though the US antitrust enforcement agencies had consider-
able early success in challenging hospital mergers that were allegedly anticompetitive, 
they lost all seven cases litigated during the 1990s. In most of these cases, the primary 
reason was that courts disagreed with the agencies on the size of the relevant geo-
graphic market. In particular since due to the presence of third-party payers a hospital’s 
price elasticity of demand is generally unknown, the standard Small but Significant 
Non-transitory Increase in Price (SSNIP or “hypothetical monopolist”) test for defining 
geographic markets is difficult to implement in hospital markets.3 
To learn from their longstanding experience with hospital merger control, in this paper 
we first take a close look at hospital merger control in the US (Section 2.2). Then we 
briefly examine hospital merger control in the European Union (Section 2.3). Since 
most hospital mergers are not covered by the EU’s supranational competition policy, 
we focus on two countries with competitive hospital markets: Germany (Section 2.4) 
and the Netherlands (Section 2.5). To illustrate antitrust enforcement agencies’ practices 
2 At least as far as mergers are concerned courts and antitrust enforcement agencies in both the US 
and Europe tend to use a consumer welfare standard (Motta, 2004, p.19). Some recent papers, however, 
discuss the proper objective of competition policy (e.g. Heyer, 2006; Carlton, 2007; Pittman, 2007). While 
economists generally prefer total welfare, an important argument in favour of the consumer welfare 
standard is that it simplifies decisions in merger cases. That is, the use of a total welfare standard would 
entail a difficult exercise in quantifying the changes in consumer and producer surplus in order to assess 
the net welfare effects. Additionally, horizontal mergers typically result in welfare transfers from consum-
ers to producers that are likely overall to be quite regressive.
3 The SSNIP test begins by positing a narrowly defined market (e.g. one particular zip code) and asking 
whether a hypothetical monopolist of all firms and products in the posited geographic market could 
profitably implement a small but significant non-transitory increase in price. If the hypothetical monopo-
list cannot do so, then the proposed market must be defined too narrow. Thus, including neighbour-
ing zip codes should expand market definition. This procedure is repeated until the SSNIP question is 
answered affirmative.
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towards hospital mergers, throughout the paper three recent case studies are discussed 
that can be viewed as important (national) landmark cases. When discussing these case 
studies the focus is on geographic market definition since this is particularly difficult in 
the hospital sector. The paper ends with some concluding remarks (Section 2.6).
2.2 Hospital merger control in the United States
2.2.1 Clayton Act and horizontal merger guidelines
In the US, Section 7 of the Clayton Act (1914) prohibits mergers and acquisitions where 
the effect “may be substantially to lessen competition, or to tend to create a monopoly.” 
At the federal level, the responsibility to enforce antitrust laws is shared by the Federal 
Trade Commission (FTC) and the Department of Justice (DOJ). The premerger notifica-
tion requirements of the Hart-Scott-Rodino Act (1976) allow the antitrust enforcement 
agencies to examine the likely effects of proposed mergers before they take place. In 
2009 parties are required to notify both the FTC and DOJ about any merger or acqui-
sition plan if the transaction has a value of more than $260 million. For transactions 
valued at less than this size-of-transaction threshold, notification is still required when 
the size of each party exceeds the size-of-person thresholds. Only relatively small merg-
ers involving relatively small parties are less likely to raise antitrust concerns and thus 
excluded from the Clayton Act’s coverage.
If a particular transaction is subject to notification, the parties must wait a specific 
period (usually 30 days) before they may complete it. During this waiting period either 
the FTC or the DOJ undertakes a preliminary review of the proposed merger.4 After the 
preliminary review, the agency can terminate the waiting period, allow the initial waiting 
period to expire, or issue a request for additional information because it decides closer 
examination of the transaction is warranted. In case of closer examination, this stage 
has three potential outcomes. First, the agency may close the investigation and let the 
transaction go forward unchallenged. Second, the agency may enter into a negotiated 
consent agreement with the parties that includes provisions that will restore competi-
tion. Third, the agency may seek to stop the entire transaction by filing for an injunction 
in court. Unless the agency takes some action that results in a court order stopping the 
merger, the parties can consummate their transaction at the end of the specific waiting 
period. The decision not to challenge a proposed merger, however, does not preclude 
the enforcement agencies from initiating a post-merger enforcement action at a later 
4 The FTC and DOJ decide between themselves which agency will be responsible for this review.
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time – as a recent hospital merger case illustrates (Section 2.2.4). According to Section 
11(b) of the Clayton Act divestiture is the usual and appropriate remedy where a con-
summated merger is found to have substantially lessened competition. 
To identify whether or not a merger is likely to cause competitive problems, the agencies 
employ the analytical process outlined in the Horizontal Merger Guidelines (FTC and DOJ, 
1992). This process consists of five steps. First, it is assessed whether the merger would 
significantly increase concentration and result in a concentrated market, which requires 
defining the relevant product and geographic market. Second, it is assessed whether 
the merger, in light of market concentration and other factors that characterise the 
market, raises concern about potential adverse competitive effects.5 Third, it is assessed 
whether entry would be timely, likely and sufficient either to deter or to counteract the 
competitive effects of concern. Fourth, any efficiency gains that reasonably cannot be 
achieved by the parties through other means are assessed (efficiency defence). Finally 
it is assessed whether either party to the transaction pre-merger would be likely to fail, 
causing its assets to exit the market (failing firm defence). 
2.2.2 Experiences with hospital merger control
Since according to the agencies many hospital mergers do not present competitive con-
cerns, an antitrust safety zone is set forth (DOJ and FTC, 1996). Hospital mergers falling 
within this zone will not be challenged, absent extraordinary circumstances. The safety 
zone applies to any merger between two general acute-care hospitals where one of the 
hospitals has an average of fewer than 100 licensed beds over the three most recent 
years, has an average daily inpatient census of fewer than 40 patients over the three 
most recent years, and is more than five years old. For hospital mergers that fall outside 
the antitrust safety zone, the five steps set forth in the Horizontal Merger Guidelines are 
followed. 
Since the first hospital merger was challenged in 1981, the DOJ and FTC had initially con-
siderable success on litigating hospital merger cases. During the 1990s, however, they 
lost all seven cases – from a total of about 900 hospital mergers – that were litigated. 
These losses in court constrained the agencies ability to control hospital concentration
5 The Herfindahl-Hirschman Index (HHI) is used for measuring market concentration. The HHI is calcu-
lated by summing the squares of all individual market shares. Where the post-merger HHI exceeds 1,800 
it will be presumed that mergers producing an increase in the HHI of more than 100 points are likely to 
create or enhance market power or facilitate its exercise (FTC and DOJ, 1992).
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and gave overly permissive signals to hospitals.6 Only recently, in a case involving ex 
post examination of a consummated hospital merger the FTC prevailed in court (Section 
2.2.4). 
Table 2.1 presents a list of hospital merger cases following the agencies’ victory in the 
Rockford, Illinois case in 1989. The cases are denoted by the name of the city in which 
the merging hospitals are located. 
Supported by empirical evidence on the anticompetitive effects of consummated hospi-
tal mergers (e.g. Vita and Sacher, 2001; Simpson, 2003), the courts’ reasoning in the cases 
of the 1990s has been widely criticized. From an economic perspective the most impor-
tant flaws in their erroneous reasoning include judges’ tendency to ignore the highly 
idiosyncratic nature of decision making by health care consumers, the propensity to 
overlook the importance of agency relationships in determining consumers’ responses, 
and the failure to take into account that hospital services are highly differentiated (e.g. 
Greaney, 2002; Conners, 2003; Richman, 2007). In particular by accepting implausibly 
large geographic markets, courts underestimated the anticompetitive effects of hospital 
mergers.
6 In this context “court” means court, or administrative law judge (ALJ), or full FTC since different cases 
are decided by different entities. If it is the FTC that seeks to stop a proposed merger by filing for an 
injunction in court, an ALJ within the FTC will decide the legality of the transaction. This decision may be 
appealed to the full five-member FTC and ultimately to the Supreme Court. If the DOJ is responsible for 
the merger case, the legality of the transaction is litigated in district court. A decision at that stage may 
be appealed to the circuit court and ultimately to the Supreme Court.
Table 2.1: Hospital merger cases litigated in the US 1991-2008a
Case Year Winner in court Primary reason(s) for court decision
Augusta, Georgia 1991 Hospitals Not-for-profit organisation
Ukiah, California 1994 Hospitals Geographic market definition
Joplin, Missouri 1995 Hospitals Geographic market definition, not-for-profit 
organisation
Dubuque, Iowa 1995 Hospitals Geographic market definition
Grand Rapids, Michigan 1996 Hospitals Not-for-profit organisation, efficiencies
Long Island, New York 1997 Hospitals Product market definition
Popular Bluff, Montana 1999 Hospitals Geographic market definition
Evanston, Illinois 2007 FTC
Falls Church, Virginia 2008 -b
a. This overview is an update of the list of cases presented in Gaynor and Vogt (2000, p.1422).
b. There is no court decision since the merging hospitals decided to abandon the transaction after the 
FTC sought to stop it.
Chapter 228
2.2.3 Geographic market definition
The DOJ and FTC have lost several court cases because the courts accepted the merg-
ing hospitals’ use of the Elzinga/Hogarty approach or critical loss analysis to define the 
geographic market much more broadly than the antitrust enforcement agency. These 
methods, however, suffer from serious methodological shortcomings and are therefore 
inaccurate.7
The Elzinga/Hogarty approach is easy to apply and only requires commonly available 
patient flow data. It begins with a narrowly defined market and then expands the 
boundary until threshold conditions are met for both imports (“little in from outside” 
= LIFO) and exports (“little out from inside” = LOFI) of hospital services. In various court 
cases, the analysis focused on identifying geographic areas such that both statistics are 
either below 25 percent (“weak market”) or 10 percent (“strong market”). The central 
problem underlying the Elzinga/Hogarty approach is the “silent majority fallacy” (Capps 
et al., 2002): the presence of some travelling patients who import and export hospital 
services does not necessarily discipline hospitals from exercising market power over 
the silent majority of non-travelling patients. Said another way, in markets with hetero-
geneous tastes for different services, the presence of travelling patients with one set 
of needs does not necessarily restrain the pricing of services to non-travelling patients 
with different needs. Suppose that 25 percent of all patients in an area travel significant 
distances to receive care. This, however, does not in any way indicate that the remain-
ing 75 percent would be willing to similarly travel in response to a price increase – the 
assumption implicit in using the Elzinga/Hogarty approach. Hence, price increases are 
certainly feasible even in the presence of significant patient outflows. One might argue 
that use of the Elzinga/Hogarty approach would be less problematic when disaggre-
gated clusters of hospital services that are close substitutes are analysed. But this would 
only solve part of the problem, since it incorrectly assumes that the only reason the 
“silent majority fallacy” exists is that patients’ propensity to travel differs across types of 
hospital care. There are, however, numerous other reasons why the propensity to travel 
differs among patients (e.g. unobserved personal preferences). Additionally, selecting 
a non-arbitrary way to aggregate the results of disaggregated, hospital service-level 
Elzinga/Hogarty analyses would also be problematic.
Critical loss analysis involves three consecutive steps. The first step is to compute the 
hospitals’ contribution margins, defined as price minus average variable costs. In the 
second step, the contribution margin is used to identify the percentage of patients the 
hospitals could lose before a small price increase – 5 percent is typically used – becomes 
7 A more detailed discussion of both methods can be found in Varkevisser et al. (2008).
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unprofitable. This is the critical loss. The final step is to analyse whether the actual 
loss of patients would exceed the critical loss if all hospitals in the proposed market 
implemented a small but significant non-transitory increase in price. If so, then the price 
increase would be unprofitable, indicating that the hypothetical geographic market is 
too narrow and should be expanded to include more hospitals. The expected actual 
loss of patients is most commonly assessed using the concept of contestable zip codes. 
That is, it is assumed that all patients currently choosing one of the hospitals within the 
proposed market but living in area where many other patients (e.g. 50 percent or more) 
select hospitals outside the proposed market would switch to those outside hospitals in 
response to a price increase. Under this assumption critical loss analysis also suffers from 
the “silent majority fallacy”. Danger and Frech (2001) detail an important methodological 
shortcoming of critical loss analysis: market definition via this approach is highly sensi-
tive to the initial degree of market power. If price is already at the monopoly level, then 
any further increase in price will by definition result in lower profits. In such a situation, 
critical loss analysis incorrectly leads to an overly broad market. 
Given their losses in court and the empirical evidence on the anticompetitive effects of 
hospital mergers, it not surprising to find that in their extensive report on competition in 
health care the US antitrust enforcement agencies specifically address the question how 
hospital merger control has worked and should work to protect existing and potential 
competition in American hospital markets (DOJ and FTC, 2004). Among other things, 
the agencies stress it is crucial that geographic hospital markets are defined properly. 
Based on their experience and research, they argue that the traditional methods dis-
cussed above are not valid or reliable in defining geographic markets in hospital merger 
cases. Instead, to properly delineate geographic markets courts should use different 
types of evidence, including strategic planning documents, customer testimonies, and 
empirical evidence regarding consumers’ willingness to travel. The FTC and DOJ also 
encourage additional research on the pros and cons of new quantitative techniques 
for defining geographic hospital markets. In recent years, several new approaches to 
defining geographic hospital markets have been suggested in the health economics lit-
erature including the time-elasticity approach, the competitor share approach, and the 
option demand approach. However, these approaches each have their own strengths 
and weaknesses and have not yet been implemented in actual hospital merger cases 
(Varkevisser et al., 2008).
2.2.4 Case study: Evanston Northwestern Healthcare Corporation
Following the seven consecutive losses in court during the 1990s, the FTC in 2002 
changed its strategy. While developing new methods for ex ante litigation of hospital 
mergers, a retrospective study of consummated hospital mergers was announced to 
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find out whether merged hospitals behave anticompetitive. If so, ex post litigation could 
be appropriate. As a result of this new strategy, in February 2004 the FTC issued an 
antitrust complaint against Evanston Northwestern Healthcare Corporation (ENH) – a 
health system located on Lake Michigan’s North shore close to Chicago, Illinois. For the 
US, this hospital merger is a landmark case since in contrast to previous cases the court 
here found that the relevant market was geographically limited. As a result, for the first 
time since the 1980s the FTC prevailed in court when challenging a hospital merger.
Antitrust complaint and ordered remedy
In their antitrust complaint the FTC alleged that following the acquisition of the nearby 
Highland Park Hospital in January 2000, ENH was able to raise its prices far above price 
increases of other comparable hospitals as a result of the transaction. When seeking 
a remedy to restore competition “to the benefit of consumers seeking competitively 
priced health care” the FTC’s complaint contemplated a divestiture of the acquired 
hospital (FTC, 2004). In his initial decision – that was issued in October 2005 – the Ad-
ministrative Law Judge (ALJ) ordered this contemplated relief. The ALJ agreed with the 
FTC that ENH’s acquisition of Highland Park Hospital in 2000 resulted in “substantially 
lessened competition” and higher prices for health insurers and consumers (FTC, 2005). 
In his decision the ALJ stated that “contemporaneous and post-acquisition evidence 
establishes that ENH exercised its enhanced post-merger market power to obtain price 
increases significantly above its pre-merger prices and substantially larger than price in-
creases obtained by other comparison hospitals.” Explanations for these price increases 
other than the exercise of market power were ruled out. To address the anticompetitive 
effects of ENH’s acquisition of Highland Park, the ALJ wrote that “divestiture is the most 
effective and appropriate remedy.” It was ordered that ENH must divest and convey the 
Highland Park Hospital assets to an FTC-approved buyer and in an FTC-approved man-
ner. ENH appealed to the ALJ’s decision. Though the initial decision has been criticised 
heavily by some legal experts for being unconvincing and analytical flawed,8 on appeal 
the full FTC confirmed it in August 2007. The Commission agreed with the ALJ that 
ENH’s acquisition of Highland Park “gave the combined entity the ability to raise prices 
through the exercise of market power” and therefore warranted a remedy (FTC, 2007a). 
However, the Commission determined that “this is the highly unusual case” in which a 
conduct remedy is more appropriate than a divestiture. Since a long time had already 
elapsed after the merger, a divestiture would be difficult with a greater risk of unfore-
8 Harris and Argue (2006), for example, criticise the decision for finding direct anticompetitive effects 
based on unilateral action while at the same time identifying a market structure that is inconsistent with 
unilateral effects. Campbell (2007) argues that the analytical tools utilised by the ALJ to prove the case 
are unorthodox, while the result does not fit comfortably with the reality of the hospital industry. 
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seen costs and failures. To restore competition, it was therefore ordered that ENH should 
establish two separate and independent negotiating teams to allow health insurers to 
negotiate separately again with ENH and its former competitor Highland Park Hospital.9 
In 2008, ENH elected to forego further appeals and accept this remedy (Haas-Wilson and 
Garmon, 2009).
Implications for geographic market definition
In contrast to previous hospital merger cases the court here found that the market 
was geographically limited. According to the FTC’s complaint the relevant geographic 
market was the area “in which a significant number of individuals who seek hospital 
care at the three ENH hospitals reside” (FTC, 2004).10 This relevant geographic market 
was evidenced, among other things, by ENH’s “ability to profitably impose significant 
and non-transitory price increases upon private payers in their purchase of acute care 
hospital services at those hospitals.” The ALJ confirmed the limited size of the relevant 
geographic market by holding it larger than that proposed by the FTC’s complaint, but 
smaller than the market advocated by ENH itself. It was therefore argued that the merger 
was indeed likely to create or enhance market power. 
More interesting from a general perspective, the ALJ’s decision contains some interest-
ing observations on defining geographic hospital markets. First, it concludes that the 
Elzinga/Hogarty test, given its methodological shortcomings (Section 2.2.3), is “not 
appropriate” for defining geographic hospital markets. Second, it is emphasized that 
though courts do not compel “scientific precision” any hospital market should be “well-
defined”. That is, it must correspond to the “commercial realities” of the hospital industry. 
Third, the ALJ states that determination of the geographic market must be based on 
a dynamic “forward looking” analysis which considers not only where consumers have 
gone in the past for hospital services, but what “practical alternatives” they would have 
in the future. Fourth, a key issue in determining the geographic market is identifying 
9 Some academic experts on health economics and the economics of industrial organisation have 
argued that this remedy is likely to be ineffective for two reasons (FTC, 2007b). First, given that both 
negotiating teams report to the same ENH central office, there will be ample, hard to oversee opportuni-
ties for collusion. Effective price competition is therefore improbable. Second, the ruling is an invitation 
to collude on quality, about which the decision says nothing. For example, ENH and Highland Park may 
decide to segment the availability of services and therefore create a “must have” status for each hospital. 
In its final opinion, the full FTC acknowledges these criticisms but argues that a divestiture would have a 
substantial negative impact on Highland Park’s cardiac surgery program (FTC, 2008d). Standing alone the 
hospital would not have the volume to maintain its program so that competition might not be restored. 
10 In this ex post examination of a consummated hospital merger, geographic market definition is 
required to assess whether the post-merger concentration level and its increase violate the federal 
antitrust laws. 
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which hospitals managed care organisations need to have in their (restricted) hospital 
networks in order to establish viable, competitive networks.11 According to the ALJ, in 
US hospital markets it is this “first stage price competition” that is of critical concern to 
the antitrust analysis. By defining the relevant product market as general acute care 
inpatient services “sold to managed care organizations” the ALJ emphasizes that in US 
hospital markets prices are determined during negotiations over network participation 
and composition between health insurers and hospitals. Hence, in a setting with man-
aged care and selective contracting, health insurers – rather than individual patients 
– appear to be the relevant hospital customers from an antitrust perspective.
Since the evidence establishes that people select managed care plans including a hos-
pital that is close both geographically and in travel time, the ALJ concludes, geographic 
hospital markets are essentially local. On appeal the full FTC agreed with ENH that 
the ALJ did not address the central issue in defining geographic markets: over what 
geographic region could a hypothetical monopolist impose a SSNIP? But since the 
consummated merger enabled ENH to raise prices by a substantial amount through the 
unilateral exercise of market power, it is concluded that the geographic area in which the 
three hospitals are located nonetheless constitutes a well-defined antitrust geographic 
market (FTC, 2007a). 
2.2.5 Renewed strength for the FTC after its success in the ENH case?
Possibly strengthened by its success in the ENH case, in May 2008 the FTC for the first time 
in many years sought to block a hospital merger ex ante. A complaint was issued chal-
lenging the proposed acquisition by Inova Health System Foundation (Inova) – based in 
Falls Church, Virginia – of Prince William Health System (PWHS). According to the FTC, the 
proposed acquisition would substantially reduce the competition for general acute care 
inpatient hospital services in Northern Virginia and therefore violate the federal antitrust 
laws. As a result of the merger, the FTC states, “consumers will pay higher prices and lose 
the benefits of non-price competition” (FTC, 2008a). As in the ENH case, the relevant 
geographic market defined by the FTC is rather small. Here it is an area no larger than 
Northern Virginia. For the hospitals located in Northern Virginia approximately 90 per-
cent of their patients came from Northern Virginia, while at the same time approximately 
90 percent of the patients who reside in Northern Virginia go to hospitals in Northern 
Virginia (FTC, 2008b). According to the FTC the explanation for these patterns is simply 
that patients “prefer to be admitted to a high quality general acute care hospital close 
to where they live.” The merger would leave only five hospitals in this relevant market. 
11 Managed care organisations include vertically integrated Health Maintenance Organisations (HMOs) 
as well as more loosely structured Preferred Provider Organisations (PPOs).
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Under various measures (beds, privately-insured discharges, and inpatient revenue from 
commercial payers) both the concentration of the relevant market and its increase are 
then well above the level at which a merger between Inova and PWHS is presumptively 
unlawful. It is therefore concluded that the merger, if consummated, would substantially 
lessen hospital competition in Northern Virginia. Following the FTC’s challenge, Inova 
and PWHS decided to withdraw their plans for a merger since it “threatened to prolong 
completion of the merger by as much as two years, which both health systems believe 
is not in the best interest of the communities they serve” (Inova, 2008). According to the 
FTC, however, the decision by Inova and PWHS to abandon their transaction is caused 
by the “strong evidence in support of its case” disclosed in a preliminary court hearing 
(FTC, 2008c). After the hospitals’ decision to terminate the proposed acquisition, the FTC 
dismissed its complaint since there was no need for further litigation. Consequently, 
details on the approach used for definition of the relevant geographic market in this 
particular hospital merger case have not been made public.
2.3 Hospital merger control in the European Union
Mergers were not made the explicit object of supranational European competition 
policy until adoption of the Merger Regulation in 1989. Pursuant to Article 2 of the 
Merger Regulation, the European Commission (EC)12 has to determine “whether the 
merger would significantly impede effective competition, in particular through the 
creation or the strengthening of a dominant position, and should therefore be declared 
incompatible with the common market” (EC, 2004a). The Merger Regulation does not 
deal with all proposed mergers in the EU: decisions should be taken by national antitrust 
enforcement agencies unless there are good reasons to take them at the centralised 
level of the EC. However, since national antitrust laws are to a large extent reproducing 
the same features as the supranational antitrust laws (Motta, 2004, p.9), major differ-
ences in enforcement policies across EU member states are not to be expected.
The EC has jurisdiction on a merger if it has a community dimension. Mergers have a 
community dimension where the aggregate turnover of the firms involved exceeds 
certain stated thresholds and is achieved in different member states. Mergers where 
each of the firms achieve more than two-thirds of their aggregate community-wide 
turnover within one and the same member state by definition do not have a community 
dimension. If a merger has a community dimension, parties should notify the EC about 
12 Or more precisely, the Directorate General for Competition that acts following the directives of the 
European Commissioner responsible for competition policy.
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their plans before consummating the merger. After a preliminary review, the EC may 
decide either to allow the merger or that the proposed transaction “raises doubts” as 
to its compatibility with the common market. In the latter case, the likely competitive 
effects of the merger will be assessed more substantively. This process has three pos-
sible outcomes. The EC may decide to allow the merger, prohibit the merger, or allow 
the merger subject to a remedy. In contrast to the US, it is not possible for European 
antitrust enforcement agencies to order a divestiture once an unchallenged merger is 
consummated. To provide guidance on its appraisal of horizontal mergers the EC has 
issued guidelines. The guidelines specify the factors and conditions that are relevant 
when assessing the likely competitive effects of a merger (EC, 2004b). These factors and 
conditions include market shares and concentration levels, possible anticompetitive 
effects, countervailing buying power, and entry. In the EC’s horizontal merger guidelines 
it is recognised that a merger may bring about efficiencies that counteract the adverse 
effects on competition and the potential harm to consumers that it might otherwise 
have. That is, any substantiated efficiency claim brought forward by the merging parties 
is considered in the overall assessment of the proposed merger. A failing firm defence is 
also stated in the EC’s merger guidelines.
Since within the EU health care systems are organised nationally, hospital mergers most 
often do not have an impact that goes beyond the national borders of an individual 
member state. But occasionally a hospital merger has a community dimension. Most 
recently, in 2007 the EC reviewed a proposed transaction under which two providers of 
investment management (APW from the UK and APSA from France) and a Jersey-based 
private equity firm (Nordic Capital) would acquire joint control over Capio. This Swedish 
provider of health care owned private hospitals, diagnostic centres and private psychi-
atric hospitals in a wide range of EU member states, including the UK where one of the 
acquiring parties (APW) already controlled a provider of health care services. Using a 
separate product market for acute general hospital services provided by private hospi-
tals, the EC concluded that the merger would raise serious competition concerns in the 
UK. Since the EC argues that most patients do not travel far for their treatment,13 geo-
graphic hospital markets are defined as local. The proposed concentration was therefore 
approved conditional upon the divestiture of Capio’s UK-based private acute general 
hospitals, its independent sector treatment centres (ISTCs) outsourcing business, and 
its specialist eye hospital. This divestiture would remove the horizontal overlap in the 
13 To substantiate this point of view, the EC refers to an earlier decision by the UK Competition Commis-
sion in which it was concluded that competition on local hospital markets is considered to take place in 
areas extending to a 30 minutes drive in each direction starting from any one hospital (CC, 2000).
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UK and therefore eliminate the risk of less effective competition in the local markets 
concerned (EC, 2007).
2.4. Hospital merger control in Germany
2.4.1 Act against Restraints of Competition
The Act against Restraints of Competition (Gesetz gegen Wettbewerbsbeschränkungen, 
abbreviated: GWB), which came into effect in 1958, assigns the task of protecting com-
petition at the national level in Germany to the Federal Cartel Office (Bundeskartellamt, 
abbreviated: BKA). A procedure for preventive merger control was introduced in the 
GWB with the second amendment in 1973. Since then this procedure has been enforced 
relatively strictly, leading to a considerable number of merger prohibitions but also 
to frequent modifications of merger proposals and the abandonment of many others 
(Motta, 2004, p.11). One of the main principles behind competition policy in Germany 
is the protection of economic freedom. Mergers could lead to the creation of dominant 
firms which could limit the economic freedom of competitors. A proposed merger will 
therefore be prohibited when it is “expected to create or strengthen a dominant posi-
tion”, unless the merger “will also lead to improvements of the conditions of competition 
and that these improvements will outweigh the disadvantages of dominance” (Section 
36.1). According to the GWB, a firm is dominant when, on a properly defined market, it 
has no competitors or is not exposed to any substantial competition or has a paramount 
market position in relation to its competitors (Section 19.2). For assessing a firm’s market 
position the GWB mentions several factors that should be taken into account. These 
include its market share, its financial power, legal or factual barriers to market entry 
by other firms, actual or potential competition by firms, and the ability of the opposite 
market side to resort to other firms.
The BKA’s preventive merger control only applies to mergers between undertakings 
whose aggregate worldwide turnover exceeds €500 million and of which at least one 
undertaking realises more than €25 million in Germany. Mergers that are subject to con-
trol must always been notified prior to be being put into effect. The BKA then examines 
the proposed merger. After a preliminary review, a more substantive examination will 
be initiated if the BKA finds it necessary. After examining the proposed merger the BKA 
decides whether it is cleared, prohibited or cleared subject to a remedy. If a merger is 
cleared, the parties should inform the BKA once it is consummated. Though the notifica-
tion threshold is rather high, it is unlikely this has resulted in an antitrust enforcement 
policy that was overly permissive because so far mergers between German hospitals 
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typically involve the acquisition of public hospitals by large private hospitals chains. 
However, it is important to recognise that mergers between independent hospitals may 
not be subject to the BKA’s merger control whereas these mergers may substantially 
reduce competition in local or regional hospital markets.
2.4.2 Experiences with hospital merger control
To date the BKA has examined more than 100 hospital merger cases. Most of these 
cases were cleared within one month, but some have been challenged (Bangard, 2007). 
Particularly since the year 2000 an increasing number of public hospitals are being sold 
to private hospital chains, which is mainly driven by the large budget deficits of public 
authorities at the regional and municipal level (Schulten, 2006). As a result of this wave 
of hospital take-overs, hospital merger control has become increasingly important in 
Germany. To ensure that hospital markets are organised as competitive as possible, 
the BKA applies the GWB rather strictly in this industry. In recent years, four proposed 
hospital mergers were prohibited and one was cleared subject to the condition that the 
merging parties should sell one hospital location to a third party. In March 2005, for the 
first time, the BKA prohibited a proposed hospital merger. Following this prohibition, the 
Federal Court of Justice (Bundesgerichtshof) in Germany has recently confirmed that the 
GWB is fully applicable to the hospital industry (BGH, 2008). There are no social law or 
hospital law provisions that preclude application of the GWB’s merger control provisions 
to markets for hospital services. Additionally, the court concluded that the objectives of 
antitrust law and health policy are not in conflict with one another. Table 2.2 presents a 
list of hospital mergers cases since the BKA first prohibited a proposed merger. The cases 
are denoted by the names of the merging hospitals. 
Table 2.2: Hospital merger cases in Germany 2005-2008
Merging hospitals Year Conclusion by the BKA
Rhön and Bad Neustadt / Mellrichstadt 2005 Prohibited and confirmed in court
Rhön and Eisenhüttenstadt 2005 Prohibited
Asklepios and LBK Hamburg 2005 Cleared, subject to the condition of selling one location
Nürnberg and Nürnberger Land 2005 Cleared
Humaine and Fresenius 2006 Cleared
Greifswald and Wolgast 2006 Prohibiteda
Hannover and Wunstorf 2007 Cleared
LBK Hamburg and Mariahilf 2007 Prohibited
Rhön and Wesermarsch Klinik 2008 Cleared
a. In January 2008, however, the Federal Minister of Economics and Technology (Bundesminister für  
 Wirstschaft und Technologie) permitted the proposed merger. It was argued that the merger, despite  
 its likely anticompetitive effects, served the public interest since one of the hospitals involved was a  
 rather small university hospital suffering from scale-related inefficiencies. 
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2.4.3 Approach to defining geographic hospital markets
The BKA defines the relevant product market as the market for acute hospital services, 
including general hospitals and specialised clinics but excluding rehabilitation and 
other nursing centres. For defining geographic hospital markets the BKA uses a static 
backward-looking approach based on the analysis of patient flow data. Rather than 
“merely theoretical” hospital alternatives, the BKA argues that only “practical” alterna-
tives should be taken into account when defining the relevant geographic market (BKA, 
2005a). By considering where patients have gone in the past for hospital services, the 
BKA infers which hospitals are substitutable from the perspective of patients. Generally, 
the BKA’s approach to defining geographic hospital markets consists of two steps. In the 
first step the catchment areas of each hospital located within a greater area of about 100 
by 120 kilometres around the merging hospitals are identified. In the second step, which 
is the decisive one, the behaviour of patients is analysed.
Since the BKA approach to defining geographic hospital markets also relies on patient 
flow data, at first sight it seems closely related to the well-known and widely criticized 
Elzinga/Hogarty approach (Section 2.2.3). There are, however, two fundamental differ-
ences. 
First, when computing the export of hospital services the BKA does not aggregate 
patient inflows to all hospitals located in the hypothesized geographic market but only 
takes into account patients travelling to the merging hospitals. Overstatement of the 
true size of geographic hospital markets, which has proven to be an important pitfall 
when analysing patient flow data, is therefore less likely to occur. Consider the following 
example to illustrate this. Suppose we start with a hypothesized geographic market that 
in addition to the merging general hospitals A and C also includes the academic teach-
ing hospital B (Figure 2.1). 
Since the latter offers hospital services that are highly differentiated from the services 
offered by the other hospitals, 70 percent of its 10,000 patients come from outside the 
hypothesized market, whereas the percentage of travelling patients for the other hospi-
tals is only 10 percent of 5,000 patients each. Under these hypothetical circumstances, 
it is easy to see how the BKA’s approach leads to a different delineation of the relevant 
geographic market than the Elzinga/Hogarty approach. To start with the latter, the 
relevant statistic for the export of hospital services (“little out from inside”, LOFI) equals 
40 percent which is higher than the threshold that is generally used for a “weak” market. 
Hence, according to the Elzinga/Hogarty approach the geographic market is too nar-
rowly defined and its boundary should therefore be expanded. When the BKA computes 
the export of hospital services from the hypothesized geographic market, however, it 
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only analyses the inflow of patients to the merging hospitals (A and C) rather than the 
aggregate inflow to all hospitals (A, B, and C) in the market. The percentage of exports 
is then rather low (10 percent), which implies that the hypothesized geographic market 
should not be enlarged. Since the highly differentiated product provided by hospital B 
induces patients to travel for specific reasons, it would indeed be incorrect to conclude 
that hospitals A and C face competition from hospitals elsewhere. Note that when hos-
pital B would provide the same services as those provided by the other hospitals while 
still attracting many patients from outside the hypothesized market (e.g. due to its high 
quality), the BKA’s approach may result in a geographic hospital market that is defined 
too small.
The second difference with the Elzinga/Hogarty approach is that the BKA’s approach 
is based on pragmatic considerations, including case-specific characteristics, rather 
than fixed thresholds. From the BKA’s decisions it follows that generally only areas from 
which a substantial percentage of the patients travel to one of the merging hospitals 
are potentially included in the relevant market (Kallfass and Kuchinke, 2006). That is, 
when patients living in the hypothesized market also visit hospitals located there so that 
mutual patient flows between both areas are substantial. Whereas the Elzinga/Hogarty 
approach tends to include gradually more areas simply to meet the 90 percent or 75 
percent import and export thresholds, the BKA only includes or excludes neighbouring 
areas after assessing their specific competitive situation.
Figure 2.1: Using the export of hospital services for hospital market definition
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• Hospital A  
- total patients = 5,000 
- inow = 500 (10%) 
 
• Hospital B  
- total patients = 10,000 
- inow = 7,000 (70%) 
 
• Hospital C  
- total patients = 5,000 
- inow = 500 (10%) 
 
Export of hospital services according to the 
Elzinga/Hogarty approach : 8,000/20,000 = 40% 
Export of hospital services according to 
the BKA approach : 1,000/10,000 = 10% 
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The BKA’s approach is unlikely to suffer from the “silent majority fallacy” because it is 
recognised that the presence of travelling patients does not necessarily restrain hos-
pitals from behaving anticompetitive. More specifically, whereas the Elzinga/Hogarty 
approach incorrectly assumes that the presence of some travelling patients already 
disciplines hospitals from exercising market power over the silent majority of non-
travelling patients, the BKA assumes that only the presence of many travelling patients 
disciplines hospitals from exercising market power over the then silent minority of non-
travelling patients. Despite its use of patient flow data to define geographic hospital 
markets the BKA is therefore not likely to overstate the true size of the relevant market. 
On the contrary, as legal experts rightly argue (Badtke, 2008), the BKA’s approach may 
result in hospital markets that are defined too small rather than too large. Hence, the 
emphasis seems to be on avoiding Type II errors (allowing the hospital merger while it 
does restrict actual hospital competition) rather than avoiding Type I errors (prohibiting 
the hospital merger while it does not restrict actual hospital competition).
2.4.4 Case study: Rhön-Klinikum AG / Bad Neustadt / Mellrichstadt
In August 2004 Rhön-Klinikum AG, one of the leading private hospitals groups in Ger-
many, notified the BKA of its plan to acquire two public hospitals: one in Bad Neustadt 
(about 150 kilometres east of Frankfurt am Main) and one in Mellrichstadt (about 15 
kilometres north of Bad Neustadt). In particular since at the time of the proposed 
merger Rhön-Klinikum nation-wide already operated 30 hospitals with an aggregate 
turnover of more than €1,000 million, the BKA decided to substantively assess the likely 
competitive effects of the proposed acquisition. From this assessment it was concluded 
that the transaction would further strengthen Rhön-Klinikum’s dominant position in the 
two different relevant markets concerned (BKA, 2005a). For Germany, this is a landmark 
case since for the first time the BKA prohibited a proposed hospital merger and also 
prevailed in court.14 
Geographic market definition
By applying its two step approach to defining geographic hospital markets, the BKA 
in this particular case concluded that (i) for most general hospitals the vast majority of 
patients are living nearby, implying that the export of hospital services from one area 
to another is low and (ii) most patients choose hospitals close to their homes and do 
not travel to more distant alternatives, implying that the import of hospital services 
14 Shortly after this decision, the BKA also prohibited Rhön-Klinikum AG from acquiring the municipal 
hospital in Eisenhüttenstadt. It was concluded that this merger would strengthen Rhön’s already domi-
nant position in the the Frankfurt/Oder region because it already owned the principal hospital in that 
area (BKA, 2005b).
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from one area to another is low too. The BKA agreed that some patients are willing to 
travel, but since they travel for particular reasons (e.g. specialised care) their behaviour 
was not expected to significantly affect hospital competition. As a result, two different 
geographic markets were defined that are both rather small: the Bad Neustadt / Bad 
Kissingen market and the Meiningen market. In these areas the proposed merger would 
have increased Rhön-Klinikum’s market shares to about 65 percent and 60 percent, 
respectively (BKA, 2005a). 
Court decisions
Following its decision to prohibit the hospital merger, the BKA has prevailed in court 
twice. First, in April 2007 the Düsseldorf Higher Regional Court (Oberlandesgericht Düs-
seldorf) confirmed the approach used by the BKA for defining the relevant geographic 
market. The court stated that patient flow data provide reliable information about the 
substitutability of hospitals and may therefore be used by the BKA for geographic mar-
ket definition. Since hospitals’ substitutability crucially depends on the distance patients 
are willing to travel from their homes to a hospital, the court argued, analysing where 
patients have gone in the past for hospital services is appropriate. It is concluded that 
areas only belong to the same geographic market when mutual patient flows between 
them are “substantial” (OGD, 2007). Second, an appeal on points of law by the merging 
hospitals against this decision was dismissed in January 2008 by the Federal Court of 
Justice (Bundesgerichtshof) which made the BKA’s prohibition of the merger final. The 
highest court in Germany confirmed that the use of patient flow data is appropriate 
when defining the relevant geographic market in hospital merger cases. Therefore, the 
BKA’s approach to defining geographic markets is found to be “legally tenable” (BGH, 
2008). In its decision the court also argued that patients’ potential hospital alternatives 
should not be taken into account when they did not actually visit these hospitals in 
the past. This implies that most value is attached to revealed preference data. However, 
the court emphasised that potential alternatives are not meaningless. These are called 
“particularly useful” when assessing the factors that may limit or extend the merged 
hospital’s market power.
2.5 Hospital merger control in the Netherlands
2.5.1 Competition Act and guidelines for antitrust enforcement in health care
The Dutch Competition Act (Mededingingswet, abbreviated: Mw), implemented in 
1998 and amended in 2004, is enforced by the Netherlands Competition Authority 
(Nederlandse Mededingingsautoriteit, abbreviated: NMa). In addition to the prohibition 
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on cartels and the prohibition on abuse of a dominant position, the Mw also includes 
preventive merger control. In general, NMa’s merger control only applies to mergers 
between undertakings whose combined turnover exceeded €113 million in the preced-
ing calendar year and of which at least €30 million was realised in the Netherlands by at 
least two of the undertakings involved. Since geographic markets for health care tend 
to be rather small, these thresholds are temporarily lowered for health care markets in 
order to safeguard the emerging and still fragile competition in the new Dutch health 
care system. Since January 1, 2008 health care providers should notify the NMa about 
merger plans when their combined turnover exceeded €55 million in the preceding 
calendar year and of which at least €10 million was realised in the Netherlands by at 
least two of the undertakings involved. To prevent these lower thresholds from applying 
to mergers between undertakings for which delivery of health care services is only a 
small part of their business, a third threshold has been added. That is, for at least two of 
the undertakings involved individual turnover from health care services must exceed 
€5.5 million.15 
Mergers qualifying for these thresholds must be reported to the NMa prior to being con-
summated. After notification, the NMa carries out a first, general review of the proposed 
merger. According to Section 37.2 of the Mw a merger requires a license when there is 
reason to assume that “a dominant position that appreciably restricts competition on 
the Dutch market or a part thereof could arise or be strengthened as a result of the 
said concentration.” If the merging parties submit an application for a license, the NMa 
starts a more specific and substantial assessment of the proposed merger. Based on its 
findings, at the end of this licensing phase the NMa decides to allow the merger, prohibit 
the merger, or allow the merger subject to a remedy. Section 41.2 of the Mw states: “A 
license shall be refused if, as a result of the proposed concentration, effective competi-
tion on the Dutch market or a part thereof would be appreciably impeded, specifically 
as a result of the creation or strengthening of a dominant economic position.” Based on 
European jurisdiction, a dominant position is defined in the Mw as “a position of one or 
more undertakings which enables them to prevent effective competition being main-
tained on the Dutch market or a part thereof, by giving them the power to behave to an 
appreciable extent independently of their competitors, their suppliers, their customers 
or end-users” (Section, 1.i). However, in addition to lowering the notification thresholds 
the Dutch government also aims at the introduction of specific merger guidelines for 
the health care industry. The bill required for this is expected to be introduced in parlia-
ment by the summer of 2011.
15 These lowered thresholds are particularly relevant for nursing homes and home health care organisa-
tions, since mergers in these markets generally do not qualify for the general thresholds.
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In 2002, the NMa issued their first guidelines for antitrust enforcement policy in mar-
kets for health care. As a result of some fundamental changes in the Dutch health care 
system (Helderman et al., 2005; Schut and Van de Ven, 2005), these guidelines were 
revised in 2007. Other than the initial guidelines, the revised ones also include a section 
on preventive merger control. After explaining the procedures of both the notification 
and licensing phase, the NMa briefly discusses how they will assess whether there is a 
dominant position. First, the relevant market is defined and then several elements are 
considered, including market shares and concentration levels, countervailing buyer 
power, and the likelihood of entry (NMa, 2007). When assessing the likely competitive 
effects of a proposed hospital merger, the NMa has to take into account the opinion of 
the Dutch Healthcare Authority (Nederlandse Zorgautoriteit, abbreviated: NZa).16 
2.5.2 Experiences with hospital merger control
Prior to 2004, the NMa did not assess proposed hospital mergers since it was argued that 
hospitals were not able to compete due to supply and price regulation. In 2004, however, 
the NMa issued a position document in which it stated that institutional and regulatory 
changes in Dutch health care markets had created scope for competition (NMa, 2004a). 
As a result, it was therefore concluded that providers of hospital services compete with 
each other so that the Mw also applies to the hospital industry. From 2004-2008, nine 
proposed hospital mergers have been assessed by the NMa. In six cases the notification 
phase ended with the conclusion that a license was not required. For three proposed 
hospital mergers the NMa ordered a more specific and substantial assessment. Table 2.3 
presents a list of hospital mergers cases since the NMa first assessed a proposed merger 
in 2004. The cases are denoted by the names of the merging hospitals. 
So far, two hospital mergers have been subject to a substantive assessment by the NMa 
during the licensing phase. In both cases the merger was cleared by the NMa at the end 
of this phase. So there has not yet been a need for any defendants to challenge any 
decision in a hospital merger case. As a result, contrary to the US and Germany, there 
have not (yet) been court decisions on hospital market definition in the Netherlands 
implying there is no industry-specific jurisprudence.
2.5.3 Case study: Ziekenhuis Hilversum – Ziekenhuis Gooi-Noord
In April 2004 two neighbouring general hospitals (Hilversum and Gooi-Noord) located 
in the region between Amsterdam and Utrecht, notified the NMa about their plan to 
merge. After the first general assessment in the notification phase, the NMa in July 2004 
16 The NZa is an autonomous administrative agency under the Dutch Ministry of Health, Welfare and 
Sport that since 2006 monitors and regulates health care markets in the Netherlands.
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concluded that a license was required for this proposed merger since it could restrict 
actual competition in the Dutch market for hospital care. Following the hospitals’ ap-
plication for a license, the NMa in December 2004 started a more specific and substantial 
assessment of the concentration. For the Netherlands, this is a landmark case since it 
was the first proposed hospital merger that has been subject to a substantive assess-
ment by the NMa and it therefore created a precedent.
Geographic market definition
Based on market research and jurisdiction from other countries (i.e. the US, Germany, 
and New Zealand), the NMa identified two separate product markets: one for inpatient 
and one for outpatient general hospital care. In the first general assessment during the 
notification phase, the Elzinga/Hogarty approach was used for defining the geographic 
market. From this approach it followed that the relevant market was rather small. The 
NMa therefore concluded that patients currently prefer hospitals located close to their 
homes and that, as a consequence, the proposed merger would substantially lessen 
competition (NMa, 2004b). At the same time, it was stated that the Elzinga/Hogarty 
approach was a static test. Further research focusing on where patients could go and 
would be willing to go when given an incentive to do so was therefore concluded to be 
necessary.
Table 2.3: NMa decisions in Dutch hospital merger cases 2004-2008
Merging hospitals Year First stage Second stage
Juliana Kinderziekenhuis/RKZ and Leyenburg 2004 No license required -
Ziekenhuis Hilversum and Ziekenhuis Gooi-Noord 2005 License required License issued
Erasmus MC and Havenziekenhuis 2005 No license required -
Ziekenhuis Walcheren and Oosterscheldeziekenhuizen 2006 License required Application withdrawn
Laurentius Ziekenhuis and St. Jans Gasthuis 2007 No license required -
Vlietland Ziekenhuis and MC Rijnmond Zuid 2007 No license required -
MC Alkmaar and Gemini Ziekenhuis 2007 No license required -
St. Lucas Ziekenhuis and Ziekenhuis Delfzicht 2008 No license required -
Ziekenhuis Walcheren and Oosterscheldeziekenhuizen 2008 License required License issueda
a. In March 2009, the NMa approved this merger in order to “safeguard the quality of basic hospital  
 care” in the central region of the sparsely populated province of Zeeland. To prevent the merged  
 hospital from exercising market power, “strict conditions” have been imposed (NMa, 2009). In this  
 particular merger case the geographic hospital market was not disputed.
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This research was carried out in the licensing phase. First, interviews were carried out 
with general practitioners (GPs),17 other hospitals, and health insurers. Whereas GPs and 
other hospitals expected patients to bypass the merging hospitals when these would 
exercise market power, health insurers did not expect patients’ willingness to travel to 
be high. Second, patients’ stated preferences were investigated by a conjoint analysis.18 
From this analysis it followed that the vast majority of patients would travel to other 
hospitals when the nearest hospital would increase its price or deteriorate its quality. 
These results indicated that the relevant geographic market was larger than initially as-
sumed. Third, econometric simulations using patients’ revealed preferences confirmed 
the initial assumption that the geographic market was rather small. 
Unfortunately for the NMa, the research findings in this merger case were ambiguous. 
Based on the geographic market defined when using stated preference data the merger 
should be allowed, whereas based on the geographic market defined when using re-
vealed preference data the merger should be prohibited. Confronted with these contra-
dictory findings, the NMa concluded as follows. Though in general greater value should 
be attached to revealed preferences, patients’ willingness to travel could be expected 
to increase in the near future due to the increasing availability of consumer information 
about quality differences within the Dutch hospital sector. According to the NMa it was 
therefore “less evident that greater weight should be given to the revealed preferences 
in the assessment of the present case” (NMa, 2005). As a result, the NMa decided there 
were “insufficient grounds” for defining a geographical market that is rather small. Since 
the reverse also holds, this decision reveals that the emphasis here was on avoiding a 
Type I error (prohibiting the merger while it does not restrict actual hospital competi-
tion) rather than on avoiding a Type II error (allowing the merger while it does restrict 
actual hospital competition).
Final decision
All things considered, in June 2005 the NMa decided to clear the merger between both 
hospitals because there was “insufficient evidence to deem it plausible that a dominant 
position will arise or be strengthened as a result of the proposed merger on the markets 
for clinical and non-clinical general hospital care” (NMa, 2005). This conclusion implies 
that indirectly greater weight was given to consumers’ stated preferences – even though 
17 In the Netherlands, patients require a referral from their GP to visit a hospital for non-emergency care.
18 Conjoint analysis deals with situations in which a patient has to choose among hospital options that 
simultaneously vary among two or more attributes. The hypothetical problem facing the patient is how 
to trade off the possibility that hospital X is better than hospital Y on attribute A but worse than hospital 
Y on attribute B, and so on. The goal of conjoint analysis is to determine how much each hospital at-
tribute contributes to patients’ preferences.
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it was admitted that what people say they will do is often not the same as what they will 
actually do if the hypothetical situation becomes reality. Additionally, the expectation 
that Dutch patients’ willingness to travel is likely to increase in the near future due to 
increased transparency is not based on empirical evidence and therefore (highly) specu-
lative. Future analysis of post-merger market outcomes should reveal whether or not the 
NMa erred in this hospital merger case. 
2.5.4 Geographic market definition in recent hospital merger cases
In contrast to the US and German antitrust enforcement agencies, the NMa does not 
appear to follow a consistent approach to defining hospital markets. Whereas in the case 
study discussed above geographic market definition played a central role, in the most 
recent hospital merger cases the NMa simply relied on a rather crude “travel time analy-
sis”. When determining the relevant geographic market, patients’ average travel times to 
both the merging hospitals as well as their potential competitors are computed. When 
it is found that for many patients of the merging hospitals at least one closer or equally 
close hospital alternative is present, the NMa decided the merger is unlikely to result in 
a dominant position. This methodology suffers from at least two major shortcomings. 
First, the heterogeneity of both patients and hospitals is not taken into account while of 
crucial importance when assessing hospital market power (Varkevisser et al., 2008). The 
NMa’s approach focuses solely on travel times, but other factors – such as (perceived) 
quality, waiting time and patients’ personal preferences – are also important when deter-
mining hospitals’ substitutability (Varkevisser et al., 2009). Second, the observation that 
the merged hospital will not have a dominant market position because after the merger 
almost all their patients apparently have at least one other hospital alternative at their 
disposal is far too simple. Most importantly, the presence of one potential competitor is 
not by definition sufficient for effective competition among hospitals.19 Additionally, a 
hospital’s market power is not only affected by the number of competitors but by other 
factors as well, including market shares, the (financial) strength of competing hospitals, 
the presence of capacity constraints or the extent to which the services of the merging 
hospitals are close substitutes. None of these were explicitly taken into account by the 
NMa in recent hospital merger cases. 
19 After empirically examining the relationship between market structure and competition for US hos-
pital markets, Abraham et al. (2007) conclude that besides mergers which take local hospital markets to 
monopoly also mergers resulting in duopoly cause significant harm to consumers.
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2.6 Conclusion
European governments increasingly rely on market-based incentives to improve 
efficiency in their health care system. Preventive merger control is then of crucial im-
portance. To learn from international experiences with hospital merger control, in this 
paper we examined antitrust enforcement practices in three different countries with 
a competitive hospital sector: the United States, Germany, and the Netherlands. For 
each of these countries one recent hospital merger is discussed as being an important 
(national) landmark case. These merger cases are summarised in Table 2.4. 
Based on the international experiences with hospital merger control discussed in this 
paper, two important lessons can be formulated. First, more than in any other industry, 
geographic market definition is the Achilles’ heel of merger control in hospital markets. 
European antitrust enforcement agencies, however, do not necessarily have to struggle 
with this issue as much as their US counterparts. In a managed care setting, which is 
typical for the US, the key issue for geographic market definition is which hospitals man-
aged care organisations need to have in their networks. When hospitals compete for in-
clusion in insurers’ networks the analysis of commonly available patient flow data alone 
for defining hospital markets is inappropriate. However, in a setting where hospitals 
compete directly for patients, which is the case in many European countries, hospitals’ 
substitutability crucially depends on patients’ willingness to travel. Patient flow data 
is then pre-eminently useful for defining geographic hospital markets.20 That is, when 
used properly. The Elzinga/Hogarty approach of expanding a hypothesized market 
until strict thresholds are met for both the imports and exports of hospitals services has 
proven inaccurate and is therefore inappropriate. When analysing where patients have 
gone in the past, antitrust enforcement should rather investigate the particular reasons 
why some patients travel while others do not. Supplemented by an empirical analysis of 
patient hospital choice using revealed preference data (Varkevisser et al., 2008), these 
insights should be used to substantiate any conclusions about other hospitals (not) 
taken into account as feasible alternatives for the merging hospitals. 
Second, recent court decisions in both the US and Germany confirmed that geographic 
hospital markets are rather small. Though the appropriate approach to defining geo-
graphic markets depends on how health insurers contract with hospitals and how 
20 Despite the gradual introduction of managed competition in the Netherlands, hospitals there also 
compete directly for patients through non-price factors. However, patient flow data would become less 
useful for defining Dutch hospital markets if insurer-hospital negotiations over network participation 
and composition increase.
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patients choose their hospital, the results seem to be consistent regardless of the 
prevailing institutions and market structure. In a managed care setting, people require 
health plans to include at least one hospital that is close to where they live which 
makes hospital markets essentially local. In a setting where patients do not commit to 
(restricted) provider networks but choose hospitals when they need care, patient flow 
data show that most patients prefer hospitals nearby. 
To conclude, since empirical studies provide clear evidence that hospital mergers may 
have serious anticompetitive effects while claimed cost savings are most often not 
achieved an asymmetry between the cost of Type I and Type II errors is likely to exist in the 
hospital sector.21 That is, the reduction in social welfare caused by allowing a proposed 
hospital merger that restricts actual hospital competition (Type II error) will generally be 
(far) greater than the reduction in social welfare caused by blocking a proposed hospital 
merger that does not restrict actual hospital competition (Type I error). This asymmetry 
21 Note that such an asymmetry has also been identified for other industries, e.g. Lévêque (2006).
Table 2.4: Summary of recent hospital mergers that are (national) landmark cases
United States Germany The Netherlands
Hospital(s) involved Evanston Northwestern 
Healthcare Corporation
Rhön, Bad Neustadt, and 
Mellrichstadt
Hilversum and Gooi-
Noord
Period 2004-2007 2005-2008 2004-2005
Type Ex post examination of a 
consummated merger.
Ex ante examination of a 
proposed merger.
Ex ante examination of a 
proposed merger.
Size of the relevant 
geographic market 
according to the 
antitrust enforcement 
agency
Limited to the area 
in which a significant 
number of the hospitals’ 
patients reside.
Rather small since patient 
flow data revealed that 
most patients choose 
hospitals nearby.
Ambiguous since the use 
of stated preference data 
indicated a larger area 
than revealed by patient 
flow data.
Conclusion by the 
antitrust enforcement 
agency
The merger substantially 
lessened competition and 
a divestiture is needed to 
restore competition.
The merger would further 
strengthen Rhön’s already 
dominant position and is 
therefore prohibited.
Insufficient evidence that 
the merger would create 
or strengthen a dominant 
position and it is therefore 
cleared.
Final court decision The merger indeed 
substantially lessened 
competition, but in this 
case a conduct remedy is 
more appropriate than a 
divestiture.
The merger would indeed 
further strengthen Rhön’s 
dominant position and is 
therefore prohibited.
-
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is even more acute when identifying the exercise of market power ex post is extremely 
difficult. Since in European countries hospitals typically compete for patients by quality 
rather than price, this observation is particularly relevant there. Even in the US, where 
research on health care quality has become increasingly more sophisticated than in 
Europe, quality issues have not had a major impact on competition law and policy 
because of its complexity and judicial scepticism (Hyman, 2004). In hospital markets 
with quality competition post-merger antitrust enforcement is therefore not likely to 
offer an effective safety net. Hence, it is better for antitrust enforcement agencies to be 
too restrictive when assessing proposed hospital mergers rather than too permissive. 
In addition to the potential welfare costs, being too permissive also prevents the devel-
opment of industry-specific jurisprudence – as the situation in the Netherlands clearly 
illustrates. Without a deeper understanding of how courts tend to deal with the unique 
attributes of hospital markets, information about the evidence required to prevail in 
court is lacking. This may seriously hamper the effectiveness of antitrust enforcement 
in future hospital merger cases. To ensure hospital markets work efficiently, antitrust 
enforcement agencies should thus be willing to litigate hospital mergers aggressively 
and to take the risk of losing a substantial proportion of the cases initiated.
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Abstract 
Effective antitrust enforcement is of crucial importance for countries with a market-based 
health care system in which hospitals are expected to compete. Assessing hospital mar-
ket power – a central issue to competition policy – is, however, complicated because the 
presence of third party payers and the general unobservability of prices make it difficult 
to apply the standard methods of market definition. Alternative, less formal methods 
historically employed in the hospital industry have proven inaccurate. These methods 
were even called inapplicable in a recent US court decision. In this paper we discuss the 
strengths and weaknesses of several new approaches to defining hospital markets that 
are suggested in recent economic literature. In particular we discuss the applicability of 
the time-elasticity approach, competitor share approach, and option demand approach 
to the recently partly deregulated Dutch hospital market. We conclude that the appro-
priate approach depends crucially on how health insurers contract with hospitals and 
how patients select their hospital.
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3.1 Introduction
Market-based health care reforms can only be successful when competition is protected 
by effective antitrust enforcement. A central issue in antitrust enforcement is measur-
ing market power, which typically requires first defining the product and geographic 
markets. Though appropriate market definition is a challenging issue in any industry, 
this is particularly so in the hospital sector. Since hospital prices (both those negotiated 
by health insurers and those faced by patients) are generally not observed, the standard 
SSNIP test for defining markets is difficult to implement here.1 Unfortunately, traditional 
alternative methods for defining hospital markets have proven inaccurate. Courts’ ac-
ceptance of those methods, and the large geographic markets they implied, played a 
significant role in the series of unsuccessful efforts by the antitrust enforcement agen-
cies in the United States to block hospital mergers. Between 1994 and 1999 US antitrust 
enforcement agencies lost six out of seven consecutive hospital merger cases because 
the courts accepted the defendants’ overly broad market definition (Gaynor and Vogt, 
2000). Only recently, in a case involving ex post examination of a consummated hospital 
merger has a set of merging hospitals failed to prevail in court. In that case, won by 
the US Federal Trade Commission (FTC), the presiding administrative law judge called 
the methods traditionally applied to defining hospital markets “inapplicable” (FTC, 2005, 
p.30). This clearly illustrates that antitrust enforcement agencies, both in the US and 
Europe, are in need of new approaches for hospital market definition. 
The aim of this paper is to discuss in general the strengths and weaknesses of several 
new approaches to hospital market definition that are suggested in recent economic 
literature and in particular their applicability to (deregulated) Dutch hospital markets. 
The remainder of the paper is organised as follows. In Section 3.2 we briefly discuss 
defining hospital product markets. Section 3.3 summarises the most important 
shortcomings of the two approaches traditionally used for defining geographic hospital 
markets: the Elzinga/Hogarty approach and critical loss analysis. The methodological 
pros and cons of three new approaches to hospital market definition are discussed in 
detail in Section 3.4: the time-elasticity approach, the competitor share approach, and 
the option demand approach. Section 3.5 focuses on how to define hospital markets in 
the Netherlands. The paper ends with some concluding remarks in Section 3.6.
1 The Small but Significant Non-transitory Increase in Price (SSNIP) test begins by positing a narrowly 
defined market and asking whether a hypothetical monopolist of all firms and products in the posited 
market could profitably implement a small but significant non-transitory increase in price. If the hypo-
thetical monopolist cannot do so, then the proposed market must be defined so narrowly as to exclude 
a close substitute. Thus the market definition should be expanded to include the next closest competitor 
or product. The process is repeated until the SSNIP question is answered affirmative.
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3.2 Hospital product market definition
Assessing market power typically involves two steps: definition of the product market 
and definition of the geographic market. The first has not been nearly as contentious as 
the latter. In US hospital merger cases, the product market has typically been defined 
as a “broad group of medical and surgical diagnostic and treatment services for acute 
medical conditions where the patient must remain in a health care facility for at least 24 
hours for recovery or observation” (DOJ and FTC, 2004). In a recent case, the FTC added 
the phrase “sold to managed care organizations” to this traditional, aggregate product 
market (FTC, 2005, p.27). This addition emphasises that in the US, hospital prices are 
determined during negotiations over network participation and composition between 
insurers and hospitals.
Despite the general lack of debate over the relevant product market, Zwanziger et al. 
(1994) recommend an alternative, disaggregated approach that attempts to capture 
the fact that inpatient care is differentiated. The key issues in their approach are (i) the 
extent to which treatments of two different diseases can be performed with the same 
personnel and equipment, and (ii) the cost for a hospital to convert from providing 
one service to another. Since many hospital services do not require highly specialised 
equipment and/or training, they argue that entry into most disease-specific markets is 
low cost. For many such markets, a hospital needs only add a physician in the appro-
priate specialty to its staff, along with a modest amount of equipment suitable to that 
specialty. They therefore suggest treating the physician as the key input into hospital 
care, and cluster Diagnosis Related Groups (DRGs) into service categories based on the 
least specialised physician capable of treating that disease. Their initial attempt to define 
such product markets resulted in 48 service categories, applicable to each local area, 
and subdivided into primary, secondary, and tertiary categories. Based on their mix of 
patients, each hospital can then be classified as a primary, secondary or tertiary hospital. 
According to Zwanziger et al. (1994, p.439), this provides a method of “bridging the 
disaggregate services categories developed by health services researchers and hospital 
administrators and the overly aggregate one used in most antitrust cases.” Based on 
an examination of two hospital markets in the state of California (San Luis Obispo and 
Sacramento), Sacher and Sylvia (1998) conclude that even a very limited disaggregation 
of the standard inpatient acute care cluster indeed can provide a fuller understanding of 
hospital competition. Nevertheless, the precise effect of the level of aggregation on the 
outcomes of antitrust analyses is unclear. 
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3.3 Traditional approaches to defining geographic markets
Due to the difficulty of implementing the SSNIP test in hospital markets, geographic 
market definition has historically relied heavily upon two alternative, less formal ap-
proaches: the Elzinga/Hogarty approach and critical loss analysis.
3.3.1 Elzinga/Hogarty approach
In many US hospital merger cases, courts relied on patient flow data to define geographic 
markets, using the method introduced by Elzinga and Hogarty (1973). This method is 
easy to apply and only requires commonly available discharge data. It begins with a 
narrowly defined market and then expands the boundary until threshold conditions are 
met for both imports (“little in from outside” = LIFO) and exports (“little out from inside” 
= LOFI) of hospital services:
(3.1) LIFO = 1–
(3.2) LOFI = 1–
In various court cases, the analysis focused on identifying geographic areas such that 
both statistics are either above 75%, or above 95% (Gaynor and Vogt, 2000). 
Overstatement and understatement
As detailed by Werden (1989), the Elzinga/Hogarty (E/H) approach suffers from serious 
methodological shortcomings. As a theoretical matter, use of the LOFI and LIFO criteria 
could either overstate or understate the true size of geographic hospital markets. Over-
statement occurs when hospitals in two areas sell horizontally differentiated products, 
which induces travel for specific (e.g. tertiary) services between those areas. Although 
hospital care is in fact highly differentiated by location and other dimensions, the E/H 
approach would incorrectly conclude that both hospitals are in the same market. In con-
trast, the E/H approach will understate true market size when hospitals in two different 
areas are very close substitutes so that there are no patient flows between them. The 
E/H approach would then incorrectly indicate that the two hospitals are not in the same 
market. Though use of the E/H approach theoretically may lead to geographic markets 
that are too small or too broad, empirical evidence indicates that using patient flow data 
for market definition in practice leads to overly broad hospital markets (e.g. Simpson, 
2003). 
patient outflows
patients living in area
patient inflows
patients treated in area
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The silent majority fallacy
Capps et al. (2001, 2002) argue that the central problem underlying the E/H approach is 
what they label the “silent majority fallacy”: the presence of a set of travellers does not 
necessarily discipline hospitals from exercising market power over the silent majority 
of non-travelling patients. Said another way, in markets with heterogeneous tastes for 
different services, the presence of some travellers with one set of needs does not neces-
sarily restrain the pricing of services to non-travelling patients with different needs. Sup-
pose that 30% of all patients in an area travel significant distances to receive care; this 
does not in any way indicate that the remaining 70% would be willing to similarly travel 
in response to a price increase – the assumption implicit in using the E/H approach. 
Hence, price increases are certainly feasible even in the presence of significant patient 
outflows. Additionally, the use of flow data is even more questionable in a managed care 
setting where patients select their insurers ex ante, before they fully learn their medical 
needs. Ex post, some patients will experience conditions for which they are willing to 
travel – and actually do travel – a great distance to receive care. This, however, in no way 
indicates that at the time of choosing their health insurance they did not place a high 
value on having one or more local hospitals in their provider network. That is, patient 
flows observed ex post cannot be directly translated into insurers’ ex ante bargaining 
power. 
Applicability to antitrust enforcement
Given the shortcomings mentioned above, it is not surprising that the US Department 
of Justice and the US Federal Trade Commission concluded that “[t]o date, the Agencies’ 
experience and research indicate that the Elzinga-Hogarty test is not valid or reliable 
in defining geographic markets in hospital merger cases” (DOJ and FTC, 2004, p.26). As 
already mentioned in the introduction, in a more recent court decision the presiding 
administrative law judge even concluded that patient flow data and the E/H approach 
are “inapplicable” to geographic market definition for a differentiated product such as 
hospital services (FTC, 2005, p.30).2 One might argue that the use of patient flow data 
would be less problematic when disaggregated clusters of hospital services that are 
close substitutes are analysed instead of one aggregate cluster of general acute care 
inpatient hospital services (Section 3.2). This, however, would only solve part of the 
problem since it incorrectly assumes that the only reason the “silent majority fallacy” 
exists is that patients’ propensity to travel differs across types of hospital care. There are, 
2 In an administrative opinion following the respondent’s appeal, the Commission agreed with this 
initial decision (FTC, 2007, p.77/78): “We should view patient flow data with a high degree of caution (…) 
and, at best, we should use it as one potentially very rough benchmark in the context of evaluating other 
types of evidence.”
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however, numerous other reasons why the propensity to travel differs among patients 
(e.g. unobserved personal preferences). Additionally, selecting a non-arbitrary way to 
aggregate the results of disaggregated, service-level E/H analyses would also be prob-
lematic.
3.3.2 Critical loss analysis
Critical loss (CL) analysis, introduced by Harris and Simons (1989), is another widely used 
technique for defining geographic hospital markets. Applying the CL approach to a 
proposed hospital market involves three steps. The first step is to compute the hospitals’ 
contribution margins, defined as price minus average variable costs. In the second step, 
the contribution margin is used to identify the percentage of patients the hospitals 
could lose before a small price increase – 5% is typically used – becomes unprofitable: 
this is the “critical loss.” The final step is to analyse whether the actual loss of patients 
would exceed the critical loss if all hospitals in the proposed market implemented a 
small but significant non-transitory increase in price (SSNIP). If so, then the SSNIP would 
be unprofitable, indicating that the hypothetical geographic market is too narrow and 
should be expanded to include more hospitals. The expected actual loss of patients 
is most commonly assessed using the concept of “contestable zip codes”. That is, it is 
assumed that all patients currently choosing one of the hospitals within the proposed 
market but living in area where many other patients (e.g. 50%) select hospitals outside 
the proposed market would switch to those outside hospitals in response to a price 
increase. Under this assumption CL analysis suffers from exactly the same “silent major-
ity fallacy” as the E/H approach.
“Cellophane fallacy”
Using CL to define geographic hospital markets has been widely criticised in the eco-
nomic literature for several reasons (e.g. Langenfeld and Li, 2001; Katz and Shapiro, 
2003; O’Brien and Wickelgren, 2004). Danger and Frech (2001) detail what is perhaps the 
most important methodological shortcoming of CL analysis: market definition via the 
CL approach is highly sensitive to the initial degree of market power. If price is already 
at the monopoly level, then any further increase in price will by definition result in lower 
profits. The expected loss is then necessarily greater than the critical loss for any price 
increase, since the latter is zero. In such a situation CL analysis would incorrectly lead 
to an overly broad market. This problem is a variation of the well-known “cellophane 
fallacy” where reduction of aggregate market demand or replacement with inferior sub-
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stitutes induced by monopoly prices is confused with substitution that would preclude 
monopoly pricing.3
Applicability to antitrust enforcement
Overall, the pros of applying the CL approach are that it is relatively easy to use and 
intuitively appealing. The most important cons are that it is only easy to do incorrectly 
and that the intuition underlying the CL approach is internally inconsistent and may 
generate false conclusions. Since the cons may well outweigh the pros, “the limitations 
and difficulties of conducting a proper critical loss analysis should be fully considered if 
this method is used to define a hospital geographic market” (DOJ and FTC, 2004, p.26). 
3.4 New approaches to defining geographic hospital markets
In recent years, US economists have proposed several new approaches to defining 
geographic hospital markets. This section discusses the methodological strengths and 
weaknesses of the time-elasticity approach (Capps et al., 2001; 2002), the competitor 
share approach (Capps et al., 2001; 2002), and the option demand approach (Capps et 
al., 2003). Since hospital markets in the Netherlands – and in other European countries 
as well – substantially differ from those in the US, the applicability of these approaches 
to Dutch hospital markets is analysed separately in Section 3.5. 
3.4.1 Time-elasticity approach
Like all the new approaches to hospital market definition, the time-elasticity approach 
is an attempt to indirectly estimate the demand elasticity faced by hospitals. When hos-
pital prices are not observed directly or when possible price differences across hospitals 
are irrelevant to patients, non-monetary factors such as travel time are likely to function 
as “prices” (Acton, 1975). 
The key questions underlying geographic market definition – and merger analysis as 
its primary application – are the degree of substitutability among (i) the merging hos-
pitals, (ii) the merging hospitals and other hospitals in the hypothetical market, and (iii) 
hospitals inside and hospitals outside of this market. Ideally one would like to identify 
the hospital and group level price elasticities of demand to answer each of these ques-
tions. The same questions, however, can also be answered, at least qualitatively, by using 
3 The theoretically correct test should not ask whether a hypothetical monopolist could increase prices 
relative to current prices, but rather relative to competitive prices (Motta, 2004, p.105). Of course, since 
these prices are typically not observed this is rather complicated. 
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time-elasticities. Within a logit demand framework the probability that patient i chooses 
hospital j is estimated using (i) patient i’s characteristics, (ii) hospital j’s attributes, and 
(iii) characteristics specific to the combination of patient i and hospital j, specifically 
travel time. To solve the “silent majority fallacy”, or at least greatly reduce its impact, 
this approach focuses explicitly on the substitutability of hospitals taking both patient 
heterogeneity and hospital differentiation into account.
Parameter estimates from a patient choice model are used to simulate the effects of 
artificially raising travel time from every patient to a particular hospital by a certain 
percentage (e.g. 5%), holding all other hospital attributes constant. To assess a merger, 
the effects of increasing travel time to a pair of hospitals simultaneously are compared 
to the effects of increasing travel time to each hospital individually. If the time-elasticity 
under jointly increased travel times is much lower than under individual travel time 
increases, then the hospitals are close substitutes and thus more likely to have market 
power post-merger. Under the simplifying assumption that consumers are willing to 
trade time for money at a constant rate,4 price elasticities are directly proportional to 
time elasticities.5 In conjunction with the inverse-elasticity pricing rule, this implies that 
margin increases resulting from a merger are directly proportional to reductions in time-
elasticity under joint travel time increases vis-à-vis unilateral travel time increases. Table 
3.1 illustrates how time elasticities can be used to define geographic hospital markets in 
merger cases. The same methodology is readily adapted to defining geographic markets 
in non-merger cases. Market definition then requires identifying the smallest set of hos-
pitals such that a simultaneous travel time increase to all hospitals in the set would lead 
to relatively little substitution to outside hospitals.
Although the assumption of direct proportionality between price and time elasticities 
underlying the time-elasticity approach is quite strong and has to be tested empirically 
(e.g. by stated preference research), the approach could definitely serve a useful role in 
assessing hospital market power. Particularly for hospital markets where patients do not 
face any monetary prices or where information on actual hospital prices is not readily 
available. Even when time elasticities would not be directly proportional to price elas-
ticities, it is reasonable to assume that patients are willing to trade travel time for money 
at an unknown (and possibly non-linear) rate. Therefore estimated time elasticities are at 
least indicative of hospitals’ market power. 
4 That is, if patients are willing to travel five more minutes to save €50, then they are willing to travel ten 
more minutes to save €100. 
5 If utility is linear in both time and income then there is a linear relationship between price elasticities 
and time elasticities. See Appendix 1 of Capps et al. (2001) for the mathematical proof of this lemma. 
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3.4.2 Competitor share approach
The competitor share (CS) approach focuses on the degree of overlap in the type of 
patients hospitals treat. By definition this approach uses a less aggregated hospital 
product market definition than commonly applied in hospital merger cases (Section 
3.2). In contrast to the conceptually similar but reduced form disaggregated approach of 
Zwanziger et al. (1994),6 the CS approach does have a theoretical underpinning: it builds 
up from the notion that hospital prices are a function of the underlying service-level 
demand elasticities. It uses a logit demand framework to derive an exact expression 
for a hospital’s price elasticity, which can be rewritten as a function of other hospitals’ 
market shares competing for the same patients.7 This implies that the increase in price 
two hospitals can obtain by merging (or colluding) depends on the degree of overlap 
in patients. Consider the extreme example of a market with three hospitals, each admit-
ting the same number of patients. Further, suppose there are only two types of hospital 
care patients could need: service 1 or service 2. Under these hypothetical circumstances 
the anticompetitive effect of a merger between any two hospitals will depend not on 
their aggregate market shares (33.3% each), but rather on their market shares in the 
submarkets 1 and 2 as well as the relative sizes of each submarket. The merger would 
not be anticompetitive if one hospital treats only type 1 conditions and the other only 
type 2. Alternatively, if the merging hospitals only overlap in type 1 patients but such 
patients are rare, then the aggregate price effects of a merger may also be negligible. 
As there are many services in hospital markets, the empirical challenge is to quantify 
6 Implementations include Keeler et al. (1999), Dranove and Ludwick (1999), and Capps and Dranove 
(2004).
7 The mathematical details of the CS approach are in Capps et al. (2001).
Table 3.1: Using time elasticities to define geographic hospital markets
Scenario Relevant question Answers from empirical simulation
Artificially raise travel time to 
hospital j
Many patients switch to 
hospital k?
Yes Yes
Artificially raise travel time to 
hospital k
Many patients switch to 
hospital j?
Yes Yes
Artificially raise travel time to 
hospital j and k simultaneously
Almost all patients stay 
with hospital j or k?
Yes No
Conclusion: Hospitals j and k are 
close substitutes and 
there are no other 
competitors in the 
relevant market. 
Hence, a merger 
between these two 
hospitals is likely to be 
anticompetitive.
Hospitals j and k are 
close substitutes, but 
there are also other 
competitors in the 
relevant market. Hence, 
a merger between 
these two hospitals 
is not likely to be 
anticompetitive.
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the extent of submarket overlap between a pair of hospitals and then map that into 
predicted merger effects.
To implement this, each hospital is modelled as setting a different price for each possible 
submarket – defined as an insurer-hospital service pair. To assess the likely effects of 
a merger, the difference in demand elasticity two hospitals face when pricing jointly 
instead of unilaterally is calculated. In general, the elasticity reduction under joint pric-
ing, and therefore the expected price increase, will be greater as the overlap between 
two hospitals in the various submarkets is greater. This methodology is also readily 
applicable to defining geographic markets in non-merger cases. Market definition then 
requires identifying the smallest set of hospitals such that a hypothetical joint price 
increase would lead to relatively little substitution to outside hospitals.
An important drawback of the CS approach is that it assumes hospitals charge insurers 
or their patients a different price for each hospital service. In the US and many other 
countries this assumption is only partially accurate since hospitals are commonly paid 
by per diem rates or case rates, rather than fee for service.8
3.4.3 Option demand approach 
Whereas both the time-elasticity approach and competitor share approach assume that 
patients select their hospitals when they need care, in a managed care setting patients 
commit to a potentially restricted network of hospitals prior to knowing their medical 
needs fully. The option demand (OD) approach was developed specifically to model 
markets in which managed care organisations (MCOs) contract with hospitals.9
Willingness-to-pay
The objective of the OD approach is to calculate each consumer’s ex ante willingness-
to-pay (WTP) for inclusion of a particular hospital in an MCO’s network. This is his WTP 
for a particular hospital at the beginning of the year when he selects his MCO, but prior 
to falling ill and requiring hospital care. Consumer i’s interim WTP (i.e. after knowing 
his health status but before evaluating hospital alternatives) for the option to select 
8 Hospitals reimbursed under a per diem system typically charge a single daily rate for general medical/
surgical admissions, a higher rate for intensive care unit days, and perhaps a small number of additional 
daily rates for other classes of services. Under a case rate system, reimbursement varies with the patient’s 
diagnosis (as measured by the patient’s Diagnosis Related Group, or DRG), but the payment is prospec-
tive and does not vary with the services actually rendered. Only fee for service reimbursement matches 
the assumption that patients or their insurers pay a different price for each hospital service.
9 The mathematical details of applying the OD approach to hospitals markets are in Capps et al. (2003). 
A similar approach is also described in Town and Vistnes (2001). 
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hospital j from an MCO’s network G is computed as his decrease in expected interim 
utility (VIU) when that hospital is removed from the network: 
(3.3) ΔVIUj = VIU(G) – VIU(G/j)
where (G/j) denotes network G with hospital j excluded. Converting this difference to 
monetary terms gives the consumer’s interim WTP (i.e. his WTP conditional upon know-
ing his illness) to retain that hospital as a feasible option. Each consumer’s ex ante WTP to 
include hospital j in the network is constructed as the sum over all possible conditions of 
the product of (i) his interim WTP for that hospital conditional upon a particular diagno-
sis, and (ii) the probability that, given his demographics and location, he will draw that 
particular diagnosis during the coming year. The population’s WTP to include hospital 
j in the network is obtained by summing the ex ante WTP for all individual consumers. 
The OD model uses the empirical joint density of the demographics, clinical indications, 
and locations to determine each patient’s distribution of clinical states conditional on 
his socio-economic characteristics and the geographical location of his home. Though 
necessary from an empirical perspective, this assumption may be questionable for two 
reasons. First, from the risk adjustment literature it follows that patient i’s probability of 
requiring hospitalisation in the year to come cannot be predicted accurately by using 
only his demographics and location (Van de Ven and Ellis, 2000). Second, the assump-
tion itself that each patient is able to ex ante predict his probability of being sufficiently 
ill during the next year to require hospitalisation seems quite strong.
Bargaining power and hospital profits
In deregulated hospital markets MCOs negotiate with hospitals over prices. Consumers 
make their choice among competing health plans on the basis of insurance premiums 
and the value each MCO’s network provides to them. The potential gain hospital j and an 
MCO can obtain and split is the difference between consumers’ ex ante WTP for inclusion 
of hospital j and the additional costs or benefits its inclusion causes: 
(3.4) ΔWTPEAj(G) – ΔCj(G)
The proportion of this surplus hospital j captures depends on the relative bargaining 
power of the hospital and the MCO. For example, a favourable location and/or other fa-
vourable characteristics give hospitals leverage against an MCO’s attempts to negotiate 
a low price. Although restrictive, Capps et al. (2003) assume that each hospital captures 
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the fixed proportion α of this gain.10 Since economically rational hospitals will only ac-
cept an MCO’s contract if its price at least covers variable costs, the contribution hospital 
j earns towards fixed costs and profit from the managed care segment of its business is
(3.5) πj = α[ΔWTPEAj(G) – ΔCj(G)] + uj
where πj denotes a hospital’s incremental contribution above variable costs. 
If consumers’ WTP is indeed an appropriate measure of hospitals’ market power, then it 
should be strongly positively correlated with profits. Capps et al. (2003) validated this 
hypothesis. First, they estimated a logit patient choice model to recover the param-
eters of the utility function. Second, they used the estimated parameters to construct 
estimates of the probability that patient i chooses hospital j, which in turn are used to 
calculate consumers’ aggregate WTP for a hospital. Third, they regressed profits from 
managed care patients on WTP in order to estimate the parameter α that translates WTP 
into profits. 
Geographic market definition
The WTP measure obtained by estimation of the OD-model can be used to predict how 
prices will change if two or more hospitals would act as a single entity, holding costs 
constant. In managed care markets, (merged) hospitals may increase their prices by 
coordinating their decision to join an MCO. Intuitively, hospitals will do much “better” 
when acting jointly if their simultaneous withdrawal imposes a much larger decrease in 
consumers’ WTP for an MCO’s network than either could impose unilaterally. Using the 
WTP measure of market power for antitrust geographic market definition requires two 
steps.
The first step is to estimate the increase in profit that hospitals can obtain by acting 
as a single entity. A set of hospitals’ joint WTP is likely to be large when they are close 
substitutes and consumers do not have an alternative closely substitutable hospital. 
Under such circumstances hospitals j and k’s joint WTP may greatly exceed the sum of 
their individual WTPs because losing access to both j and k is then far worse than losing 
access to either j or k alone. The formula for estimating the profit effect of a merger 
between two hospitals is
(3.6) Δπj+k = α[ΔWTPEAj+k(G) – ΔWTPEAj(G) – ΔWTPEAk(G)]
10 It is possible to incorporate more sophisticated bargaining models, such as the model of intra-firm 
bargaining in Stole and Zwiebel (1996). 
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where α is the coefficient on WTP estimated by regressing hospital profits on consumers’ 
WTP. The additional leverage two hospitals obtain by working together is the difference 
between their joint WTP and the sum of their individual WTPs. Because consumers’ ex 
ante utility (weakly) increases when they have more options for their hospital care this 
difference is, by definition, equal to or greater than zero.11 This difference will be smaller 
when hospitals j and k are not closely substitutable while other hospitals are, and vice-
versa.
The second step in defining the geographic market is to estimate the associated change 
in prices. Following the SSNIP guidelines, this exercise is conducted under the assump-
tion that the merger does not affect costs.12 As the SSNIP question is generally formu-
lated in terms of prices rather than profits, the expected percentage increase in profits 
derived from the OD model is translated into an expected percentage increase in price 
by assuming quantity is unchanged. This price change reflects the increase in average 
revenue necessary to generate the predicted increase in profits, under the assumption 
that (i) the number of patients and (ii) the average cost at each hospital do not change 
as a result of the merger. In their original paper, Capps et al. (2003) simply regressed 
hospital profits on consumers’ ex ante WTP to estimate the dollar value of additional 
units of WTP. For example, if each unit of WTP is worth an additional €5,000 in profit 
and for a merger of hospitals j and k ∆WTPEAj+k is estimated to be 2,500 then the merger 
would increase joint profits by €12.5 million. This additional profit would come about 
due to higher prices at hospitals j and k. Because most patients’ marginal payment does 
not depend on which contracted hospital they choose, higher hospital prices charged 
to third party payers will not affect patients’ hospital choice decisions. This implies that 
a price increase should not affect quantity. Given this, the effect of a merger on aver-
age revenue is computed by dividing the revenue change by the combined number of 
admissions. Table 3.2 illustrates this.
Using the OD approach for geographic market definition in merger and non-merger 
cases is straightforward: identify the smallest set of competitors such that the implied 
increase in profits should these hospitals set prices jointly exceeds some threshold (e.g. 
5%).
11 Although the WTP to pay for a particular hospital is weakly decreasing in the size of the network, 
assuming free disposal, patients would never pay more for fewer options.
12 The objective of this exercise is to identify the geographic market, not whether the merger is, on net, 
beneficial or harmful. The latter question is addressed after the market is defined.
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3.5 How to define relevant hospital markets in the Netherlands?
In the previous sections we discussed the general pros and cons of several new ap-
proaches to hospital market definition. Since the current market-based health system 
reform in the Netherlands calls for effective antitrust enforcement, we now focus on 
defining markets for Dutch hospitals. 
3.5.1 Hospital product markets
As explained in Section 3.2, the appropriate level of hospital service aggregation de-
pends on the extent to which hospitals are able to shift personnel, equipment, and other 
inputs across service categories. Using this concept of substitution in supply Zwanziger 
et al. (1994) argue that the physician should be considered as the key input into hospital 
care. Therefore a key factor for determining the appropriate level of (dis)aggregation 
of hospital services seems to be the extent to which the hospital management can 
substitute one type of medical specialist for another. 
Contrary to US hospitals, Dutch hospitals have a “closed” medical staff in which the only 
way a physician can join a hospital’s staff is to be accepted by the incumbent medical 
group and the hospital management.13 Most Dutch medical specialists are self-employed 
entrepreneurs organised in partnerships per specialty, which are represented at the 
13 US hospitals typically have an “open” medical staff, which offers the hospital management more 
opportunities to hire and fire medical specialists. For example, the Federal Trade Commission and the 
Department of Justice summarised their views on hospitals’ discretion over physician privileges as fol-
lows (DOJ and FTC, 2004, p.27): “Generally speaking, antitrust law does not limit individual hospitals from 
unilaterally responding to competition (…) by terminating physician admitting privileges.”
Table 3.2: Using WTP to estimate the effects of a merger (hypothetical example)
Hospital Admissions
Total 
revenue
Revenue per 
admission
Consumers’ 
ex ante WTP
Hospital j 6,000 €45.0 mln. €7,500 9,000
Hospital k 3,000 €25.0 mln. €8,333 5,000
j+k, pre-merger 9,000 €70.0 mln. €7,778 14,000
j+k, post-merger 9,000 €82.5 mln. €9,167 16,500
Estimated merger effects:
ΔWTPEAj+k
ΔREVENUEj+k
2,500
+17.9%
€12.5 mln.
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hospital level. Though the hospital board has the formal power to admit new physicians, 
it is largely dependent on the co-operation of the medical specialists (Scholten and Van 
der Grinten, 2002; 2005). Once accepted, new medical specialists sign an “admission 
contract” with the hospital. The terms of this contract are based on a uniform model 
contract, formulated by the national association of medical specialists. Most admis-
sion contracts are permanent (valid until the age of 65) and cannot be terminated by 
the hospital, except for forceful reasons such as malpractice, (mental) illness or loss of 
license. As a consequence, most Dutch medical specialists have a lifetime affiliation with 
a single hospital. The rigid admission contracts make it difficult for hospital manage-
ment to substitute one type of medical specialist for another. The limited possibilities for 
physician input substitution imply that two Dutch hospitals offering different services 
cannot readily compete by adjusting their product mix. Thus, in contrast to the US, a 
more disaggregated approach to hospital product market definition may be appropri-
ate in the Dutch context. This does not imply, however, that each specialty constitutes 
a separate relevant product market. From an antitrust perspective, medical specialties 
may be analysed as a group if “there is no compelling reason to believe demand and 
supply substitution opportunities, entry conditions, or market shares differ significantly” 
(Baker, 1988, p.138).
Varkevisser et al. (2004) apply this pragmatic approach to non-emergency care in Dutch 
hospitals. Taking into account each medical specialty’s complexity, volume of patients, 
and potential economies of scale and scope, they identify five different economically 
homogeneous specialty clusters that could be used for antitrust analysis: (1) medical 
specialties that are or could be provided by general hospitals as well as specialised 
health providers such as specialty hospitals and/or stand-alone ambulatory surgery 
centres, (2) high-volume complex medical specialties, (3) low-volume complex medi-
cal specialties, (4) high-volume regular medical specialties, and (5) low-volume regular 
medical specialties. The results of their analysis are summarised in Table 3.3.
3.5.2 Geographic hospital markets 
As discussed in Section 3.4, three new approaches to defining geographic hospital 
markets are suggested in recent economic literature: the time-elasticity approach, the 
competitor share approach, and the option demand approach. The assumptions un-
derlying each of these approaches, summarised in Table 3.4, determine their suitability 
for defining Dutch hospital markets. The two critical factors that determine how well 
each approach fits with the prevailing market structure are (i) how Dutch health insurers 
contract with hospitals and (ii) how patients select their hospital. 
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Table 3.3: Pragmatic approach to economically homogeneous specialty clusters
Complexity? Regular Regular Complex
Feasible in specialty hospitals 
and/or ambulatory surgery 
centres?
Yes No No
High volume Cardiology
Surgery
Dermatology
Internal medicine
Paediatrics
Ophthalmology
Orthopaedics
Cosmetic surgery
Gastroenterology 
Gynaecology & 
obstetrics
ENT
Urology
Pulmonary medicine 
Neurology
Low volume Allergology 
Dental surgery
Nuclear medicine
Radiotherapy
Rheumatology
Geriatrics
Neurosurgery
Source: Varkevisser et al. (2004, p.80)
Table 3.4: Key features of three new approaches to hospital market definition
Time-elasticity 
approach
Competitor share 
approach
Option demand 
approach
How do hospitals 
compete?
Patients select their 
hospital when they 
actually need care. When 
selecting their hospital 
patients do not face 
monetary prices (or 
prices do not vary across 
hospitals).
Patients select their 
hospitals when they 
actually need care. When 
selecting their hospital 
patients face monetary 
prices that differ across 
hospitals.
Patients commit to a 
network of hospitals 
before knowing their 
medical needs fully. 
Insurers market health 
plans with (restricted) 
provider networks.
Crucial assumption(s)? Since out-of-pocket 
payments are absent 
or do not differ across 
hospitals, actual 
transaction prices are 
not relevant for patient 
hospital choice. Travel 
time functions as a “price” 
for quality differences.
Hospitals charge insurers 
(or their patients) 
different prices for each 
hospital service category. 
Each hospital’s price 
elasticity is therefore a 
function of its underlying 
service-level demand 
elasticities.
Insurers negotiate with 
hospitals over prices. The 
financial gain hospitals 
and insurers can split 
by bargaining depends 
on consumers’ ex ante 
WTP for inclusion of a 
particular hospital in 
their network.
How can this approach 
be used for geographic 
market definition?
Time-elasticities are 
assumed to be (directly 
proportional) related 
to price-elasticities. By 
artificially raising travel 
time, expected demand 
responses can be 
simulated.
The difference in demand 
elasticity is simulated 
when hospitals set prices 
jointly as opposed to 
unilaterally. This elasticity 
reduction depends on 
the hospitals’ degree of 
geographic and service 
overlap. 
Hospitals’ joint WTP 
determines the 
additional profit they 
can gain by working 
together. If hospitals 
are close substitutes 
(i.e. strong competitors) 
then their joint WTP will 
significantly exceed the 
sum of individual WTPs.
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Insurer-hospital contracting in the Netherlands
In a managed care setting health insurers, rather than individual patients, appear to be 
the relevant hospital customers from an antitrust perspective. In an environment with 
managed care and selective contracting, the option demand (OD) approach accurately 
depicts hospital competition. Despite the (gradual) introduction of managed competi-
tion since 2005 in the Netherlands (Schut and Van de Ven, 2005), the OD approach is 
currently less suitable for defining Dutch hospital markets than it may appear. The new 
Health Insurance Act allows health insurers to selectively contract with hospitals. So far, 
however, this option has hardly been used: health insurers do not offer contracts with 
restricted provider networks. There are several reasons for the absence of selective con-
tracting (Varkevisser et al., 2006). First, health insurers have very limited experience with 
bargaining and information about differences in quality and efficiency across hospitals 
is lacking. Second, due to the absence of reliable performance indicators, consumers 
seem to distrust any contracting policy that restricts their freedom of choice. Third, 
insurers are only allowed to negotiate prices for a minority of total hospital services. 
Using the OD approach’s WTP measure for geographic market definition may also be 
problematic from an empirical perspective since it requires an estimate of the increase 
in profits that hospitals can obtain by acting as a single entity. To estimate hospitals’ 
monetary value of additional units of consumers’ WTP hospital profits are regressed on 
aggregated WTP. In the Netherlands, however, most hospital care is still price-regulated, 
and all Dutch hospitals have a not-for-profit status. As a result, any empirical relationship 
between WTP and profits does not (necessarily) reflect differences in hospitals’ attrac-
tiveness to either insurers or patients. 
Based on the arguments mentioned above, we believe that the OD approach does not 
accurately depict the current competition in Dutch hospital markets. Except for the 
likely difficulty obtaining suitable data, however, it could be useful for analysing hospital 
competition in the deregulated sub-market if insurers begin selectively contracting for 
these services. If the new Dutch health system evolves such that more prices are actu-
ally determined during insurer-hospital negotiations over network participation and 
composition, then the model of OD will become more appropriate. 
Patient hospital choice in the Netherlands
Since patients do not commit to a potentially restricted network of hospitals before 
knowing their medical needs fully, they select their hospital when they actually need 
medical care. Both the competitor share (CS) approach and the time-elasticity approach 
use this assumption. The CS approach further assumes out-of-pocket payments vary by 
procedure and hospital so that patients are – at least to some extent – price sensitive. 
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However, almost all Dutch citizens are fully insured for hospital care. Only 5 percent of 
the population opted for a small voluntary deductible, ranging from €100 to €500. More-
over, for the Dutch formerly privately insured Van Vliet (2004) found that the demand 
for hospital care is minimally affected by the level of deductible. The CS approach’s as-
sumption that hospitals charge different prices for each hospital service category is also 
inaccurate for the Netherlands. First, most hospital prices are still fixed and therefore not 
subject to insurer-hospital bargaining at all. Second, in the deregulated part of the hos-
pital market insurers and hospitals usually bargain one uniform discount for all hospital 
services in question (NZa, 2006). In sum, the CS approach – like the OD approach – does 
not (yet) depict actual competition among Dutch hospitals and is therefore at present 
not the most appropriate approach to defining hospital markets. 
Since Dutch hospitals compete with each other directly for patients through non-price 
factors only – such as travel time (i.e. location), hospital waiting time, and (perceived) 
quality of care – the time-elasticity approach seems at present the appropriate approach 
to defining hospital markets in the Netherlands. Its application in both merger and 
non-merger cases is simple in principle: identify the smallest set of hospitals such that 
a simultaneous and hypothetical travel time increase to all hospitals in the set would 
lead to relatively little substitution to outside hospitals.14, 15 The time-elasticity approach, 
however, does require estimating a patient choice model. Though challenging in any 
hospital market, this is particularly so in Dutch hospital markets since reliable data on 
patient characteristics and hospital attributes are not (yet) widely available.16 The lack 
of data on observed hospital quality may seriously hamper estimation of a model that 
correctly predicts patient flows if it is an important determinant of consumer choice 
(Tay, 2003). Varkevisser and Van der Geest (2007) find that hospital attributes reflecting 
(perceived) quality significantly affect patients’ decisions to visit or bypass the nearest 
hospital in the Netherlands. Therefore, crucial questions are which quality dimensions 
patients recognize and how they act upon any differences. More research is definitely 
needed in this area.
14 Capps et al. (2002) show that, despite its simplicity, this approach yields results consistent with those 
of the theoretically more sophisticated CS and OD approach. This is perhaps not surprising, given the 
common underlying logit demand structure.
15 Since the approach focuses on travel times that are exogenous to hospitals rather than market deter-
mined prices, the well-known “cellophane fallacy” is avoided. That is, the defined market does not include 
hospitals which only impose an apparent “competitive” constraint due to the fact that current prices at 
the hospital(s) at investigation are already above competitive levels.
16 Additionally, Dutch hospitals markets are currently in transition, so that revealed preference data 
needed to estimate a model of patient choice are not necessarily indicative of future behaviour. 
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3.5.3 Recent hospital merger cases
Though the Dutch hospital industry was already quite concentrated (Varkevisser et al., 
2004) the Netherlands Competition Authority (NMa) from 2004 to 2007 has permitted all 
hospital mergers that required approval – without providing an exact definition of the 
relevant market (Table 3.5). Since there was clearly no need for the defendants to chal-
lenge the outcomes, there are no Dutch court decisions on hospital market definition. 
Table 3.5: Hospital merger cases in the Netherlands 2004-2007a
Merging hospitals Year Product 
market(s)
Geographic 
market
Conclusion
Juliana Kinderziekenhuis/Rode Kruis 
Ziekenhuis and Ziekenhuis Leyenburg
2004 Inpatient and 
outpatient general 
hospital care
EH-test: 
no exact definition 
Initial 
investigation: 
license is not 
required
Ziekenhuis Hilversum and Ziekenhuis 
Gooi-Noord
2005 Inpatient and 
outpatient general 
hospital care
EH-test, 
time-elasticity 
approach, and 
conjoint analysis: 
no exact definition
Permitted after 
a substantive 
assessment 
Erasmus MC and Havenziekenhuis 2005 Inpatient and 
outpatient general 
hospital care
EH-test: 
no exact definition
Initial 
investigation: 
license is not 
required
Ziekenhuis Walcheren and 
Oosterscheldeziekenhuizen
2006 Inpatient and 
outpatient general 
hospital care
EH-test and 
patient travel time 
analysis
Initial 
investigation: 
license is requiredb
Laurentius Ziekenhuis and 
St. Jans Gasthuis
2007 Inpatient and 
outpatient general 
hospital care
Patient travel time 
analysis: 
no exact definition
Initial 
investigation: 
license is not 
requiredc
Samenwerkende Schiedamse en 
Vlaardingse Ziekenhuizen and MC 
Rijnmond Zuid
2007 Inpatient and 
outpatient general 
hospital care
Patient flow data: 
no exact definition
Initial 
investigation: 
license is not 
requiredc
MC Alkmaar and Gemini Ziekenhuis 2007 Inpatient and 
outpatient general 
hospital care
Patient travel time 
analysis: 
no exact definition
Initial 
investigation: 
license is not 
required
Notes:
a. Prior to 2004 the NMa did not assess hospital mergers since, according to the competition authority, 
there was no scope for competition among hospitals.
b. During the substantive assessment, the hospitals in 2007 withdrew their application for a license. 
Following a new application, the NMa in 2009 approved the merger subject to conditions.
c. Though permitted, this merger has not been consummated.
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Only for the merger between the two general hospitals Hilversum and Gooi-Noord the 
geographic market has been assessed substantively. After an initial investigation in 
2004, the NMa concluded that a license was required for this proposed merger, since 
it could restrict actual competition in the Dutch market for hospital care. Following the 
hospitals’ application for a license the NMa carried out further research. With respect 
to definition of the product market a division into separate markets for inpatient and 
outpatient general hospital care was assumed. Since it was recognised that the static 
E/H approach used in previous hospital merger cases was “not sufficiently reliable” for 
geographic market definition, both patients’ revealed and stated preferences were 
analysed. Stated preferences were investigated by a conjoint analysis and revealed 
preferences by examining residents’ willingness to travel to alternative hospitals. 
The results from these analyses were not unambiguous: the use of stated preference 
data resulted in a larger geographic market than the use of revealed preference data. 
It was argued that although in general greater value should be attached to revealed 
preferences, patients’ willingness to travel could be expected to increase in the near 
future due to the increasing availability of transparency information on quality differ-
ences within the Dutch hospital sector. As a result, the NMa (2005, p.29) stated “it is 
therefore less evident that greater weight should be given to the revealed preferences 
in the assessment of the present case.” In the end, in June 2005 the NMa approved the 
proposed merger since there was “insufficient evidence to deem it plausible that a 
dominant position will arise or be strengthened as a result of the proposed merger on 
the markets for clinical and non-clinical general hospital care.” This conclusion implies, 
indirectly, that greater weight was given to consumers’ stated preferences; even though 
it was admitted that what people say they will do is often not the same as what they will 
actually do if the hypothetical situation becomes reality. Future analysis of post-merger 
market outcomes should demonstrate whether or not the NMa erred in this specific 
merger case. 
3.6 Concluding remarks 
Assessing hospital market power is a serious problem for antitrust authorities: the 
standard method for market definition is difficult to implement in hospital markets and 
alternative, less formal methods have proven inaccurate. Since an effective competition 
policy is of crucial importance to countries with a market-based health care system in 
which hospitals are expected to compete, antitrust enforcement agencies need new 
approaches to defining hospital markets. 
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In this paper we discuss three such approaches suggested in the recent economic litera-
ture: the time-elasticity approach, competitor share approach, and option demand ap-
proach. Since these methods were developed within the context of US hospital markets, 
we also examine their applicability in the Dutch context where, since partial deregula-
tion in 2005, health insurers are now allowed to selectively contract with hospitals. We 
conclude that the suitability of these new approaches to defining geographic markets 
crucially depends on the hospital industry’s prevailing institutions and market structure.
With regard to hospital product market definition, in the Netherlands a more disag-
gregated definition seems appropriate than in the US because the lifetime hospital staff 
privileges for Dutch medical specialists make it difficult for hospitals to adjust their prod-
uct mix. The appropriate approach to defining geographical hospital markets depends 
on how health insurers contract with hospitals and how patients select their hospital. 
We conclude that the competitor share approach and the option demand approach do 
not accurately depict the way Dutch hospitals currently compete. Despite the gradual 
introduction of managed competition in 2005/06, most hospital prices are still fixed, 
out-of-pocket payments are absent, and most patients do not face restricted hospital 
networks. Dutch hospitals therefore compete directly for patients through non-price 
factors only, such as travel time and (perceived) quality. As a result, in the current context, 
the time-elasticity approach seems to be the appropriate approach to defining hospital 
markets in the Netherlands. However, if the expected further deregulation of hospital 
prices is implemented and insurer-hospital negotiations over network participation and 
composition increase, the option demand approach may become more appropriate.
Though the focus of this paper is on defining hospital markets, it includes two important 
lessons for other types of health care as well. First, given their methodological short-
comings, the traditional approaches to defining geographic markets (Elzinga-Hogarty 
approach and critical loss analysis) are inaccurate and therefore inapplicable. Second, 
the appropriate approach to market definition in any deregulated health care market 
depends crucially on (i) how health insurers contract with providers, and (ii) how pa-
tients select their provider.
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Abstract
Using data for 2003, we find that both for non-emergency orthopaedic care (38%) and 
neurosurgery (54%) numerous Dutch patients did not visit the nearest hospital. Our 
estimation results show that extra travel time negatively influences the probability of 
hospital bypassing. Good waiting time performance by the nearest hospital also sig-
nificantly decreases the likelihood of a bypass decision. Patients seem to place a lower 
negative value on extra travel time for orthopaedic care than for neurosurgery. The 
valuation of shorter waiting time also varies between these two types of hospital care. 
A good performance of the nearest hospital on waiting time decreases the likelihood 
of a bypass decision most for neurosurgery. In both samples, patients are more likely 
to bypass the nearest hospital when it is a university medical centre or a tertiary teach-
ing hospital. Patient characteristics, such as age and social status, are also found to 
significantly affect hospital bypassing. From our analysis it follows that both patient and 
hospital care heterogeneity should be taken into account when assessing the substitut-
ability of hospitals.
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4.1 Introduction
Patients’ decisions which hospital to visit have been debated in the health economics 
literature for several decades. Empirical studies were aimed initially at health planners 
and hospital administrators, since effective planning and management of health care 
require models that explain and predict regional hospital utilisation (Lee and Cohen, 
1985). In the late eighties, however, a wider range of people became interested in which 
factors influence patient choice among hospitals. In particular health insurers who are 
marketing health plans with a limited set of providers need to know the attributes that 
affect the choice of hospital. Since many developed countries are experiencing the 
urgency of an incentive-based health system reform and start to deregulate hospital 
markets (Cutler, 2002), such knowledge is becoming increasingly important. The inter-
national health policy virus of “reform” also affects Europe; health insurers and patients 
now have greater freedom of choice in many EU member states (Maynard, 2005). In the 
Netherlands, competing health insurers are now allowed to contract selectively. Since 
February 2005 they are able to negotiate contracts with individual hospitals (Schut and 
Van de Ven, 2005). 
Research on patient decision behaviour is especially important for health insurers in 
deregulated hospital markets. Experience from the United States shows that insurers’ 
bargaining clout depends crucially on their ability to channel patients to hospitals with 
which favourable discounts have been negotiated (Sorensen, 2003). For patients, such 
channelling may imply that they have to bypass the nearest hospital and travel to a 
more distant hospital. As patients generally dislike travelling, it can reasonably be as-
sumed they would be willing to bypass the nearest hospital for particular reasons. For 
example, higher quality of care or shorter waiting times may compensate patients for 
the inconveniences of increased travel time (Montefiori, 2005). 
This paper is the first empirical analysis of actual hospital visits in the Netherlands (re-
vealed preferences). Using individual patient level non-emergency hospital utilisation 
data for the year 2003, we estimate a logit model to assess which patient characteristics 
and hospital attributes affected decisions to visit or bypass the nearest hospital. To take 
the heterogeneity of hospital care into account, we analysed two different medical spe-
cialties: orthopaedic care, reflecting a regular type of hospital care, and the more sophis-
ticated medical specialty of neurosurgery. Differences in medical complexity between 
these two types of care can be illustrated by the percentage of total hospital visits that 
ultimately result in an inpatient hospital admission. In the Netherlands each year over 
515,000 patients need specialised orthopaedic care of which only around 15 percent is 
admitted as inpatient. For neurosurgery the corresponding figures are approximately 
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30,000 and almost 40 percent, respectively. Our analysis indicates that for both medical 
specialties, travel time and hospital attributes as well as patient characteristics signifi-
cantly affect patients’ decisions to bypass the nearest hospital. 
4.2 Empirical literature on hospital bypassing: United States only
Several previous papers examined patients’ decisions to visit or bypass the nearest hos-
pital.1 These papers exclusively analyse hospital bypassing in the United States. Bron-
stein and Morrisey (1991) find that for rural pregnant women in the state of Alabama, 
travel distances and hospital equipment (reflecting perceived quality differences) were 
important considerations in the choice of an obstetrics hospital. These authors conclude 
that rural women with more resources travelled away from their nearest hospital toward 
hospitals in metropolitan areas, hospitals with high birth volumes, and those with so-
called high-risk bassinets. White and Morrisey (1998) report that, in California, bypass 
rates were higher for more complex procedures (such as back, joint, and vascular sur-
gery) and highest for highly complex procedures such as open heart surgery and kidney 
transplant. They do not, however, control for individual service offerings by hospitals 
what may bias their results. Tai et al. (2004) analyse the hospital bypassing behaviour of 
rural Medicare beneficiaries. The results of their estimation reveal that distance, hospital 
attributes (greater size and scope) as well as patient characteristics (age and income) 
had a substantial influence on the decision to visit or bypass the nearest hospital. 
4.3 Previous studies on patient behaviour in the Netherlands
Prior to the introduction of the new Health Insurance Act in January 2006, Dutch citizens 
were either enrolled in compulsory social health insurance (about two-thirds of the 
population) or voluntarily insured with private health insurers (nearly the remaining 
one-third of the population). Within both health insurance schemes, patients were free 
to choose any hospital. In the social health insurance scheme, patients’ hospital costs 
were always fully reimbursed. Cost sharing arrangements were common only in the pri-
vate health insurance scheme. Research by ECORYS-NEI (2003) indicates that travel time 
is the most important hospital attribute for Dutch patients, followed by (perceived) hos-
pital expertise and own previous experiences with a hospital. Van der Schee et al. (2005) 
find that the Dutch patient’s ideal hospital has a good reputation, requires 15 minutes 
1 Since this paper focuses on hospital bypassing in particular, we do not discuss the extensive literature 
on patient hospital choice in general.
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of travel time at most, has an 7x24 emergency department, guarantees each patient a 
regular physician, has sufficient parking facilities, participates in a regional network of 
health providers, and has short waiting times. Non-emergency care patients especially 
seem to prefer hospitals that have a good reputation, while the other attributes (includ-
ing travel time) are of minor importance to these patients. From NMa (2005), it follows 
that patients in the Netherlands attach a higher value to quality indicators such as 
reputation than they do to travel time. This result suggests that when hospitals improve 
quality, patients are willing to accept more travel time. 
4.4 Conceptual model and estimation method
In this paper we empirically analyse hospital bypass decisions made by Dutch patients. 
The empirical specification and the underlying conceptual model are similar to those 
used in previous empirical studies (Bronstein and Morrisey, 1991; Tai et al., 2004). Both 
are based on standard utility theory. From this theory it follows that the decision to 
visit or bypass the nearest hospital is determined by characteristics of that hospital 
in combination with specific characteristics of the patient. Theoretically, patients are 
expected to choose between the nearest and a further hospital taking extra travel time 
and (perceived) quality into consideration. The type of hospital competition that results 
can be considered as a variant of the standard Hotelling model (Calem and Rizzo, 1995; 
Xavier, 2003).
From previous research it follows that, in the Netherlands, the decision which hospital 
to visit is most often made by patients themselves, alone or in consultation with their 
general practitioner (ECORYS-NEI, 2003). Since Dutch GPs do not face economic incen-
tives to refer patients to particular hospitals, it is not in their interest to neglect patients’ 
interests when deciding which hospital to visit. Our empirical specification therefore 
asserts that patients (or GPs as their agents), given their needs and preferences, decide 
to visit or bypass the nearest hospital on the basis of its attractiveness. We estimate the 
following linear logit specification:
(4.1) Bi = a + βTi + δXi + λZi + εi
where Bi is a dummy variable that has value one when patient i bypassed the nearest 
hospital providing the medical specialty analysed and value zero otherwise; Ti reflects 
extra travel time that is required for patient i to reach the next-nearest hospital provid-
ing the medical specialty analysed; Xi is a vector of patient characteristics; Zi is a vector 
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of attributes of the nearest hospital providing the medical specialty analysed; and εi is 
the error term. 
We expect the likelihood of a bypass decision to decrease when extra travel time to the 
next-nearest hospital increases. In addition to this variable, we distinguish eight patient 
characteristics: gender, age, retirement, unemployment, disability, social security, self-
employment, and geographic environment. Note that, since all patients are enrolled in 
social health insurance, their annual income in 2003 did not exceed €31,750. Because 
the opportunity costs of increased travel time are likely to depend on income, the po-
tential impact of any remaining differences in income is expected to be captured by the 
explanatory variables reflecting the patient’s social status (retirement, unemployment, 
disability, social security, and self-employment). The effect of gender on patients’ bypass 
decisions is unclear in advance. Older or disabled patients are likely to be less mobile 
than younger ones and thus less likely to bypass the nearest hospital. Unemployed pa-
tients may be more likely to bypass the nearest hospital because their opportunity costs 
of increased travel time are lower, whereas the opposite may hold for self-employed 
patients. We expect patients living in urban areas to be more likely to bypass the nearest 
hospital, because they most often have more nearby hospital alternatives than patients 
living in rural areas.
Our model specification suggests that patients, given their personal characteristics, will 
accept the inconvenience and higher costs of travelling to a more distant hospital when 
they perceive the nearest hospital as unattractive. Based on the insights gained from 
previous research on stated preferences (Van der Schee et al., 2005), we examine five im-
portant features of the nearest hospital to test their ability to attract patients: university 
medical centre, tertiary teaching hospital, total number of beds, volume of relevant first 
hospital outpatient visits, and waiting time performance. Note that, because all patients 
in our sample are fully insured for hospital care and co-payments are absent, hospital 
prices do not affect patients’ bypass decisions. Due to perceived quality differences, 
patients may prefer both academic and teaching hospitals over general hospitals. We 
expect the likelihood of a bypass decision to be negatively affected by hospital size. 
Patients may prefer larger hospitals that also treat many similar patients. Relatively low 
waiting time is also expected to increase the attractiveness of the nearest hospital. 
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4.5 Data
Our principal data source is the Agis Health Database.2 This database contains detailed 
information on non-emergency first hospital outpatient visits (in Dutch “eerste polikli-
niek bezoeken”; i.e. EPBs) by socially insured Agis enrolees during the year 2003. The 
available data include the patient’s age, gender, zip code, social status, and administra-
tion number; the medical specialty attended; and the zip code and name of the hospital 
visited. We extracted observations on hospital visits for orthopaedic services (n = 62,213) 
and neurosurgical services (n = 5,648). From these samples we omitted all observations 
on patients younger than 18 years, because for under-aged children the decision to by-
pass the nearest hospital may be complicated by unobserved individual characteristics. 
Patients older than 90 years were also excluded from our sample, because the (medical) 
condition of such patients is most often highly specific. We also omitted all observations 
on patients who travelled more than 60 minutes, because it is likely that these patients 
were away from home when they needed hospital care. The resulting study sample 
contained 53,307 EPBs for orthopaedic care and 5,168 EPBs for neurosurgical care. Table 
4.1 reports the descriptive statistics of all variables included in our specification.
4.5.1 Dependent variable
The dependent variable has the value one when patient i bypassed the nearest hospital 
and the value zero otherwise.3 Despite the fact that, in 2003, Dutch patients did not face 
any financial incentives to bypass the nearest hospital, numerous patients travelled to 
an alternative hospital. On average, patients in our sample travelled 15.7 minutes for 
an orthopaedic EPB and 18.4 minutes for a neurosurgical EPB.4 Because average travel 
time to the nearest hospital providing orthopaedic care and neurosurgery is only 11.9 
and 12.6 minutes respectively, these figures show that for both medical specialties a 
substantial number of patients went to a more distant hospital. For orthopaedic services 
almost four out of every ten patients did not visit the nearest hospital. The percentage 
of patients who bypassed the nearest hospital is even higher for neurosurgical services. 
2 In 2003 Agis was one of the largest Dutch health insurers representing approximately 1.7 million 
customers of which more than 85 percent was enrolled in social health insurance.
3 To test the robustness of our results, we also tried an alternative definition of the dependent variable; 
i.e. assigning the value one only when patients bypassed the nearest hospital by travelling at least 5 
minutes extra. This did not significantly alter the estimated coefficients.
4 In this study estimated travel times refer to the fastest route by car. These are obtained using a data-
base that includes all 4-digit zip codes in the Netherlands and accounts for differences in average speed 
that exist between different road types.
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Over 50 percent visited a more distant hospital than strictly necessary.5 For those pa-
tients who decided to bypass the nearest hospital, travel time on average increased by 
10.0 minutes in case of an orthopaedic EPB and by 10.8 minutes in case of a neurosurgi-
cal EPB. 
4.5.2 Independent variables
We expect the decision to bypass the nearest hospital to be negatively affected by 
travel time to the next-nearest hospital. Therefore, we calculated the extra time that is 
minimally required to reach another hospital in case a patient would decide to bypass 
the nearest one. Because hospital output quality was not measured in 2003, our speci-
fication includes several attributes of the nearest hospital as a proxy for its (perceived) 
5 Note that, in contrast to White and Morrisey (1998), we explicitly control for individual hospitals’ service 
offering. Orthopaedic care is provided by all Dutch hospitals, whereas neurosurgical services are offered 
by around two-thirds of the hospitals.
Table 4.1: Descriptive statistics of the study samples
Orthopaedic care Neurosurgery
Mean SD Min Max Mean SD Min Max
Bypassed nearest hospital 0.38 0.49 0 1 0.54 0.50 0 1
Minimum extra travel time
(minutes)
6.77 5.90 0 54 5.76 5.43 0 51
Nearest hospital attributes:
University medical centre 0.07 0.26 0 1 0.09 0.29 0 1
Tertiary teaching hospital 0.22 0.41 0 1 0.32 0.46 0 1
Hospital beds (x100) 5.42 2.28 1 14 6.14 2.03 2 14
Relevant EPBs (x100) 62.27 22.65 4 227 5.87 4.08 0 24
Waiting time below average 0.49 0.50 0 1 0.43 0.50 0 1
Patient attributes:
Female 0.63 0.48 0 1 0.60 0.49 0 1
Age (years) 53.65 18.13 18 90 52.56 15.13 18 90
Unemployed 0.02 0.14 0 1 0.02 0.14 0 1
Incapacitated for work 0.17 0.37 0 1 0.25 0.43 0 1
Retired 0.35 0.48 0 1 0.26 0.44 0 1
On social security 0.04 0.21 0 1 0.06 0.24 0 1
Self-employed 0.02 0.14 0 1 0.02 0.14 0 1
Total EPBs in 2003 1.18 0.45 1 5 1.25 0.50 1 4
Urbanisation 2.38 1.24 1 5 2.15 1.18 1 5
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quality: type of hospital, hospital size, and waiting time performance. Type of hospital 
is captured by two dummy variables. First, we constructed a variable that has value one 
when the nearest hospital is a university medical centre and value zero otherwise. Sec-
ond, we constructed a variable that has value one when the nearest hospital is a tertiary 
medical teaching hospital and zero otherwise. Data on hospital size is obtained from 
the Dutch Ministry of Health, Welfare and Sports. To capture possible care-specific size 
effects, we included not only the nearest hospital’s number of beds but also its annual 
number of EPBs for orthopaedics and neurosurgery, respectively. An issue that may arise 
in estimation of our logit model is whether it is smaller hospital size that increases the 
likelihood of hospital bypassing or higher bypass rates that lead to smaller hospital size. 
This possible endogeneity may bias the estimated coefficient for hospital size. In this pa-
per, however, the latter variable is treated as exogenous. The fact that our model is static 
and does not deal with dynamic issues supports this assumption. Since it takes some 
time to adjust hospital capacity, the possible impact of patients’ decisions to bypass the 
nearest hospital is a function of the cumulative number of patients over past years.
Data on individual hospital waiting times was obtained from the Netherlands Hospital 
Association. Since it was not compulsory for Dutch hospitals to report waiting times, this 
data contained many missing values. We therefore had to construct a dummy variable 
to test whether patients’ hospital choice was affected by differences in waiting times. 
This variable has value one when the nearest hospital’s average waiting time for an 
orthopaedic or neurosurgical EPB was known to be below the national average in 2003 
and zero otherwise. One could argue that hospital waiting time is affected by patients’ 
bypassing decisions and therefore endogenous which may bias the estimated coef-
ficient of hospital waiting time. Since this paper uses a static specification of hospital 
bypassing, however, we are able to treat hospital waiting time as exogenous. 
Data on patient characteristics was obtained from the Agis Health Database. From this 
database we were able to specify several socio-economic explanatory variables for 
each patient. The patient’s age is included as a continuous variable, whereas gender is 
captured by a dummy variable that was assigned the value one for female patients. Each 
patient’s total number of EPBs in 2003 and social status were also incorporated.6 The 
latter is captured by five different dummy variables that were assigned the value one 
when the patient was retired, unemployed, incapacitated for work, on social security, 
or self-employed and the value zero otherwise. Using data from Statistics Netherlands 
we also specified a multinomial discrete variable to test for the possible effect of ur-
6 Patients’ own previous experiences with hospitals may also affect their bypass decisions. Unfortunately, 
such information is lacking in the database.
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banisation. This variable was assigned the value 1 (very urban areas), 2 (urban areas), 3 
(moderate urban areas), 4 (rural areas) or 5 (very rural areas). Although one might expect 
the opposite, the correlation matrix reveals that this explanatory variable is not highly 
correlated with the variable that captures minimum extra travel time (Table 4.2).
4.6 Estimation results
4.6.1 Orthopaedic care
Our findings for orthopaedic care confirm the expected negative relationship between 
extra travel time required to reach the next-nearest hospital and the decision to bypass 
the nearest hospital (see Table 4.3). Holding all patient characteristics hospital attributes 
constant, the results suggest that patients are more than 10 percent less likely to bypass 
their nearest hospital if going to an alternative hospital implies at least 5 minutes of 
extra travel time. 
The patient characteristics gender, unemployment and social security did not signifi-
cantly affect the decision to bypass or use the nearest hospital for orthopaedic services. 
The likelihood of bypassing the nearest hospital decreases with patient age. As expected, 
older patients are less likely to bypass the nearest hospital. When patients retire, how-
ever, the probability that they visit a further hospital increases. This suggests that the 
opportunity costs of increased travel time are lower for these patients. The same seems 
to hold for patients who are incapacitated to work. Self-employed patients are also 
more likely to bypass the nearest hospital, as are patients admitted to a hospital more 
frequently and patients who live in rural areas. The latter result conflicts with our ex ante 
expectation. Apparently patients in rural areas are less averse to travel for orthopaedic 
care than patients in urban areas. This can perhaps be explained by the fact that those 
Table 4.2: Correlation matrix
Independent variable (1) (2) (3) (4) (5) (6) (7)
(1) Urbanisation 0.18 -0.07 -0.20 -0.16 -0.01 0.01
(2) Minimum extra travel time 0.16 -0.17 -0.23 -0.06 -0.14 -0.15
(3) University medical centre -0.03 -0.18 -0.15 0.06 0.43 0.03
(4) Tertiary teaching hospital -0.32 -0.04 -0.22 0.25 0.07 0.01
(5) Relevant EPBs -0.09 -0.23 0.68 -0.01 0.41 -0.45
(6) Hospital beds 0.18 0.11 0.46 -0.11 0.43 -0.19
(7) Waiting time below average 0.25 0.11 -0.22 -0.53 -0.10 0.07
Correlation coefficients for orthopaedics are in bold.
Correlation coefficients for neurosurgery are in italic.
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patients are already more used to travel for specific services like specialised health care, 
since these services are often not available locally.
We were surprised to find that, holding all other attributes constant, patients were almost 
35 percent more likely to bypass the nearest hospital when this hospital was a university 
medical centre.7 The marginal effect for tertiary teaching hospitals is much smaller, but 
still positive and significant. The probability of a bypass increases by almost 6 percent 
when the nearest hospital is a tertiary teaching hospital. In our opinion there are three 
plausible explanations for these results. First, GPs may advise patients to bypass these 
hospitals for their first outpatient visit. Research by the weekly magazine Elsevier in 2003 
revealed that Dutch physicians, nurses and hospital managers did not classify university 
medical centres among the best hospitals they know, despite their excellent medical 
expertise. It appeared that, according to the respondents, university hospitals especially 
suffered from bureaucracy (Elsevier, 2003). Second, patients themselves may prefer ad-
mittance to a general hospital for their first hospital visit because of (perceived) quality 
differences that are particularly relevant to them, such as doctor communication skills 
and hospital staff’s responsiveness (Sofaer et al., 2005). They may, for example, expect 
to get more personal attention in a general hospital than in a relatively large university 
medical centre that is aimed at scientific research. Furthermore, in the latter type of 
hospital it is far more likely for patients to be (initially) treated by a medical resident 
instead of a fully qualified physician. Third, and additional to the preceding demand 
side considerations, both university and tertiary teaching hospitals may be reluctant 
to accept too many patients for their first outpatient visit because they are oriented 
primarily towards providing highly specific care.
Patients, however, seem to prefer larger general hospitals over smaller ones. Hospital 
size, measured by the number of beds and the annual number of orthopaedic EPBs, 
significantly affects patients bypass decisions. Although the estimated marginal effects 
are rather small, on average patients are less likely to bypass the nearest hospital when 
it has more beds or treats more patients. 
As expected, patients are significantly less likely to bypass their nearest hospital when 
they know its waiting time for an orthopaedic EPB is relatively low. The marginal effect of 
this hospital attribute, however, is quite small. A good waiting time performance of the 
nearest hospital decreases the probability of a bypass by only around 2 percent. 
7 This result is not a spurious finding due to collinearity. Although there is some correlation between the 
explanatory variables university medical centre and number of beds (Table 4.2), exclusion of the latter 
does not change the sign and significance of the estimated coefficient.
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4.6.2 Neurosurgery
For neurosurgery, the estimated marginal effects also reveal that patients are less likely 
to bypass the nearest hospital when travel time to the next-nearest hospital increases 
(Table 4.3). A minimum extra travel time of 5 minutes decreases the probability of a by-
pass by approximately 6.5 percent. Patient gender does not significantly affect hospital 
bypass decisions. The same holds for social security and self-employment. Holding all 
other attributes constant, older patients are less likely to travel farther than necessary 
for neurosurgical hospital care. That is, the likelihood of a bypass decision decreases with 
Table 4.3: Estimation results
Orthopaedic care Neurosurgery
Coeff. (SE) Marginal effect Coeff. (SE) Marginal effect
Minimum extra travel time -0.111 (0.002) *** -2.27% -0.065 (0.008) *** -1.33%
Nearest hospital attributes:
University medical centre 1.592 (0.048) *** 34.21% 1.785 (0.214) *** 29.81%
Tertiary teaching hospital 0.274 (0.026) *** 5.70% 0.486 (0.106) *** 10.02%
Hospital beds (x100) -0.098 (0.007) *** -2.01% -0.218 (0.025) *** -4.45%
Relevant EPBs (x100) -0.004 (0.001) *** -0.08% -0.104 (0.013) *** -2.13%
Waiting time below average -0.107 (0.024) *** -2.19% -0.490 (0.096) *** -10.39%
Patient attributes:
Female 0.009 (0.021) 0.18% -0.092 (0.067) -1.88%
Age (years) -0.013 (0.001) *** -0.26% -0.012 (0.004) *** -0.24%
Unemployed 0.047 (0.075) 0.97% 0.671 (0.251) *** 13.03%
Incapacitated for work 0.207 (0.030) *** 4.31% 0.303 (0.087) *** 6.14%
Retired 0.152 (0.041) *** 3.13% 0.229 (0.133) * 4.63%
On social security -0.021 (0.051) -0.43% -0.191 (0.145) -3.92%
Self-employed 0.163 (0.072) ** 3.39% 0.320 (0.228) 6.41%
Total EPBs in 2003 0.250 (0.022) *** 5.14% 0.102 (0.068) 2.08%
Urbanisation 0.143 (0.011) *** 2.73% -0.123 (0.036) *** -2.48%
Constant 0.731 (0.072) *** 2.916 (0.248) ***
Included observations 48,778 4,545
Correct predictions:
- bypass = 0 87% 53%
- bypass = 1 33% 79%
- overall 67% 68%
Note: *** Significance at 1%; ** at 5%; and * at 10%. To account for unobserved geographic differences we 
also included dummy variables capturing patients’ province of residence. These estimation coefficients 
are available on request. Exclusion of these provincial dummy variables did not significantly alter the 
estimation results. Correct predictions are obtained when the predicted probability is ≤50% and the 
observed bypass = 0, or when the predicted probability is >50% and the observed bypass = 1. 
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age. The opposite is true, however, once patients retire. After retirement the probability 
of bypassing the nearest hospital increases by almost 5 percent. Unemployed patients 
in need of neurosurgical hospital care are also more likely to bypass the nearest hospital. 
Patients who are incapacitated to work are also more likely to bypass. Urbanisation has 
a significant and negative effect on patients’ decisions not to visit the nearest hospital. 
Patients living in more rural areas are less likely to bypass the nearest hospital providing 
neurosurgery. This is not surprising, because travel time is already relatively high for 
these patients as neurosurgical services are only available in larger (regional) hospitals. 
The total number of hospital admissions in a year, measured by EPBs per patient, does 
not significantly affect patients’ bypass decisions for neurosurgical care. Patients who 
visited a hospital more frequently in 2003 are as likely to bypass the nearest hospital as 
patients who are referred to a hospital only once.
Again, the likelihood that a particular patient bypasses the nearest hospital strongly 
increases when this hospital is a university medical centre or a tertiary medical teaching 
hospital.8 These hospital attributes have positive marginal effects of almost 30 percent 
and 10 percent, respectively. As mentioned before, we are not sure whether this effect 
reflects GPs’ advices to patients, the latter’s own preferences based on perceived qual-
ity differences, or admission restrictions imposed by these types of hospital. Just as we 
found for the orthopaedic sample, on average, patients prefer larger general hospitals 
above smaller ones for neurosurgical services. They are less likely to bypass the nearest 
hospital that provides these services when it has more beds and more neurosurgical 
EPBs.
For our neurosurgery sample we find a strong negative relationship between hospital 
waiting time performance and the likelihood of hospital bypassing. Holding the other 
attributes constant, patients were more than 10 percent less likely to bypass the nearest 
hospital that provides neurosurgery when its waiting time was known to be relatively 
low.
4.6.3 Differences between orthopaedic care and neurosurgery
Table 4.3 reveals similarities as well as differences regarding the factors affecting patients’ 
hospital bypass decisions for orthopaedic care and neurosurgery. The first interesting 
difference between the two medical specialties analysed in this paper refers to patient 
attitudes towards extra travel time. Although for both samples patients are less likely 
8 Again, this result is not a spurious finding due to collinearity. Although there is some correlation 
between university medical centre and hospital size (Table 4.2), exclusion of the number of beds or 
neurosurgical EPBs does not change the sign and significance of the estimated coefficient.
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to bypass the nearest hospital when travel time to the next-nearest hospital increases, 
this effect is much stronger for orthopaedic EPBs than for neurosurgical EPBs. This result 
suggests that, in the case of more complex treatments, patients place a lower negative 
value on extra travel time, which is consistent with previous findings (White and Mor-
risey, 1998). Another interesting difference concerns the estimated marginal effect for 
urbanisation. Whereas we find that patients from rural areas are more likely to bypass 
the nearest hospital for orthopaedic care, we find the opposite for neurosurgery. Our 
explanation for this result is that in rural areas a substantial number of patients are not 
able to visit the hospital closest to their home for neurosurgical care because it simply 
does not offer such services. These patients may therefore be less likely to bypass the 
nearest hospital providing the care they need than patients in the orthopaedic sample, 
as for the latter admission to the geographically closest hospital is always feasible. The 
third difference that catches the eye is perhaps the most interesting. Hospital waiting 
time performance appears to have a much stronger effect on patients’ bypass decisions 
for neurosurgical services than for orthopaedic services. Apparently, the valuation of 
shorter waiting time varies with types of hospital care. The importance of waiting time 
as a determinant of hospital bypass decisions seems to be more important for complex 
procedures. 
4.7 Conclusion
Despite the absence of financial incentives, in 2003 numerous Dutch patients bypassed 
the nearest hospital for both orthopaedic care (38 percent) and neurosurgery (54 per-
cent). The estimation results of our logit specification reveal that extra travel time and 
hospital waiting time performance significantly affect the decisions made by patients 
to visit or bypass the hospital closest to their homes. As expected, we find a negative 
relationship between extra travel time and hospital bypassing. Relatively low waiting 
time also significantly decreases the likelihood of patients deciding to bypass the near-
est hospital. Patients, however, seem to place a lower negative value on extra travel time 
for orthopaedic care than for neurosurgery. The valuation of shorter waiting time also 
varies between these two types of hospital care. A good performance of the nearest 
hospital on waiting time decreases the likelihood of a bypass most for neurosurgery. We 
are surprised to find that, in both samples, patients were more likely to bypass the near-
est hospital when this was a university medical centre or a tertiary teaching hospital. 
Apparently patients did not prefer admission to such hospitals for their initial visit. In 
addition to travel time and hospital attributes, patient characteristics, such as age and 
social status, also significantly affected hospital bypass decisions. These results have 
important policy implications for European health planners, hospitals, and especially 
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health insurers who are marketing health plans with a limited set of providers. To prop-
erly assess the substitutability of hospitals that underlies hospital market power, they 
explicitly have to take both patient and hospital care heterogeneity into account.
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Abstract
Health care reforms in several European countries provide health insurers with incen-
tives and tools to become prudent purchasers of health care. The potential success of 
this strategy crucially depends on insurers’ bargaining leverage vis-à-vis health care 
providers. An important determinant of insurers’ bargaining power is the willingness of 
consumers to consider alternative providers. In this paper we examine to what extent 
consumers are willing to switch hospitals when they are fully covered for hospital ser-
vices, which is typical for many European countries. Since prices do not matter to these 
patients, we estimate time-elasticities to assess hospital substitutability. Using data from 
a large Dutch health insurer on non-emergency neurosurgical outpatient hospital visits 
in 2003, we estimate a conditional logit model of patient hospital choice taking both 
patient heterogeneity and hospital characteristics into account. We use the parameter 
estimates to simulate the demand effect of an artificial increase in travel time by 10 
percent for every patient, holding all other hospital attributes constant. Overall, the 
resulting point estimates of hospitals’ time-elasticities are fairly high, although variation 
is substantial (-2.6 to -1.4). Sensitivity tests reveal that these estimates are very robust 
and differ significantly across individual hospitals. This implies that all hospitals in our 
study sample have at least one close substitute which is an important precondition for 
effective hospital competition.
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5.1 Introduction
After decades of central price and capacity control, several European governments are 
now reforming their health care system by introducing competition. In countries like 
Germany, the Netherlands, and Switzerland competition has recently been introduced 
in social health insurance to motivate health insurers to act as prudent purchasers of 
health care. Differential and selective contracting of providers is expected to encourage 
providers to reduce prices of services, increase quality and to better tailor services to 
consumer needs. In order to obtain these benefits it is important that health insurers 
have sufficient bargaining power vis-à-vis health care providers. Empirical evidence 
indicates that the willingness of consumers to switch providers is most important in 
determining insurers’ abilities to negotiate favourable contracts (Sorensen, 2003). As in 
any market, the intensity of competition among health care providers will therefore be 
driven by consumers’ preferences for different providers.
To assess the feasibility of effective provider competition typically the price-elasticity 
of demand for individual providers is estimated. If the demand faced by an individual 
provider is price-inelastic, the provider has a strong market position which may hamper 
competition. But what if prices do not matter to consumers? In the Netherlands as well as 
in many other European countries health insurance coverage is very comprehensive and 
out-of-pocket payments are either absent or do not differ across provider alternatives. 
This implies that consumers are insensitive to differences in price. In addition, as op-
posed to the United States, consumers in Europe typically do not commit to a restricted 
provider network when buying health insurance.1 Under these circumstances, providers 
compete directly for patients by non-price factors only and travel time is then the “price” 
consumers face when selecting a health care provider (Varkevisser et al., 2008). 
In this paper we argue that when monetary prices do not matter to consumers, provider 
substitutability that underlies each provider’s individual bargaining clout can be as-
sessed by estimating time-elasticities. A provider’s time-elasticity measures consumers’ 
propensity to switch to other providers in response to an artificial increase in travel 
time. A relatively low time-elasticity implies that compared to other providers only a few 
patients are likely to switch when that particular provider would become more costly 
(in terms of travel costs) and therefore less attractive, suggesting the absence of close 
1 Models specifically designed to estimate the value consumers place on different provider networks 
(Town and Vistnes, 2001; Capps et al., 2003) do therefore not accurately depict markets for health care in 
European countries. Switzerland may be an exception, since there integrated insurer-provider organisa-
tions have a significant and increasing market share.
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substitutes. In that case, the provider has a stronger bargaining position than other 
providers which lowers the health insurer’s ability to negotiate price discounts and/or 
quality improvements. It is more difficult for an insurer to divert patients from a provider 
with time-inelastic demand than to divert patients from a provider with time-elastic 
demand. Time-elasticities thus at least have an ordinal meaning. Assuming that patients 
are willing to trade time for money at a constant rate, price-elasticities are directly 
proportional to time-elasticities (Capps et al., 2001). However, since we do not know 
patients’ time-money trade-off there is no cardinal meaning to the time-elasticities we 
estimate in this paper.
Computing time-elasticities requires the estimation of a patient choice model from 
which the demand for each provider can be derived. In this paper, we use a unique 
dataset from a large Dutch health insurer on non-emergency neurosurgical outpatient 
hospital visits in 2003 to analyse patients’ preferences for hospitals. We assume that 
patients visit the hospital that maximizes their utility given their own characteristics 
and the characteristics of the hospitals (e.g. travel time to the hospital, quality) in their 
choice set. Based on this theoretical framework, we estimate a conditional logit model 
(McFadden, 1974). A hospital’s time-elasticity is then computed by simulating the de-
mand effect of an artificial increase in travel time to the hospital by 10 percent for every 
patient, holding all other attributes constant. Our results show that patient demand for 
neurosurgery is rather time-elastic, but estimated time-elasticities differ significantly 
across individual hospitals. Hence, in the market for neurosurgery some hospitals face 
fewer close substitutes than others and therefore have a stronger market position. Infor-
mation about hospital substitutability revealed by the estimation of time-elasticities is 
relevant for assessing the feasibility of selective contracting by health insurers and also 
for assessing proposed hospital mergers by antitrust enforcement agencies.
Our contribution to the existing literature is twofold. First, we provide a test for the fea-
sibility of effective competition among health care providers in a setting where prices 
do not matter to consumers. Studies on patient hospital choice are almost exclusively 
performed in the context of US hospital markets, which is quite different from the more 
regulated health care setting in most European countries. We show how predicted 
patient flows following an artificial change in travel time can be used to identify which 
hospitals are competitors. Second, unlike previous studies that only present point esti-
mates of hospitals’ demand elasticities we use a parametric bootstrap method to obtain 
confidence intervals for the estimated time-elasticities.
The remainder of this paper is structured as follows. Section 5.2 describes the regu-
lated context in which during our study period hospital prices were determined in the 
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Netherlands. Section 5.3 gives a brief overview of the existing empirical literature on 
patient hospital choice. Section 5.4 describes our conditional logit model of patient 
hospital choice and the data used for the empirical analysis. Section 5.5 presents the 
time-elasticities of Dutch hospitals based on our simulation results and the results of the 
robustness tests. Section 5.6 concludes.
5.2 Price determination in the Dutch hospital sector
From 1983 to 2005 per diem rates for Dutch hospitals were derived from a global budget 
(Schut and Van de Ven, 2005). The hospital budget was partly fixed and partly deter-
mined by the volume of production that each hospital had to negotiate with health 
insurers. If actual hospital production exceeded the ex ante negotiated level of output, 
next year’s prices had to be reduced to compensate for the resulting difference between 
a hospital’s revenue and its budget. For each hospital, all health insurers paid the same 
price (per diem rate). During this period, people entitled to social health insurance (two 
thirds of the total population) were fully covered for hospital care. Hence, for the major-
ity of the Dutch population hospital prices did not matter. As a result of price regulation, 
however, Dutch patients’ price-insensitivity and the absence of selective contracting did 
not result in arbitrarily high prices for hospital services.
Only since 2005 hospitals and health insurers are able to freely negotiate prices, service, 
and quality for part of the hospital services. From 2005 to 2009 the proportion of the 
freely negotiable hospital production has been increased from 10 percent to 34 percent 
of total hospital expenditure. 
5.3 Empirical literature on patient hospital choice: a brief overview
Most of the early literature on patient hospital choice examines patterns of hospital 
utilisation using spatial interactions models, most commonly in the form of gravity 
models. Such models hypothesise that a greater level of spatial interaction between two 
areas is expected when the population masses of those areas are larger and the spatial 
distance between them is smaller. Representative studies include Morill et al. (1970), 
Roghmann and Zastowny (1979), and McGuirk and Porell (1984). Since the mid-eighties, 
however, researchers have used random utility theory to analyse in more detail why 
patients prefer a particular hospital to others (e.g. Folland, 1983; Lee and Cohen, 1985). 
The widespread availability of individual patient level utilisation data in the United 
States enabled the development of sophisticated econometric methods to estimate the 
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probability that patients will be admitted to a particular hospital, explicitly incorporat-
ing the existence of other hospitals.2 From these studies it follows that, in addition to 
distance or travel time, both hospital and patient attributes have a substantial impact on 
hospital admission choices. In particular hospital quality seems to affect patient choice. 
It is important to notice that most studies reveal the trade-off between travel time and 
hospital quality to vary with patient characteristics. These studies include Bronstein 
and Morrisey (1991), Burns and Wholey (1992), Phibbs et al. (1993), Hodgkin (1996), Tay 
(2003), Tai et al. (2004), and Howard (2005). From these findings it can be concluded 
that hospitals offer a differentiated product to a segmented market. As a result, simply 
aggregating all patients may lead to biased estimation results, even when these patients 
suffer from the same specific medical condition.
5.4 Conditional logit model of patient hospital choice
5.4.1 The model
Our model is based on standard random utility theory. It uses a patient-level utility func-
tion in which travel time and hospital attributes reflecting quality differences are the 
main determinants of patient hospital choice. When selecting a hospital, patients are 
assumed to weigh the costs of increased travel time (including both monetary costs as 
well as the opportunity costs of time for themselves and/or their relatives) against the 
benefits (higher quality). The utility of patient i who visits hospital j is represented by 
(5.1) 
where tij reflects travel time from patient i’s home to hospital j; H.j is a vector of hospital j’s 
attributes; P.i is a vector of patient i’s socio-economic characteristics; and γij represents the 
idiosyncratic part of patient i’s evaluation of hospital j. Note that prices are not included 
in this function because we study patient choice in a setting where prices are irrelevant: 
patients are fully insured for hospital services without facing any out-of-pocket pay-
2 In their extensive review article, Porell and Adams (1995) summarise and assess the historical develop-
ments in hospital choice literature from the late 1960s until the early 1990s.
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ments. We assert that patient i, given his needs and preferences, visits hospital j when 
visiting any other alternative hospital would result in lower utility.3
By interacting travel time and hospital attributes with the individual patient character-
istics, we allow the trade-off between travel time and hospital quality to vary across 
patients.4 When a particular hospital would become less attractive, its patients possibly 
make different decisions. Depending on their place of residence and other individual 
characteristics some patients may still decide to visit this hospital, while others may 
change to another nearby hospital or prefer to travel further for their hospital care. 
This flexibility is a major advantage of the model, because it allows us to analyse the 
substitutability of hospitals more precisely. 
5.4.2 Empirical specification
For the empirical specification of Equation 5.1, we define the dependent variable HCij 
which is assigned the value 1 when patient i visited hospital j and the value 0 otherwise. 
For each patient a choice set of feasible hospital alternatives is defined (Ni). We estimate 
Equation 5.1 as a conditional logit model (McFadden, 1974). It is therefore assumed that, 
for each patient, the relative probabilities of visiting any two hospitals are independent 
of any other available alternatives. This restriction, called the independence of irrel-
evant alternatives (IIA) assumption, implies that one assumes all systematic variation 
in patients’ taste to be sufficiently captured by the explanatory variables incorporated 
into the logit model. The remaining, unobserved portion of utility is then essentially 
white noise. To test whether the IIA-assumption is valid in this context, we perform the 
Hausman-McFadden (1984) test. If this assumption is not violated patient i’s probability 
of visiting hospital j is represented by
(5.2) 
3 In the Netherlands the decision which hospital to visit is made by patients themselves, most often in 
consultation with their general practitioner (GP). Since Dutch GPs do not face any economic incentives to 
refer patients to particular hospitals, it is not in their interest to ignore patients’ preferences.
4 In this paper quality as perceived by the patient and his advising GP determines hospital choice, rather 
than hospitals’ unobservable intrinsic clinical quality.
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This study analyses choices concerning patients’ first outpatient non-emergency hospital 
visits for neurosurgery.5 Since these visits to the hospital’s outpatient clinic are patients’ 
first appointment with a physician for initial consultation or examination, the severity 
of their illness is at that moment not yet fully known.6 The decision to visit hospital j 
is expected to be negatively affected by the travel time from patient i’s home. Based 
on the findings from previous research, we include four additional hospital attributes 
to test for their ability to attract patients: university medical centre, overall reputation, 
reputation for neurosurgery, and waiting time. Previous research revealed that Dutch 
patients are less likely to choose academic hospitals for their first hospital visit, whereas 
a shorter waiting time increases the attractiveness of a hospital (Varkevisser and Van der 
Geest, 2007). Since in the Netherlands hospital clinical quality was not yet systematically 
measured in 2003, in this paper indicators of hospitals’ overall reputation and reputation 
for neurosurgery are included as a proxy for hospital quality as perceived by the patient 
and his advising GP.
An issue that arises when estimating a model of patient hospital choice is the potential 
endogeneity of quality: does high quality attract patients or does a high number of pa-
tients lead to high quality? If the latter is true, hospitals with geographically attractive lo-
cations may gradually become high-quality hospitals over time. In our sample, however, 
there is no correlation between a hospital’s reputation and its size. Hence, higher-quality 
hospitals are not systematically higher-volume hospitals. We therefore treat quality as 
exogenous in the model, so that the causation runs from quality to patient choice and 
not in reverse.
Another potential endogeneity problem may occur if hospital waiting time is affected 
by patients’ hospital choice. This would be the case if consumers have a preference for 
hospitals with high waiting times because they interpret higher waiting times as a signal 
of higher quality. However, empirical evidence for the Netherlands (NZa, 2007) as well 
as for other countries (e.g. Hanson et al., 2004; Martin et al., 2007) shows that patients 
tend to avoid hospitals with relatively high waiting times. We also do not observe any 
correlation between waiting time, overall reputation and reputation for neurosurgery 
in our data. Hence, high quality is here not associated with high waiting time. Therefore 
5 For emergency visits it is likely that patients simply choose the nearest hospital rather than the hospital 
that, given its attributes, would maximise their utility.
6 Neurosurgical conditions include primarily brain, spinal cord, vertebral column and peripheral nerve 
disorders. By far the most common procedure is surgery to correct a hernia.
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we treat each hospital’s waiting time as an exogenous explanatory variable and expect 
a negative sign for it.7
All other things equal, patients are more likely to end up in large hospitals than in smaller 
ones. To control for this exogenous size effect, hospital j’s total number of beds and its 
annual volume of first outpatient hospital visits for neurosurgery are also included as 
explanatory variables. 
The patient characteristics in our model include gender, age (adult vs. non-adult), em-
ployment, and social status.8 The effect of gender on patients’ hospital choice is unclear 
beforehand. Non-adult patients may be associated with a higher propensity to travel, 
since parents are likely to be less averse to travel when seeking the best neurosurgical 
hospital care available for their children.
Since all patients in our dataset are enrolled in social health insurance, their an-
nual income during our study period (2003) did not exceed the threshold for eligibility 
(€31,750). Most patients are salaried employees (or their dependents). Those who are 
not, are identified by the following dummy variables: unemployment, retirement, in-
capacity for work, social security, and self-employment. Retired patients may be more 
averse to travel than others because they are more likely to have physical problems 
restricting their mobility. More distant hospitals are also expected to be less attractive 
to unemployed patients and patients on social security. Given their low income, it is 
likely that they are less willing to incur travel expenses. Patients who are incapacitated 
for work are likely to have a serious chronic condition which could make them more 
sensitive to (perceived) hospital quality differences. Hence, they may be more willing 
to travel to a distant but better performing hospital. On the other hand, these patients 
are also likely to have physical impairments that may reduce their propensity to travel. 
Finally, self-employed patients may be less willing to travel because they are likely to 
have higher opportunity costs of (travel) time since – in contrast to salaried employees 
– their income is directly related to actual working time.9 
7 Nevertheless, if hospital waiting time – contrary to our expectations – would be perceived as a high 
quality signal, patients’ disutility of waiting time is likely to be underestimated. We do not have sufficient 
data to construct reliable instrumental variables to correct for this potential bias. As long as we find 
hospital waiting time to be negatively correlated with hospital choice, this potential bias may not be a 
serious problem. 
8 Patients’ own previous experiences with hospitals may also affect their decisions. Unfortunately, such 
information is lacking in our dataset.
9 As a result of collective labour agreements, nearly all salaried employees in the Netherlands have the 
right to visit a doctor during working time without loss of income.
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5.4.3 Data
Our principal data source is the Agis Health Database that contains individual patient 
level data from a large Dutch health insurer (Agis). In 2003, Agis was one of the largest 
Dutch health insurers representing approximately 1.4 million socially insured amount-
ing to a nationwide market share of 14 percent. Its key geographical areas include both 
urban (Amsterdam, Utrecht) and rural areas. Since all patients in the sample are enrolled 
in a social health insurance plan no-one has to pay an out-of-pocket price for hospital 
services. 
From the Agis Health Database we obtained observations on non-emergency first 
outpatient hospital visits for neurosurgery in 2003. In addition to each patient’s 
socio-economic characteristics, the available data include the zip code and name of the 
hospital visited. There are 66 hospitals in the Netherlands providing neurosurgery. The 
most common types of neurosurgery (such as hernia repairs) are performed in all these 
hospitals. 
Patients’ travel times are defined as the fastest route by car from patient i’s home to 
each hospital and are calculated in minutes. This route is obtained from a database that 
includes all 4-digit zip codes in the Netherlands and accounts for differences in average 
speed that exist between different road types.10 If patients travelled extremely long to 
the hospital visited, it can reasonably be assumed that they were away from home when 
they needed health care. For those patients, travel time from their place of residence 
incorrectly measures the travel costs incurred, which may bias the estimation results. 
In this paper we therefore exclude all patients who travelled more than 60 minutes (4.6 
percent). For the remaining patients a set of hospital choices is defined (Ni). Each patient’s 
choice set consists of all hospitals providing neurosurgery that can be reached within 
60 minutes of travel time. Note that on average patients travelled 19 minutes, while for 
95 percent of the patients actual travel time did not exceed 45 minutes. More than 80 
percent travelled less than 30 minutes. In the Netherlands, even patients who need a 
very complex neurosurgical treatment do not have to travel more than 60 minutes to 
the nearest hospital capable of performing the surgery. Hence, within the Dutch context 
a limit to each patient’s hospital choice set of 60 minutes of travel time is not likely to be 
restrictive when analysing actual choice behaviour. Since Dutch health insurers were not 
allowed to contract selectively with hospitals in 2003 there are no further restrictions on 
patients’ choice sets.
10 As Dutch zip codes consist of four numbers followed by two letters (e.g. 3000 DR), the maximum 
inaccuracy in distance between this point and the actual starting point and destination could be about 
250 meters in urban areas and 1,000 meters in rural areas at most.
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The resulting study sample contains 5,389 individual patient hospital visits. From Table 
5.1 it follows that for almost 90 percent of these patients the choice set includes at least 
15 hospitals. Only little more than 2 percent of the patients can reach at most 5 hospitals 
within 60 minutes of travel time from their home. On average, patient i’s choice set in-
cludes 26 hospitals. Average travel time to the nearest hospital providing neurosurgery 
is 13 minutes. Varkevisser and Van der Geest (2007) found that for their first outpatient 
hospital visit 54 percent of the neurosurgery patients bypassed the nearest hospital al-
ternative. For these patients bypassing the nearest hospital resulted in about 11 minutes 
more travel time than would be strictly necessary.
Table 5.1: Number of hospitals in patients’ choice sets
Hospitals (#) Patients (#) Patients (%) Patients (cum. %)
1 1 0% 0%
2 20 0% 0%
3 31 1% 1%
4 30 1% 2%
5 40 1% 2%
6 74 1% 4%
7 68 1% 5%
8 43 1% 6%
9 90 2% 7%
10 39 1% 8%
11 19 0% 8%
12 28 1% 9%
13 26 1% 9%
14 78 1% 11%
15 9 0% 11%
16 26 1% 12%
17 88 2% 13%
18 74 1% 15%
19 33 1% 15%
20 198 4% 19%
21 176 3% 22%
22 256 5% 27%
23 112 2% 29%
24 165 3% 32%
25 219 4% 36%
26 88 2% 38%
27 97 2% 40%
28 394 7% 47%
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As already mentioned, a lack of data forces us to use indicators such as hospitals’ reputa-
tion as a proxy for quality. However, we do not consider this to be a serious shortcoming. 
Due to the absence of clinical quality indicators during the study period, patients at that 
time also had to rely on (information about) hospitals’ reputation for making choices. 
Information on hospital’s overall reputation and reputation for neurosurgery are both 
taken from an annual survey among Dutch physicians, nurses and hospital managers 
published in a popular news magazine (Elsevier, 2003). The explanatory variable reflect-
ing each hospital’s overall reputation measures several hospital-specific items, including 
both positive items (e.g. attitude towards patients, medical and nursing staff expertise, 
facilities) and negative items (e.g. financial problems, medical staff disputes, high staff 
turnover). This dummy variable has the value 1 if hospital j’s unweighted sum of its 
bonus and penalty points exceeds the national average and the value 0 otherwise. The 
reputation for neurosurgery is also captured by a dummy variable. This variable has the 
value 1 if hospital j is recommended by at least 33 percent of the respondents and the 
value 0 otherwise. 
Data on individual hospital waiting times is obtained from the Netherlands Hospital 
Association. In 2003, this data was accessible for patients by the internet and also 
frequently published in a Dutch newspaper. To test our hypothesis that hospitals with 
Table 5.1: Number of hospitals in patients’ choice sets (continued)
Hospitals (#) Patients (#) Patients (%) Patients (cum. %)
29 541 10% 57%
30 779 15% 71%
31 155 3% 74%
32 364 7% 81%
33 258 5% 86%
34 149 3% 89%
35 210 4% 92%
36 158 3% 95%
37 46 1% 96%
38 79 2% 98%
39 60 1% 99%
40 61 1% 100%
41 7 0% 100%
Sum 5,389 100%
Mean 26
Modus 30
Note: each patient’s choice set comprises all hospitals providing neurosurgery within 60 minutes of travel 
time.
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lower waiting times are more attractive to patients than other hospitals, we use a dummy 
variable that has value 1 when hospital j’s waiting time for a neurosurgical first hospital 
visit was reported to be below the national average in 2003 and the value 0 otherwise. 
Finally, we control for exogenous hospital size effects by including two additional ex-
planatory variables on hospital size that are obtained from the Dutch Ministry of Health, 
Welfare and Sports. To capture possible diagnosis-specific size effects, we did not only 
include hospital j’s total number of beds but also its annual number of first outpatient 
hospital visits for neurosurgery. This variable includes patients from all social health 
insurance plans and private insurers. 
Table 5.2 reports the descriptive statistics of all variables that are included in our logit 
specification. 
5.4.4 Estimation results
For the conditional logit estimation of Equation 5.1 we use the maximum likelihood 
estimation method and standard iterative procedures for its optimisation. Maximum 
likelihood estimation of the conditional logit model can be shown under very general 
conditions to provide estimators that are asymptotically efficient and normally distrib-
Table 5.2: Descriptive statistics of the study sample
Variable Mean St. dev. Minimum Maximum
Actual travel time (in minutes by car) 19 12 0 60
Patient attributes (n = 5,389)
Female 0.59 0 1
Non-adult 0.04 0 1
Retired 0.25 0 1
Unemployed 0.02 0 1
Incapacitated for work 0.25 0 1
Social security 0.06 0 1
Self-employed 0.02 0 1
Hospital attributes (n = 66)
University medical centre 0.12 0 1
Good overall reputation 0.48 0 1
Good reputation for neurosurgery 0.09 0 1
Waiting time below average 0.39 0 1
Total hospital beds 611 268 210 1,368
First hospital visits for neurosurgery 655 591 0 2,380
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uted (McFadden, 1974). In particular when the dataset has many combinations of hos-
pitals and residency zip codes with no actual visits (“zero flows”), maximum likelihood is 
the preferred estimation method for conditional logit models of patient hospital choice. 
As shown by Garnick et al. (1989), maximum likelihood estimates are far less sensitive to 
the presence of zero flows than alternative estimation techniques.
As already mentioned, we perform the Hausman-McFadden test to test the validity 
of the IIA assumption. This chi-squared test compares the estimated parameters and 
covariance matrices from the full choice set with a restricted choice set. For this study, 
the test statistic indicates we cannot reject the null hypothesis that the difference in 
coefficients is not systematic. Hence, the IIA assumption seems to hold here implying 
that all systematic variation in patients’ taste is sufficiently captured by the explanatory 
variables.
In order to measure goodness of fit we analyse predicted versus actual hospital choice. 
Following Town and Vistnes (2001), a “hit-or-miss” criterion is constructed where the 
predicted choice for a patient is the hospital having the maximum predicted probability. 
The model correctly predicts 43 percent of patients’ hospital choices. Given the large 
number of hospital alternatives available to patients (on average 26), this prediction 
rate suggests the model provides a high degree of explanatory power. The hospital 
choice model estimated by Town and Vistnes (2001) correctly predicts about 30 percent 
of hospital choices for their different samples. Most studies on patient hospital choice, 
however, do not report how well their estimated models predict patients’ actual choices. 
By exception, Capps et al. (2001) report that 35 percent of the patients in their sample 
visited the hospital having the maximum predicted probability. 
Detailed estimation results are presented in Table 5.3.11 The coefficient for travel time is nega-
tive and statistically significant at 1% indicating that in general patients are averse to travel. 
11 We also estimated a full model including all possible interactions of patient characteristics and hos-
pital attributes. The likelihood-ratio test indicates that the full model is statistically preferred over the 
reduced one. However, we prefer to use the latter since most interaction variables included in the full 
model are insignificant and the reduced model’s estimated parameters are more easy to interpret, while 
both the overall model performance and predicted market shares do not substantially differ between 
both models.
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Table 5.3: Estimation results conditional logit model
Coefficient SE
Travel time -0.1600 ** 0.0037
Hospital attributes:
University medical centre -1.7820 ** 0.0870
Good overall reputation 0.1101 * 0.0448
Good reputation for neurosurgery 0.0161 0.0599
Waiting time below average 0.3397 ** 0.0356
Total hospital beds 0.0016 ** 0.0001
First hospital visits for neurosurgery 0.0018 ** 0.0001
Interacted with Female:
Travel time -0.0105 ** 0.0038
University medical centre -0.0164 0.0712
Interacted with Non-adult:
Travel time 0.0532 ** 0.0085
University medical centre 4.1262 ** 0.2804
Interacted with Retired:
Travel time -0.0180 ** 0.0052
University medical centre 0.1213 0.0916
Interacted with Unemployed:
Travel time 0.0135 0.0125
University medical centre -0.1924 0.2746
Interacted with Incapacitated for work:
Travel time 0.0171 ** 0.0045
University medical centre 0.6456 ** 0.0867
Interacted with Social security:
Travel time -0.0257 ** 0.0096
University medical centre 0.1249 0.1561
Interacted with Self-employed:
Travel time 0.0174 0.0115
University medical centre 0.0118 0.2618
Log likelihood -8951.69
Degrees of freedom 21
Number of patients 5,388
Number of patient-hospital combinations 142,037
Note: ** denotes significance at 1%; * at 5%.
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The estimation results for the hospital attributes show that patients are generally less 
likely to choose a university medical centre for their first outpatient neurosurgical 
hospital visit. There are two plausible explanations for this. First, for non-tertiary care 
Dutch physicians, nurses and hospital managers do not classify university medical 
centres among the best hospitals they know (Elsevier, 2003) which may explain patients’ 
preferences for general hospitals. Second, patients may expect to get more personal at-
tention in a general hospital than in a university medical centre that is aimed at scientific 
research as well as medical education and where it is more likely for them to be (initially) 
treated by a medical resident instead of a fully qualified physician. From the estimation 
results it follows that a hospital’s overall reputation significantly affects patients’ choices. 
A good overall reputation increases a hospital’s attractiveness. The estimated parameter 
for a hospital’s reputation for neurosurgery is also positive, though not statistically 
significant. This may be due to the fact that only 6 of the 66 Dutch hospitals providing 
neurosurgery have a specifically good reputation for this medical speciality. Patients 
are in general also more likely to choose hospitals for which waiting time is below the 
national average. 
From Table 5.3 it follows that several patient characteristics significantly affect hospital 
choice, particularly in relation to travel time. Both female patients, retired patients, and 
patients on social security are significantly less inclined to travel. The opposite holds for 
non-adults and patients incapacitated for work. The latter are likely to suffer from chronic 
diseases and to have previous experiences with hospitals. This may explain why they are 
less averse to travel and more likely to visit a university medical centre. Our finding that 
also children are more likely to visit a university medical centre can be explained by the 
fact that in the Netherlands specialised facilities for paediatric care are concentrated in 
these hospitals. Overall, 26 percent of the adult patients included in our study sample 
visit a university medical centre for their first neurosurgical outpatient visit, while this 
percentage for non-adult patients is 89 percent.
5.5 Using time-elasticities to assess hospital competition
5.5.1 Computing time-elasticities
In this section we demonstrate how to compute time-elasticities for individual hospitals 
and use these to assess hospital substitutability. The underlying general methodology 
is obtained from Capps et al. (2001). Estimating the time-elasticity of hospital j involves 
four successive steps. In the first step, hospital j’s market share is predicted by summing 
up patients’ estimated choice probabilities for hospital j. In the second step, travel time 
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to hospital j is artificially increased by a certain percentage (e.g. 10 percent) for every 
patient while holding travel time to all other hospitals at their true level. This implies that 
patients are virtually moved away from hospital j and brought relatively closer to other 
hospital alternatives in their choice set. These hospitals therefore become relatively 
more attractive to them. In the third step, hospital j’s “new” market share is calculated. 
Using the estimated parameters from the patient choice model, new choice probabili-
ties are calculated and summed up for hospital j as well as all other hospitals to reveal 
substitution patterns. In the final step, hospital j’s time-elasticity is computed dividing its 
percent change in predicted market share (number of patients) by the percent change 
in travel time. This exercise identifies the extent to which other hospitals are substitutes 
for hospital j, holding all other things equal.12 
Since many of the 66 hospitals included in our dataset have individual market shares 
that are negligible, we only estimate time-elasticities for the hospitals with a predicted 
market share of at least 2.5 percent since those are located in Agis’ key geographical 
areas. Together these hospitals have a predicted cumulative market share of almost 85 
percent (n = 13). Using the parameter estimates from Table 5.3, for each of these hospi-
tals we predict the percent change in market share when travel time to that particular 
hospital is artificially increased by 10 percent. From Table 5.4 it follows that the resulting 
time-elasticities show considerable differences.13 
The highest time-elasticity (-2.6) is found for hospital 22. This general hospital looses 
41 of its 158 predicted neurosurgical patients to other hospitals when travel time is 
artificially raised by 10 percent for every patient in our study sample. As revealed by the 
thirteenth column of Table 5.5, 10 patients switch to hospital 32 (24 percent). The closest 
substitute for hospital 22, however, appears to be hospital 18 that is not included in the 
table but gains 13 patients (32 percent) when patients’ “price” for visiting hospital 22 
increases by 10 percent. Its relatively high time-elasticity implies that from all thirteen 
hospitals for which we have estimated time-elasticities hospital 22 potentially has the 
least bargaining power vis-à-vis health insurers.
12 Buchmueller (2006) applies a quite similar approach when analysing the health plan choices of 
retirees. He uses the coefficient estimates from a conditional logit model for calculating the predicted 
change in each plan’s markets share caused by a hypothetical $5 increase in premium while holding the 
premiums of all competing plans constant. Since the observed prices differ considerably among the 
plans included in his analysis, the hypothetical percentage increase in premiums is (much) higher for the 
less expensive health plans. As a result, the predicted changes in market shares are ambiguous.
13 For reasons of confidentiality, hospital names are not revealed. 
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Table 5.4: Estimated time-elasticities
Predicted
patients
Travel time +10%
Hospital j ∆Patients Time-elasticity
Hospital 56 714 -137 -1.9
Hospital 32 669 -99 -1.5
Hospital 52 550 -85 -1.5
Hospital 46 464 -91 -2.0
Hospital 37 344 -63 -1.8
Hospital 03 315 -69 -2.2
Hospital 59 293 -63 -2.1
Hospital 63 248 -53 -2.1
Hospital 14 242 -52 -2.2
Hospital 39 239 -33 -1.4
Hospital 22 158 -41 -2.6
Hospital 48 149 -31 -2.1
Hospital 64 136 -30 -2.2
Table 5.5: Where do patients go if travel time to their first-best hospital is artificially increased?
Predicted 
patients 
(#)
∆Patients (#) for each hospital when 
travel time to hospital j is increased by 10%:
Hospital j 56 32 52 46 37 03 59 63 14 39 22 48 64
Hospital 56 714 -137 26 4 4 19 7 5 8 15 2 2 8 6
Hospital 32 669 32 -99 4 5 8 5 3 14 9 2 10 3 7
Hospital 52 550 4 4 -85 26 2 12 14 4 1 8 1 2
Hospital 46 464 4 4 22 -91 2 11 12 5 1 6 1 2
Hospital 37 344 22 8 2 3 -63 3 2 2 9 1 7 2
Hospital 03 315 8 5 11 12 3 -69 10 5 2 4 1 2
Hospital 59 293 5 3 11 11 2 9 -63 3 1 4 1 1
Hospital 63 248 11 14 5 6 3 6 3 -53 3 2 1 4
Hospital 14 242 16 8 1 2 8 2 1 3 -52 1 4 2
Hospital 39 239 2 2 11 11 1 6 6 2 1 -33 1
Hospital 22 158 2 7 -41
Hospital 48 149 10 3 1 1 7 1 1 1 4 -31 1
Hospital 64 136 8 8 2 2 2 2 1 5 2 1 1 -30
Other hospitals 868 12 8 10 10 6 5 6 2 3 2 27 4 1
Sum 5,388 0 0 0 0 0 0 0 0 0 0 0 0 0
Note: since “fractional” patients are here rounded up/down to the nearest value, the columns are subject 
to round-off errors.
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For the hospital with the highest predicted market share, hospital 56, a time-elasticity 
with the value -1.9 is estimated. When we artificially increase travel time to this univer-
sity medical centre by 10 percent for every patient, it looses 137 of its initially predicted 
714 patients for neurosurgery. The closest substitutes for this hospital appear to be the 
hospitals 32, 37, and 14. The number of patients substituting toward these alternative 
hospitals is 32, 22, and 16, respectively. Jointly these three general hospitals located 
nearby adopt more than 50 percent of the patients leaving hospital 56 following an 
increase in “price” there.
The hospital with the lowest time-elasticity (-1.4) is hospital 39: a medium-sized general 
hospital located in the inner city of Amsterdam. Only 33 of its predicted 239 patients 
switch to another hospital for their first neurosurgical outpatient visit when more travel 
time would be required. Patients apparently have relatively strong preferences for this 
hospital. Hence, in our study sample hospital 39 potentially has the best bargaining 
position with health insurers.
As revealed by Table 5.6, all hospitals in our study sample face substitutes. When a hos-
pital would become less attractive, other hospitals will experience an increase in market 
share. If we identify competitors as those hospitals that at least 5 percent of the patients 
would substitute toward, Table 5.6 reveals that for all hospitals the number of competi-
tors is fairly high. The minimum number of substitutes is 4 (hospitals 22, 37, and 48) and 
the maximum number is 7 (hospitals 3, 56, 63, and 64). However, the hospital substitu-
tion patterns found here reveal that overall about 25 percent of all switching patients 
are adopted by hospital j’s closest substitute. The three closest substitutes jointly adopt 
more than half of the patients predicted to leave hospital j following an artificial increase 
in travel time. Hence, the vast majority of hospital alternatives are only appealing to 
relatively few patients each. We therefore computed an HHI for the diverted patients.14 
The lower the value of this HHI, the more scattered the patients substituting away from 
hospital j are among the other hospitals. Note that if this “diversion HHI” tends to 1, the 
market is likely to be either a monopoly (if the time-elasticity estimated for hospital j is 
low) or duopoly (if the time-elasticity estimated for hospital j is high). Since the estimated 
time-elasticities are fairly high while the computed HHIs are rather low, all hospitals in 
our study sample seem to face strong competition in the market for neurosurgery.
14 We thank one of the reviewers for making this suggestion.
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5.5.2 Sensitivity tests
To test for the robustness of our findings, we use the vector of estimated parameters 
and corresponding covariance matrix from our conditional logit model to randomly 
draw 1,000 sets of alternative, equally probable model parameters from a multivariate 
normal distribution with this vector and matrix as means and covariance, respectively.15 
For each of these sets of coefficients hospital j’s time-elasticity is computed, resulting in 
a sample of 1,000 different time-elasticities from which we construct a 95% confidence 
interval for the time-elasticity of hospital j. Since the estimated time-elasticity is defined 
as the percent change in number of patients divided by the percent change in travel 
time, it may depend on the size of the artificial travel time change used. As an additional 
sensitivity test, using the same sets of alternative model parameters, we therefore also 
compute hospitals’ time-elasticities using a 5 percent increase in travel times. The results 
from both Monte Carlo simulations are summarised in Table 5.7 and Figure 5.1. From the 
sensitivity tests it follows that the estimated time-elasticities are very robust. 
15 This parametric bootstrap is also referred to as the Krinsky-Robb method. The only assumption this 
method requires is that the estimated coefficients are joint normally distributed (Krinsky and Robb, 1986; 
1990), which is in fact a statistical property of the conditional logit model. Maximum likelihood estima-
tion of this model under very general conditions provides estimators that are normally distributed. The 
approximation is reasonably good even in quite small samples (McFadden, 1974, pp.119/120). 
Table 5.6: Assessing hospital substitutability (travel time +10%)
∆Patients
Hospital 
substitutesa
Percentage patients switching to hospital j’s:
HHIbClosest 
substitute
Two closest 
substitutes
Three closest 
substitutes
Hospital 56 -137 7 24% 40% 52% 0.119
Hospital 32 -99 6 26% 41% 49% 0.121
Hospital 52 -85 5 26% 39% 53% 0.131
Hospital 46 -91 6 28% 41% 54% 0.137
Hospital 37 -63 4 30% 43% 55% 0.143
Hospital 03 -69 7 17% 33% 46% 0.108
Hospital 59 -63 6 22% 40% 56% 0.130
Hospital 63 -53 7 25% 41% 51% 0.128
Hospital 14 -52 5 28% 46% 63% 0.154
Hospital 39 -33 6 24% 43% 56% 0.137
Hospital 22 -41 4 31% 56% 67% 0.179
Hospital 48 -31 4 27% 48% 59% 0.147
Hospital 64 -30 7 24% 43% 57% 0.135
Notes:
a. Those hospitals that at least 5 percent of the patients substitute toward.
b. This HHI is a concentration measure for the diverted patients. 
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Table 5.7: Sensitivity tests estimated time-elasticities
Travel time +10% Travel time +5%
Results parametric bootstrap (n = 1,000) Results parametric bootstrap (n = 1,000)
Mean St. dev. 95% confidence Mean St. dev. 95% confidence 
Hospital 22 -2.6 0.02 -2.6 -2.6 -2.8 0.02 -2.9 -2.8
Hospital 64 -2.2 0.01 -2.2 -2.2 -2.4 0.01 -2.4 -2.4
Hospital 03 -2.2 0.02 -2.2 -2.2 -2.4 0.02 -2.4 -2.3
Hospital 14 -2.2 0.02 -2.2 -2.1 -2.3 0.02 -2.4 -2.3
Hospital 63 -2.1 0.01 -2.2 -2.1 -2.3 0.01 -2.3 -2.3
Hospital 59 -2.1 0.02 -2.2 -2.1 -2.3 0.02 -2.3 -2.3
Hospital 48 -2.1 0.01 -2.1 -2.1 -2.2 0.01 -2.3 -2.2
Hospital 46 -2.0 0.02 -2.0 -1.9 -2.1 0.02 -2.1 -2.1
Hospital 56 -1.9 0.01 -1.9 -1.9 -2.0 0.02 -2.1 -2.0
Hospital 37 -1.8 0.01 -1.9 -1.8 -2.0 0.01 -2.0 -1.9
Hospital 52 -1.5 0.01 -1.6 -1.5 -1.6 0.01 -1.6 -1.6
Hospital 32 -1.5 0.00 -1.5 -1.5 -1.6 0.00 -1.6 -1.6
Hospital 39 -1.4 0.01 -1.4 -1.4 -1.5 0.01 -1.5 -1.4
Figure 5.1: Estimated time elasticities’ robustness (travel time +10%)
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5.6 Concluding remarks
In several European countries, governments increasingly rely on competition as a 
strategy to encourage health care providers to reduce prices and increase quality. 
The success of this strategy depends on consumers’ propensity to switch health care 
providers. Health insurers will not be able to negotiate favourable contracts (i.e. price 
discounts and/or quality improvements) with health care providers whose demand is 
rather inelastic. 
In this paper we illustrate how to assess the feasibility of competition among hospitals 
in a setting where patients are insensitive to hospital prices, which is the case in many 
European countries. When insurance coverage is comprehensive for hospital services 
and out-of-pocket payments are absent or do not differ across hospitals, travel time 
functions as the only “price” for patients. In this setting hospitals’ relative bargaining 
power with insurers can be assessed by computing their time-elasticities: the percent 
change in market share divided by the artificial percent change in travel time.
The time-elasticity approach starts by estimating a conditional logit model of patient 
hospital choice. Using data from a large Dutch health insurer on non-emergency neu-
rosurgical outpatient hospital visits in 2003, we find that patients are indeed averse to 
travel. We use the parameter estimates to compute time-elasticities for thirteen Dutch 
hospitals. We simulate how patients, given their own characteristics, would respond 
when more travel time is required to visit the hospital, holding all other hospital at-
tributes constant. 
From our simulations it follows that the point estimates of hospitals’ time-elasticities 
range from -1.4 to -2.6. When travel time is raised by 10 percent for every patient, the 
former hospital looses 14 percent of its patients to other hospitals while the latter looses 
as many as 26 percent of its patients. Our analysis reveals that overall hospital demand in 
the Netherlands is rather time-elastic which may suggest that effective hospital compe-
tition for neurosurgery is feasible. Estimated time-elasticities differ significantly across 
individual hospitals. In the market for neurosurgery some hospitals thus face fewer close 
substitutes than others and therefore have a stronger market position. 
One should keep in mind that this paper analyses hospital substitutability in one 
particular submarket, defined as an insurer-hospital service pair. The empirical findings 
are therefore not necessarily representative for hospitals’ substitutability in other sub-
markets. From a conceptual perspective, however, our findings clearly indicate that in a 
setting where patients’ decisions which hospital to visit are based on non-price factors 
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only, the time-elasticity approach can be a useful instrument to assess hospital substi-
tutability that underlies hospital competition. Such information is not only relevant for 
assessing the feasibility of selective contracting by health insurers, but also for assessing 
proposed hospital mergers by antitrust enforcement agencies. First, time-elasticities 
can be used for ruling out hospitals as close substitutes allowing for instance for quick 
review of mergers not involving close substitutes. Second, by using time-elasticities for 
ranking hospital substitutes, antitrust analysis can focus on a particular set of hospitals 
that are the merging hospitals’ closest substitutes. The ensuing analysis might then 
be qualitative and quantitative in nature, but it would be at least focused on the right 
hospitals.
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Abstract
In hospital markets with regulated prices, competition among hospitals may increase 
quality. This requires reliable and detailed information about hospital quality, sufficient 
patient responsiveness to observed differences in quality, and the availability of a suf-
ficient number of hospital alternatives. Using detailed claims data for 2006, we estimate 
a conditional logit model to examine how patients respond to consumer information 
about hospital quality in the Dutch market for angioplasty. We find that patient hospital 
choice is significantly affected by publicly available performance indicators despite that 
these indicators provide patients with conflicting signals. Since the available outcome 
measures are not adjusted for differences in case-mix increasing the room for competi-
tion, as recently proposed by the government, may encourage hospitals to select risks.
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6.1 Introduction
In hospital markets with regulated prices hospitals compete for patients on non-price 
dimensions; i.e. geographic location and observed quality. In such markets competition 
may increase quality and improve consumer welfare if some preconditions are fulfilled. 
Patients must be able to choose from a sufficient number of hospitals, and information 
about hospital quality must be reliable, comprehensive, and publicly available. Patients 
(and/or their health insurers) otherwise can not choose a hospital with confidence 
that it is the most preferred combination of quality and travel time without incurring 
prohibitive search costs (Dranove and Satterthwaite, 2000). Furthermore, patients must 
respond to observed quality information, implying that the information must be easily 
accessible and understandable. 
There is some empirical evidence that if prices are regulated observed quality is higher 
in more competitive hospital markets (Gaynor, 2006). Other studies, however, show that 
increased competition may have adverse effects on hospital quality. First, empirical stud-
ies about the effects of competitive reforms in the UK National Health Service show that 
increased competition in combination with a lack of consumer information may induce 
hospitals to reduce unmeasured and unobserved quality in order to improve measured 
and observed performances (Propper et al., 2004 and 2008). Second, empirical studies 
in US hospital markets show that if quality information is not adequate hospitals may be 
encouraged to avoid sick patients and/or seek the healthy ones. For instance, Dranove 
et al. (2003) find that the adoption of mandatory coronary artery bypass graft (CABG) 
surgery report cards in the states of New York and Pennsylvania in the early 1990s led 
to substantial risk selection by providers. To minimise this incentive it is essential to 
adjust health outcomes for differences in patient characteristics. Without some sort of 
risk-adjustment, hospitals treating the most serious cases necessarily appear to have 
low quality. 
In this paper we examine both the appropriateness of publicly available quality indica-
tors and how patients respond to this information to assess the feasibility of effective 
quality competition among hospitals. We focus on the Dutch market for angioplasty, 
or percutaneous coronary intervention (PCI), since this market provides a unique op-
portunity to empirically assess quality competition in a regulated hospital market. In 
this market patient hospital choice is only affected by observed quality and geographic 
location. Additionally, hospital prices are fixed by the Dutch Healthcare Authority (NZa) 
and entry is restricted by the Minister of Health. Moreover, several quality indicators are 
publicly available, so consumers may choose among providers that differ in observed 
quality. Assessing patients’ responsiveness to observed quality differences and its 
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potential effect on quality competition in this market is also interesting from a policy 
perspective. The Dutch government recently announced its intention to repeal the cur-
rent entry regulation, implying an expected increase in competition in the market for 
angioplasty. 
For this study, we use claims data from a large Dutch health insurer that provides a 
record of all enrolees who were admitted to a hospital for non-emergency angioplasty 
in 2006. The dataset includes detailed information about individual patients and their 
hospital choices. Supplemented by publicly available consumer information from two 
different sources we are able to examine the impact of observed quality differentiation 
on patient choice in the market for angioplasty given hospitals’ geographic location and 
other exogenous attributes. 
The paper is structured as follows. Section 6.2 describes the main features of the market 
for angioplasty in the Netherlands. Section 6.3 examines the publicly available hospital 
quality indicators and evaluates their consistency. Section 6.4 presents the data used for 
analysing patient hospital choice. Section 6.5 discusses both the model as well as the 
estimation results obtained by using a conditional logit framework. Section 6.6 analyses 
how patients respond to publicly available consumer information about hospital qual-
ity by computing their willingness to travel for improvements in a particular hospital 
quality indicator. Section 6.7 assesses (potential) hospital competition in this regulated 
market by simulating patient demand responses to hypothetical changes in observed 
quality, taking into account actual hospital differentiation. Section 6.8 concludes by 
summarising the most important findings and discussing their policy implications.
6.2 Market for angioplasty in the Netherlands
6.2.1 Supply regulation
In the Netherlands, the Health Council (GHR) evaluates the effectiveness, efficiency, 
safety, and availability of (new) health technologies. Since 1998 this mandate is based on 
the Special Medical Procedures Act (WBMV). The WBMV focuses on quality of care and 
appropriate use, rather than on cost containment (Den Exter et al., 2004).1 Since much of 
the care provided to patients with cardiovascular disease consists of interventions that 
are highly complex in nature, cardiac surgery and interventional cardiology were made 
1 For cost containment other supply constraints were introduced by the Dutch government, including 
the Hospital Facilities Act (WZV) and the Health Care Prices Act (WTG).
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subject to the provisions of the WBMV. Accordingly, only hospitals with a permit granted 
by the government are allowed to perform angioplasty.2 
The planning instrument provided by the WBMV made it possible for the government 
to exercise control over the quality and accessibility of specialised cardiac procedures 
in the Netherlands in order to safeguard the care provided to patients, both in terms of 
quality, capacity, as well as geographical distribution.3 In 2006, nineteen hospitals were 
allowed to perform PCI and about 95 percent of the Dutch population was able to reach 
at least one of these hospitals within 60 minutes of travel time (Figure 6.1).
After the introduction of PCI in the 1970s, this type of intervention has been performed 
more often than foreseen. In 1995 it was anticipated that by 2000 a total of 12,000 PCIs 
2 Angioplasty is performed to improve blood flow to the heart. It is a medical procedure in which a 
balloon is used to open a blockage in a coronary (heart) artery narrowed by atherosclerosis, a condition 
in which plaque builds up on the inner walls of the arteries. In the Netherlands, this procedure is also 
referred to as “dotteren” (named after C.T. Dotter, one of the pioneers who developed the procedure).
3 In the United States certificate of need (CON) entry regulation was mainly imposed to contain costs 
by preventing a costly medical arms race. As in the Netherlands, such regulation also required hospitals 
to obtain approval from the state government before establishing certain services, such as angioplasty. 
Because prospective payment and managed care lessened the need for these supply controls, since the 
mid-1980s many states have repealed CON regulation for angioplasty (Vaughan Sarrazin and Rosenthal, 
2004).
Figure 6.1: Travel time to nearest PCI hospital in the Netherlands (2006)
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would be carried out. The actual figure that year, however, was 17,000. By 2005, this 
number had even increased to 32,000. This figure is expected to increase further to well 
over 40,000 interventions by 2010 (GHR, 2007). The main cause of this increase is that PCI 
has successfully replaced more complicated and risky surgical interventions, particularly 
coronary artery bypass grafting (CABG). By now, due to new techniques angioplasty 
on an outpatient same-day discharge base can be safely performed in the majority of 
patients with stable and unstable angina pectoris and with single- and multivessel PCI 
(Slagboom et al., 2005). 
Anticipating these developments and responding to hospitals willing to enter the mar-
ket for angioplasty,4 the Dutch Minister of Health asked the Health Council whether it 
would be desirable to either modify or repeal the current entry regulation. In 2007 the 
Health Council concluded that maintaining the requirements concerning the minimum 
number of procedures and the availability of interventional cardiologists remained 
essential (GHR, 2007). First, a hospital should at least perform 600 PCI procedures per 
year.5 Second, within a hospital at least four interventional cardiologists should be avail-
able. According to the Council, if additional capacity would be required the decision 
to allow new hospitals to enter the market for angioplasty needs to be prepared and 
implemented at the regional level to facilitate close collaboration at the level of primary 
care (GPs and ambulance services) and secondary care (PCI centres and cardiac centres 
with on-site heart surgery facilities). Despite the ongoing discussion regarding the argu-
ments for and against further expansion of the number of PCI centres in the Netherlands 
(e.g. Zijlstra and De Boer, 2007), the Minister of Health recently expressed his intention 
to repeal the current entry regulation so that any hospital would be free to enter the 
market for angioplasty.6 That is, if they are able to meet the requirements for starting a 
PCI programme mentioned in the Dutch guidelines for interventional cardiology (see 
Aengevaeren et al., 2005). First, there has to be a formal cooperation agreement with 
one of the existing centres that has cardiac surgery on site for the purpose of supervi-
sion, support, backup, and training in the initial phase. Second, the new centre has to 
demonstrate that 400 PCIs can be reached within two years and 600 PCIs within three 
to five years. 
4 Since hospitals and physicians are reasonable well reimbursed for their efforts per PCI procedure, 
financial arguments are very likely to play a role in the minds of the hospitals that have ambitions to start 
a new PCI centre (Zijlstra and De Boer, 2007).
5 Studies examining the relation between the number of patients undergoing angioplasty at a hospital 
and their post-surgical outcomes indicate that minimum procedure volumes for hospitals and physicians 
contribute to yielding better outcomes (e.g. Ho, 2004).
6 Urged by the parliament, in September 2009 this policy measure has been postponed to a later year.
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6.2.2 Price regulation
Each patient admitted to a Dutch hospital or visiting a hospital’s outpatient clinic is 
categorised into a Diagnosis and Treatment Combination (DBC). Each DBC includes all 
hospital activities and services (both inpatient and outpatient) associated with the pa-
tient’s demand for care, from his initial consultation or examination to the final check-up. 
Since 2005, hospitals and insurers are able to negotiate prices per DBC for a number of 
routine hospital services. From 2005 to 2009 the proportion of freely negotiable hospital 
production, called B-segment, has been increased from about 10 to about 34 percent of 
total hospital expenditure. However, for the vast majority of hospital production, called 
A-segment, prices per DBC are still determined by the Dutch Healthcare Authority and 
do not differ across individual hospitals. This price regulation also applies to angioplasty. 
In 2006 the fixed price (including the reimbursement for hospital costs and a fixed physi-
cian fee, but excluding the cost of capital) of an outpatient and inpatient PCI was €6,400 
and €9,000, respectively. As a result, for PCI procedures hospitals and insurers are only 
able to negotiate volume and quality.
6.2.3 Quality information
As a result of recent initiatives, hospital quality information becomes more available for 
patients in the Netherlands. Since 2005 some hospital quality information has become 
easily accessible on the government sponsored patient-oriented health care portal 
www.KiesBeter.nl (literally: “make better choices”). Already in its first year about 1.7 mil-
lion people visited this website and early 2006 about 23 percent of the Dutch population 
was aware of its existence (Gravestein et al., 2006). Patients can use the portal for com-
paring individual hospitals on different sets of hospital outcome measures developed 
by the Dutch Healthcare Inspectorate (IGZ) in cooperation with stakeholders (hospitals 
and physicians). These sets, published on the internet with a one-year time lag, include 
hospital wide quality indicators and treatment-specific indicators. Indicators measuring 
the quality of PCI procedures performed by hospitals however are not (yet) available.7 
When comparing hospitals for PCI procedures, patients can use the quality indicator 
measuring the percentage of heart failure patients that was readmitted to the same 
hospital within 12 weeks after discharge. The hospital’s readmission rate after treatment 
for heart failure is a general indicator of the success of its cardiac treatment. If the Dutch 
guidelines on heart failure are followed, morbidity and the number of readmissions are 
7 Such data is being collected only recently within the context of the National Cardiovascular Data Reg-
istry (NCDR) database for PCIs (Van der Velde et al., 2008). However, though participation is mandatory 
for all PCI hospitals, public disclosure of their performances is not. Each individual hospital is the owner 
of its own data and information about performances are not available to third parties.
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likely to decrease. The quality of life for heart failure patients will then also increase. 
An important limitation of this indicator is however that, as all other IGZ performance 
indicators, it is not adjusted for differences in the case-mix of hospitals. 
Another quality indicator available to patients is the percentage of patients with pres-
sure ulcers that arose after admission to the hospital. This indicator provides patients 
with general information about hospital wide quality. Pressure ulcers can be extremely 
painful, cause discomfort and, in some cases, even lead to life-threatening complica-
tions. Proper care can prevent them from occurring in the hospital. 
In addition to the patient-oriented health care portal, patients can rely on hospital rat-
ings provided by the media. A popular Dutch news magazine (Elsevier) annually ranks 
Dutch hospitals on overall reputation using information obtained from an annual ques-
tionnaire among general practitioners, medical specialists, residents, nurses, hospital 
managers, and hospital board members. The same questionnaire also provides informa-
tion about hospitals’ reputation for cardiology, which is also published in this magazine. 
6.3 Consistency of publicly available quality information
For consumer information to be helpful, the available indicators should agree on the 
ranking of hospitals. If not, information may confuse rather than inform patients (e.g. 
Rothberg et al., 2008). Taking the perspective of a patient seeking to choose the best 
hospital for angioplasty, we here examine the quality information publicly available for 
angioplasty patients in 2006 and evaluate their consistency. For each of the four quality 
indicators discussed above, we rank all hospitals. As Figure 6.2 illustrates, the publicly 
available consumer information fails to agree on either top- or bottom-performing PCI 
hospitals. Hospitals ranked first by one indicator are often ranked much lower by another 
indicator and vice versa. This is likely to complicate patient choice, particularly since no 
guidance is offered to patients what specific indicator benefits them most. For example, 
is it more important to choose a hospital with a low prevalence of pressure ulcers or one 
that has a good reputation? 
Even when two indicators claim to measure the same type of performance (quality of a 
hospital’s cardiac department), agreement among them seems to be poor as illustrated 
by Figure 6.3. Since tied ranks exist, we compute the Pearson Product Moment Correla-
tion for assessing the degree of linear relationship between any two indicators. As Table 
6.1 shows, pair wise correlations are all fairly low implying that the measures are only 
weakly associated.
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Correlation is highest between pressure ulcers and readmission rate after heart failure (r = 
-0.32), pressure ulcers and reputation for cardiology (r = -0.30), and overall reputa-
tion and reputation for cardiology (r = 0.30). While both measuring the quality of the 
hospital’s cardiac department, correlation between readmission rate for heart failure 
Figure 6.2: PCI hospitals’ rankings based on four different indicators
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Figure 6.3: Readmission rate after heart failure and reputation for cardiology
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Table 6.2: Number of PCI hospitals in patients’ choice sets 
Hospitals # Patients # Patients % Patients cum. # Patients cum. % 
 %1 22 %1 22 31
12 206 7% 228 8% 
11 270 10% 498 18% 
10 606 22% 1,104 40% 
9 564 20% 1,668 60% 
8 153 6% 1,821 66% 
7 369 13% 2,190 79% 
6 176 6% 2,366 85% 
 %88 824,2 %2 26 5
 %98 084,2 %2 25 4
 %39 775,2 %3 79 3
 %69 076,2 %3 39 2
1 104 4% 2,774 100% 
Number of hospitals in choice set:    
    9 naeM
    01 sudoM
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patients (IGZ) and reputation for cardiology (Elsevier) is very low (r = -0.20). This lack of 
consistency may be explained by the shortcomings of both the hospital outcome mea-
sures as well as the publicly available information about hospital reputation. The first are 
not adjusted for differences in the case-mix of hospitals and the latter are criticised for 
lacking validity. 
Quality scores for the university medical centre UMC St. Radboud, located in the city of 
Nijmegen, provide a clear illustration of how publicly available consumer information 
may complicate patient choice in the market for angioplasty. The observed readmission 
rate after heart failure (less than 4 percent; n = 52 patients) suggests high performance 
of this hospital’s cardiac department, whereas its reputation for cardiology is among 
the worst in the Netherlands. In this case, the latter indicator better reflects the actual 
situation in 2006 than the first: in April 2006 the IGZ ordered the hospital to “cease to 
perform cardiac surgery on adults” with immediate effect since cardio-surgical care pro-
vided to adults was “not of the required standard” (IGZ, 2006). This order was repealed in 
October 2006.8 Within this context the low readmission rate is less strange than it may 
appear. Preceding the order not to perform heart surgery on all adults, the IGZ in 2005 
already ordered the hospital not to perform heart surgery on high-risk patients. In the 
absence of risk-adjustment, this “mandatory risk selection” is very likely to have reduced 
the observed percentage of readmissions after heart failure.
To summarise, publicly available consumer information about hospital quality in the 
Netherlands is incomplete and provides patients with conflicting information. Key 
question is then whether patients nevertheless use this information and respond to 
differences in observed quality between PCI hospitals.
8 Note that in the period April-October 2006 UMC St. Radboud was still allowed to perform PCIs.
Table 6.1: Correlation between publicly available indicators measuring hospital quality
Pressure ulcers
Readmission after 
heart failure
Overall reputation
Reputation for 
cardiology
Pressure ulcers 1.00
Readmission after 
heart failure
-0.32 1.00
Overall reputation -0.09 -0.21 1.00
Reputation for 
cardiology
-0.30 -0.20 0.30 1.00
Note: association is measured by the Pearson Product Moment Correlation.
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6.4 Data
Our principal data source is the Agis Health Database that contains individual patient 
level data from a large Dutch health insurer (Agis). We obtained data on 2,916 hospital 
visits for non-emergency angioplasty in 2006. In 2006 this insurer represented about 
1,200,000 enrolees corresponding with a national market share of 9 percent. The geo-
graphical key market of Agis includes both urban (Amsterdam, Utrecht) and rural areas. 
For each patient we observe the name of the hospital visited and the zip code of his 
residence. The available data also provides individual patient characteristics (gender, 
age) and information about the severity of the patient’s illness and his medical condi-
tion. First, the data allows us to distinguish whether PCI was performed as an inpatient 
procedure or on an outpatient same-day discharge base. Second, we know whether the 
patient before or after he underwent PCI in 2006 also suffered a heart attack and/or 
was diagnosed for open heart surgery. Remember that our study sample includes non-
emergency PCI procedures only. Hence, the latter variables reflect the general health 
status of the patient. In addition to the variables described above, to further capture 
patient heterogeneity a dummy variable is defined indicating whether the patient lives 
in a major city.9
Patients’ travel times are defined as the fastest route by car from the patient’s home to 
each hospital and are calculated in minutes. This route is obtained from a database that 
includes all 4-digit zip codes in the Netherlands and accounts for differences in average 
speed that exist between different road types. As already mentioned in Section 6.2.1, 
travel times to the nearest PCI centre are rather small in the Netherlands. If patients 
travelled extremely long, it can therefore reasonably be assumed that these patients 
were away from home when admitted to a hospital. For those patients, travel time from 
their place of residence incorrectly measures the travel costs incurred, which may bias 
the estimation results. To avoid this bias we exclude all patients who travelled more than 
60 minutes (n = 142; i.e. 5 percent). For the remaining patients (n = 2,774) a fixed set 
of hospital alternatives is defined (Ni). Each patient’s choice set consists of all hospitals 
performing PCI that can be reached within 60 minutes of travel time. As Figure 6.1 il-
lustrates, this threshold is not too restrictive.
Since Dutch health insurers in 2006 did not contract selectively with hospitals we im-
pose no further restrictions on patients’ choice sets. Almost 90 percent of the patients 
included in our study sample have at least 4 PCI hospitals in their choice set. As shown 
9 The four major cities in the Netherlands are Amsterdam (744,000 inhabitants), Rotterdam (534,000 
inhabitants), The Hague (476,000 inhabitants), and Utrecht (259,000 inhabitants).
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by Table 6.2, the most common choice set (n = 606; i.e. 22 percent) includes 10 hospitals. 
There are some patients who have only one hospital in their choice set. These patients (n 
= 104; i.e. 4 percent) are excluded from the estimation sample because they do not make 
a choice. As a result, the final study sample includes 2,670 patients. On average, these 
patients travelled 25 minutes to a hospital for PCI. Table 6.3 summarises the individual 
patient characteristics for the empirical analysis.
The hospital attributes observed by patients in 2006 include both general characteris-
tics (type, size) as well as publicly available consumer information about hospital quality 
(Section 6.2.3). Because long waiting lists are absent for angioplasty (GHR, 2007), PCI 
hospitals are not differentiated in terms of this attribute. There is also no differentiation 
in prices across hospitals. Hospitals’ prices are fixed by the government and the deci-
sions of patients are not affected by prices: angioplasty is included in the mandatory 
basic health insurance package, out-of-pocket payments for enrolees with a (voluntary) 
deductible do not differ across hospital alternatives (and are also far below the costs of 
a PCI procedure), and insurers do not offer preferred provider contracts with differenti-
ated co-payments.
Table 6.2: Number of PCI hospitals in patients’ choice sets
Hospitals (#) Patients (#) Patients (%) Patients (cum. #) Patients (cum. %)
13 22 1% 22 1%
12 206 7% 228 8%
11 270 10% 498 18%
10 606 22% 1,104 40%
9 564 20% 1,668 60%
8 153 6% 1,821 66%
7 369 13% 2,190 79%
6 176 6% 2,366 85%
5 62 2% 2,428 88%
4 52 2% 2,480 89%
3 97 3% 2,577 93%
2 93 3% 2,670 96%
1 104 4% 2,774 100%
Number of hospitals in choice set:
Mean 9
Modus 10
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Data on hospital type (university medical centre or general hospital) and size (number of 
beds) is obtained from the web-based Dutch National Atlas of Public Health (www.zorg-
atlas.nl). IGZ provided the data on hospitals’ readmission rate after treatment for heart 
failure and point prevalence of pressure ulcers. Since the hospital outcome measures 
become available with a one-year time lag, we use data from 2005 for analysing patient 
hospital choice in 2006. Data on hospital reputation is obtained from Elsevier (2006) 
presenting the results of a questionnaire among more than 7,000 respondents. We use 
the hospital’s average score on a 1 (the hospital’s overall reputation is very poor) to 10 
(the hospital’s overall reputation is excellent) rating scale to measure its overall reputa-
tion. The variable capturing hospital’s reputation for cardiology has the maximum value 
+3 if >50% of the respondents compliment on the hospital’s cardiology department. 
It has the minimum value -3 if >50% of the respondents criticise the hospital’s cardiol-
ogy department. The other values +2 (-2), +1 (-1), and 0 represent situations in which 
33-49%, 20-32%, or <20% of the respondents compliment on (criticise) the hospital’s 
cardiology department, respectively. Table 6.4 lists the hospital attributes used in this 
paper and their descriptive statistics.
Table 6.3: Descriptive statistics patients in study sample
Variable Mean SD Minimum Maximum
Actual travel time (in minutes by car) 22 13 0 60
Patient characteristics (n = 2,670)
Female 0.34 0 1
Age ≥75 0.24 0 1
Inhabitant of major city 0.43 0 1
Inpatient admission 0.67 0 1
Diagnosed for open heart surgery 0.39 0 1
Suffered from heart attack 0.26 0 1
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Table 6.4: Descriptive statistics PCI hospitals in the Netherlands (2006, n = 19)
Hospital City UMCa Number 
of beds
Readmission 
after heart 
failurec
Pressure 
ulcersb
Overall 
reputationd
Reputation 
for 
cardiologye
1. MC Alkmaar Alkmaar No 913 3.4 7.0 7.1 1
2. AMC Amsterdam Yes 1,200 12.7 11.1 7.5 2
3. VUmc Amsterdam Yes 713 5.4 8.9 6.8 0
4. OLVG Amsterdam No 550 9.3 9.3 8.0 3
5. Alysis Zorggroep Arnhem No 750 8.6 5.9 7.5 1
6. Amphia Ziekenhuis Breda No 1,368 11.5 9.9 6.7 2
7. HaGa Ziekenhuis Den Haag No 1,017 6.0 6.0 6.7 2
8. Catharina Ziekenhuis Eindhoven No 600 12.8 2.3 7.5 3
9. MS Twente Enschede No 1,070 5.9 3.9 6.8 2
10. UMC Groningen Groningen Yes 1,339 10.4 5.4 7.4 1
11. Noorderbreedte Leeuwarden No 930 6.2 7.2 7.6 1
12. LUMC Leiden Yes 882 5.1 6.7 7.2 1
13. AZM Maastricht Yes 715 17.7 2.8 7.1 2
14. St. Antonius Ziekenhuis Nieuwegein No 584 3.0 4.4 7.8 3
15. UMC St. Radboud Nijmegen Yes 953 3.8 8.7 7.1 0
16. Erasmus MC Rotterdam Yes 1,237 18.0 2.4 7.2 2
17. MC Rijnmond-Zuid Rotterdam No 745 7.2 7.2 6.6 1
18. UMC Utrecht Utrecht Yes 822 7.6 7.0 7.4 0
19. Isala Klinieken Zwolle No 1,004 6.9 5.1 7.1 3
Mean 915 8.5 6.4 7.2 2
Minimum 550 3.0 2.3 6.6 0
Maximum 1,368 18.0 11.1 8.0 3
Standard deviation 247.50 4.4 2.5 0.4 1.0
Notes:
a. University medical centre.
b. Measured as point prevalence (t = 2005).
c. Measured as the percentage heart failure patients readmitted to the hospital within 12 weeks after 
discharge (t = 2005).
d. Average hospital score on a rating scale from 1 (very poor reputation) to 10 (excellent reputation).
e. Hospital score on a rating scale from -3 (very poor reputation) to 3 (excellent reputation).
Sources: www.zorgatlas.nl, Dutch Healthcare Inspectorate (IGZ), and Elsevier (2006).
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6.5 Model and estimation results
6.5.1 The model
Our choice model is based on the assumption that patients are rational agents that 
maximise utility.10 We use a patient-level utility function in which travel time and hos-
pital attributes are the main determinants of patient hospital choice. When selecting a 
hospital, patients are assumed to weigh the costs of increased travel time against higher 
quality.11 The utility that patient i derives from being admitted for angioplasty at hospital 
j is specified as follows:
(6.1) 
where tij reflects travel time from patient i’s home to hospital j; H.j is a vector of hospital 
j’s attributes observed by the patient; P.i is a vector of patient i’s observed characteristics; 
and γij represents the idiosyncratic part of patient i’s evaluation of hospital j. We assert 
that patient i, given his needs and preferences, will choose hospital j when choosing any 
other alternative hospital included in his choice set (Ni) would result in lower utility. Note 
that prices are not included in Equation 6.1 because prices for angioplasty are regulated 
and not relevant for patients when making hospital choices. Angioplasty is included in 
the mandatory basic health insurance package and out-of-pocket payments do not dif-
fer across hospital alternatives. Consequently, hospitals are differentiated by geographic 
location and observed quality only. By interacting travel time and hospital attributes 
with the individual patient characteristics, we allow the trade-off between the costs and 
benefits of increased travel time to vary across patients. 
When estimating a patient choice model the potential endogeneity of quality might 
cause problems in two different ways. First, does high quality attract patients or does 
a high number of patients lead to high quality? If the latter is true, hospitals with geo-
10 One issue that arises in modelling patient hospital choice in the Netherlands is the role of the referring 
general practitioner (GP). In general, however, the decision of which hospital to visit is most often made 
by the patients themselves, alone or in consultation with their GP. Since Dutch GPs do note face financial 
incentives to refer patients to particular hospitals, it is not in their interest to neglect patients’ prefer-
ences. However, if (some) GPs know more about hospital quality than observed in the publicly available 
data, the estimation results may be biased. Since we do not have data on the characteristics of individual 
patients’ GPs, we are not able to correct for this potential bias. 
11 Since Dutch insurers do not selectively contract with hospitals, models specifically designed to esti-
mate the value consumers place on different provider networks (Town and Vistnes, 2001; Capps et al., 
2003) do not accurately depict hospital markets in the Netherlands (Varkevisser et al., 2008).
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graphically attractive locations may gradually become high-quality hospitals over time. 
In our sample, however, hospitals with higher observed quality are not systematically 
higher-volume hospitals. We therefore treat quality as exogenous in the model. That is, 
the causation runs from quality to patient choice and not in reverse. Second, hospital 
outcome measures and patient choice are potentially endogenous. Hospitals might 
avoid sick patients and/or select healthy patients which in turn could affect observed 
quality because the IGZ performance indicators (prevalence of pressure ulcers, percent-
age readmissions after heart failure) are not adjusted for differences in the case-mix 
of hospitals. For several reasons, however, this is unlikely to be the case: (1) because 
patients observe last year’s outcome measures when comparing hospitals, we use qual-
ity data from 2005 for analysing patient hospital choice in 2006; (2) public reporting on 
hospital outcomes has been introduced in 2005, so it is unlikely that hospitals responded 
immediately by starting to select patients, particularly since they had limited incentives 
to do so;12 (3) in our study sample observed differences (gender, age, and medical condi-
tion) among a hospital’s PCI patients in 2006 are not correlated with its observed quality 
in the same year, suggesting the absence of a selection bias.
Assuming that the random component of utility affecting hospital choice is indepen-
dent and identically distributed (iid) extreme value, we apply a conditional logit model 
(McFadden, 1974). This implies that patient i’s probability of visiting hospital j is repre-
sented by:
(6.2) 
For the conditional logit estimation of Equation 6.1 we use the maximum likelihood 
estimation method and standard iterative procedures for its optimisation. Maximum 
likelihood estimation of the conditional logit model can be shown under very general 
conditions to provide estimators that are asymptotically efficient and normally distrib-
uted (McFadden, 1974). 
6.5.2 Estimation results
The model estimates, shown in Table 6.5, are generally as expected. The coefficient for 
travel time is negative and statistically significant. With the exception of the performance 
indicator measuring the percentage of patients with pressure ulcers, publicly available 
consumer information on hospital quality is found to have an impact on patient hospital 
choice with the expected signs. The coefficient on the readmission rate after treatment 
12 Hospitals are reasonably well reimbursed for PCI procedures and supply regulation prevents entry.
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for heart failure is negative and significant, while the coefficients on hospitals’ overall 
reputation and reputation for cardiology are both positive and significant. These out-
comes suggest that patients respond to the publicly available consumer information 
about hospital quality. 
Table 6.5: Conditional logit estimates of patient hospital choice
Coefficient SE
Travel time -0.1529 * 0.0119
University medical centre 9.1235 * 0.9532
Number of beds -0.0055 * 0.0012
Readmission rate after treatment for heart failure -0.3687 * 0.0535
Point prevalence of pressure ulcers 0.0203 0.0685
Overall reputation 1.8668 * 0.4525
Reputation for cardiology 2.8832 * 0.2970
Interacted with Age ≥75:
Travel time 0.0017 0.0100
University medical centre -0.8206 0.4303
Number of beds 0.0015 * 0.0007
Readmission rate for heart failure -0.1726 * 0.0514
Point prevalence of pressure ulcers 0.2679 * 0.0648
Overall reputation 1.1370 * 0.3904
Reputation for cardiology -0.2880 0.1487
Interacted with Female:
Travel time 0.0076 0.0087
University medical centre 0.0632 0.4011
Number of beds -0.0001 0.0006
Readmission rate for heart failure 0.0930 * 0.0380
Point prevalence of pressure ulcers -0.1422 * 0.0495
Overall reputation -0.7502 * 0.3363
Reputation for cardiology 0.1032 0.1370
Interacted with Major city:
Travel time -0.0336 * 0.0098
University medical centre -1.0554 * 0.5180
Number of beds -0.0014 0.0007
Readmission rate for heart failure 0.1887 * 0.0510
Point prevalence of pressure ulcers -0.0909 0.0616
Overall reputation -0.8997 0.4739
Reputation for cardiology -0.1806 0.1687
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When statistically significant, the coefficients of the interaction terms capturing patient 
heterogeneity generally have plausible signs. For instance, patients living in a major 
city as well as more seriously ill patients (i.e. non-emergency PCI patients who in 2006 
were also diagnosed for open heart surgery) have a more negative coefficient on travel 
time, suggesting that ceteris paribus these patients are less willing to travel. Patients’ 
willingness to travel for improvements in observed quality will be discussed in detail in 
the next section.
Table 6.5: Conditional logit estimates of patient hospital choice (continued)
Coefficient SE
Interacted with Open heart surgery: 
Travel time -0.0371 * 0.0098
University medical centre 0.2952 0.4117
Number of beds -0.0004 0.0007
Readmission rate for heart failure -0.0541 0.0492
Point prevalence of pressure ulcers 0.2034 * 0.0608
Overall reputation -4.2509 * 0.3744
Reputation for cardiology 1.3317 * 0.1569
Interacted with Heart attack:
Travel time 0.0099 0.3150
University medical centre 0.4627 0.4124
Number of beds -0.0006 0.0007
Readmission rate for heart failure 0.0945 0.0559
Point prevalence of pressure ulcers 0.0774 0.0432
Overall reputation -1.9504 * 0.3978
Reputation for cardiology 0.6995 * 0.1489
Interacted with Inpatient:
Travel time -0.0001 0.0120
University medical centre -8.3613 * 0.9631
Number of beds 0.0083 * 0.0012
Readmission rate for heart failure 0.1016 0.0577
Point prevalence of pressure ulcers -0.0826 0.0728
Overall reputation 1.0880 * 0.4602
Reputation for cardiology -3.0575 * 0.3028
Number of patients 2,670
Number of patient-hospital combinations 22,722
Note: * Significance at 5%.
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To measure our model’s goodness of fit we analyse predicted versus actual hospital 
choice. Each hospital’s predicted market share (MSj) is computed by summing up pa-
tients’ estimated choice probabilities for that hospital:
(6.3) 
where Prij is the probability that patient i will choose hospital j. As Table 6.6 shows, 
hospitals’ predicted market shares are very similar to actual market shares. Hence, at the 
individual hospital level model predictions are quite accurate. As an additional measure, 
following Town and Vistnes (2001), we construct a “hit-or-miss” criterion where the 
predicted choice for a patient is the hospital having the maximum predicted probability. 
Overall, the model correctly predicts 67 percent of patients’ hospital choices suggesting 
a high degree of explanatory power. The hospital choice model estimated by Town and 
Vistnes (2001) correctly predicts about 30 percent of hospital choices for their differ-
Table 6.6: Predicted versus actual hospital choice
Hospital name
Actual patients Predicted patients
MSj % MSj % cum%
St. Antonius Ziekenhuis 625 23% 635 24% 24%
OLVG 548 21% 545 20% 44%
AMC 487 18% 495 19% 63%
UMC Utrecht 315 12% 271 10% 73%
VUmc 215 8% 224 8% 81%
Isala Klinieken 205 8% 181 7% 88%
Alysis Zorggroep 38 1% 71 3% 91%
Zorggroep Noorderbreedte 62 2% 49 2% 93%
UMC St. Radboud 48 2% 44 2% 94%
LUMC 27 1% 40 1% 96%
UMC Groningen 10 0% 22 1% 97%
MC Alkmaar 12 0% 19 1% 97%
Erasmus MC 8 0% 17 1% 98%
HaGaZiekenhuis 18 1% 13 0% 98%
Catharina Ziekenhuis 15 1% 12 0% 99%
Amphia Ziekenhuis 16 1% 12 0% 99%
MC Rijnmond-Zuid 13 0% 10 0% 100%
Medisch Spectrum Twente 8 0% 10 0% 100%
AZM 0 0% 0 0% 100%
Sum 2,670 2,670
Σ
=
=
n
i
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ent samples (8,000 patients per sample and 109 California hospitals). Most studies on 
patient hospital choice, however, do not report how well their estimated models predict 
patients’ actual choices. By exception, Capps et al. (2001) and Varkevisser et al. (2009) 
report the percentage of patients actually visiting the hospital having the maximum 
predicted probability to be 35 percent (27,631 patients and 22 San Diego hospitals) and 
43 percent (5,389 patients and 66 Dutch hospitals), respectively.
6.6 Patients’ willingness to travel for improvements in quality
To examine patients’ responsiveness to publicly available consumer information in more 
detail, we compute patients’ willingness to travel for improvements in observed quality. 
This willingness to travel reflects the value (in terms of travel costs) patients place on 
improvements in a particular aspect of observed hospital quality. For assessing the po-
tential implications of patient choice behaviour in the market for angioplasty, we are pri-
marily interested in patients’ willingness to travel for changes in a hospital’s readmission 
rate rather than changes in its reputation. The reason for this is that hospital outcome 
measures are more suitable for assessing potential short run demand responses under-
lying hospital competition because changes in reputation usually take more time.13 
From the general properties of discrete choice models it follows that the sum of 
estimated coefficients on readmission rate for heart failure divided by the sum of 
estimated coefficients on travel time represents the patient’s willingness to travel for 
improvements in this hospital outcome measure (WTTi). This relation is derived from 
Equation 6.1 as follows. We first take the total derivative of utility with respect to travel 
time and readmission rate and set this derivative to zero. Then we solve this equation 
for the change in travel time that keeps utility constant if the percentage of heart failure 
patients readmitted to the hospital changes. WTTi is then the increase in travel time that 
keeps patients’ representative utility constant given an improvement in readmission 
rate. Since in our patient choice model both travel time and hospital quality measures 
are interacted with the individual patient characteristics (see Equation 6.1), WTTi is al-
lowed to vary across patient groups:
(6.4) 
13 In the short run, a hospital’s reputation can be treated as a fixed asset giving it a competitive advan-
tage or disadvantage.
 
Σ
Σ
=
=
⋅+
⋅+
= m
l
lil
m
l
lil
i
P
P
WTT
1
1
ρδ
σλ
 
 
Quality competition in regulated hospital markets 137
where P.i is a vector of patient i’s observed characteristics. 
Based on the patient characteristics observed in the data, we distinguish 48 different 
patient groups in the market for angioplasty (Appendix 6.A). The largest patient group 
(n = 234) consists of all male patients admitted as an inpatient who are less than 75 years 
old, live outside one of the major cities, and are relatively healthy (i.e. in 2006 they did 
not suffer a heart attack nor were they diagnosed for open heart surgery). Most patient 
groups, however, comprise a very small number of patients. The 25 smallest patient 
groups jointly account for little more than 20 percent of the study sample, whereas the 
aggregate share of the 10 largest patient groups is 53 percent. 
Overall, patients’ willingness to travel for hospitals with lower readmission rates seems to 
be quite modest. In our study sample patients are only willing to travel about 6 minutes 
extra for a one-standard-deviation (4.4%-point) lower readmission rate. Or alternatively, 
a similar decrease in travel time would be required to keep patients’ utility constant 
given a 4.4%-point higher readmission rate. Given that average actual travel time in our 
study sample is only 22 minutes, patients are willing to travel about 27 percent further 
for a standardised reduction in the readmission rate when expressed in relative terms. 
However, as illustrated by Figure 6.4 (see Appendix 6.A for details), it follows from our 
estimation results that willingness to travel for better observed quality differs signifi-
cantly across patient groups. For some patient groups the point estimate of WTTi at the 
5%-level does not statistically differ from zero.14 Since patients in these groups are 
relatively sick and live in a major city (Amsterdam, Utrecht), geographic proximity and 
reputation for cardiology appear to be far more important to them when choosing a 
hospital for angioplasty. 
For some other patient groups willingness to travel is found to be quite substantial. 
Patients not living inside a major city have the highest WTTi. Depending on their other 
personal characteristics, the increase in travel time that keeps these patients’ utility 
constant given a 4.4%-point lower readmission equals 8 to 16 minutes. In relative terms, 
these patients are willing to increase travel time by as much as 40 percent (or more) for 
visiting a hospital whose cardiac treatment appears to be more successful.
14 Confidence intervals are obtained by a parametric bootstrap (Krinsky and Robb, 1986; 1990). We used 
the vector of estimated parameters and corresponding covariance matrix from our conditional logit 
model to randomly draw 1,000 sets of alternative, equally probable model parameters from a multivari-
ate normal distribution with this vector and matrix as means and covariance, respectively. 
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From the analysis presented above it follows that the trade-off between travel time and 
a hospital’s readmission rate significantly differs across patients, depending on their 
personal characteristics. So the answer to the question whether Dutch patients in the 
market for angioplasty respond to this publicly available hospital outcome measure is 
ambiguous: most patients do while some don’t. 
6.7 Assessing competition among PCI hospitals in the Netherlands
From the previous section it follows that most patients in the market for angioplasty are 
willing to travel for a lower readmission rate. However, estimating patients’ willingness 
to travel does not reveal predicted demand effects of unilateral changes in observed 
quality for individual hospitals. To assess hospital substitutability that underlies compe-
tition among PCI hospitals in the Netherlands, we here simulate short-run patient de-
mand responses to changes in a hospital’s readmission rate taking into account patient 
heterogeneity and actual hospital differentiation (location, type, size, and reputation). 
The more patients are predicted to substitute toward alternative hospitals following 
an increase in this performance indicator, the more important it is for hospitals to care 
about publicly available outcome measures in order to avoid a loss of market share.
6.7.1 Hypothetical hospital closure
For identifying hospital substitutability in the market for angioplasty in the Netherlands 
in general, we first consider the hypothetical closure of a hospital by removing that hos-
pital from each patient’s choice set. Considering the closure of a hospital is equivalent 
to analysing an extreme fall in all aspects of hospital quality to the point where demand 
for hospital j is zero. The goal of this simulation is to assess hospital substitutability by 
identifying patients’ second-best hospital given the geographic location, observed 
quality, and reputation of the then remaining hospital alternatives. From this simula-
tion it follows that the geographically nearest hospitals appear to be hospital j’s closest 
competitors (Appendix 6.B). For those hospitals with neighbouring hospitals within 40 
kilometres (25 miles) the effect of a hypothetical closure on further hospitals is quite 
small or even absent. 
We identify competitors as those hospitals that at least 10 percent of the patients would 
substitute toward. We also computed an HHI for the diverted patients. The lower the 
value of this HHI, the more scattered the patients substituting away from hospital j 
are among the other hospitals. If the value of this “diversion HHI” increases, (potential) 
competition from other hospitals decreases. The value 1 would suggest that the market 
for hospital j includes one other hospital at most. Table 6.7 reveals that for more than 
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half of the Dutch PCI hospitals the number of potential competitors is two at most. For 
most of these hospitals computed HHIs are also fairly high, suggesting these hospitals 
have relatively strong market positions. 
6.7.2 Predicted demand effect of reduction in observed readmission rate
To further examine Dutch PCI hospitals’ substitutability, we determine the impact of a 
standardised increase in each hospital’s readmission rate on its own demand and that 
of all other hospitals. Note the relation of the logit choice probability to representa-
tive utility is S-shaped. This shape implies that if the representative utility of a hospital 
alternative is very high compared with other alternatives, a small decrease in utility has 
little effect on the probability of being chosen: it is still sufficiently better than the other 
alternatives such that this small deterioration doesn’t hurt. The point at which a reduc-
tion in observed quality has the strongest effect on an individual hospital’s demand is 
when at least two hospital alternatives are almost equally attractive to the patient. An 
increase in hospital j’s readmission rate after heart failure will have less effect on patient 
demand when other hospitals are far less attractive than when simulating the same 
Table 6.7: Assessing potential hospital competition
Hospital name City
Hospital 
substitutesa
Diversion
HHIb
UMC Groningen Groningen 1 0.881
UMC Utrecht Utrecht 2 0.593
Medisch Spectrum Twente Enschede 2 0.548
Zorggroep Noorderbreedte Leeuwarden 2 0.517
Catharina Ziekenhuis Eindhoven 2 0.462
OLVG Amsterdam 2 0.421
VUmc Amsterdam 2 0.409
Alysis Zorggroep Arnhem 2 0.403
St. Antonius Ziekenhuis Nieuwegein 2 0.345
Amphia Ziekenhuis Breda 2 0.343
UMC St. Radboud Nijmegen 3 0.380
MC Rijnmond-Zuid Rotterdam 3 0.362
HaGaZiekenhuis Den Haag 3 0.313
AMC Amsterdam 3 0.311
MC Alkmaar Alkmaar 3 0.282
Isala Klinieken Zwolle 3 0.240
Erasmus MC Rotterdam 4 0.251
LUMC Leiden 4 0.197
Notes:
a. Those hospitals that at least 10 percent of the patients substitute toward.
b. This HHI is a concentration measure for the diverted patients.
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quality reduction for a hospital located in an area where other hospitals are sufficiently 
attractive to induce a moderate share of patients to choose it.
From the simulation results it follows that when the readmission rate increases by one-
standard-deviation (4.4%-point), a hospital’s demand among the angioplasty patients 
studied decreases by about one-third on average. However, as revealed by Table 6.8 and 
Figure 6.5, depending on local/regional hospital differentiation the predicted impact 
of a standardised reduction in observed quality substantially differs across individual 
hospitals though some of the confidence intervals obtained by a parametric bootstrap 
are quite large. For instance, despite its point-estimate of -24 percent the predicted loss 
of patients for the university medical centre in Rotterdam is not statistically significant 
at the 5%-level. The smallest statistically significant impact is found for two general 
hospitals in The Hague and Eindhoven. The predicted loss of patients for these hospitals 
is 13 percent and 19 percent, respectively. The biggest impact on patient demand (-45 
percent or more) is found for university medical centres in Amsterdam, Leiden, and 
Nijmegen. 
From the estimated demand effects it follows that for most hospitals decreased observed 
quality is predicted to cause many patients to substitute towards alternative hospitals. 
Again, predicted substitution patterns indicate that in the market for angioplasty 
competition is most intense among neighbouring hospitals. For instance, following a 
unilateral increase in the readmission rate of the biggest university medical centre in 
Amsterdam (AMC) the vast majority of all switching patients (65 percent) is predicted to 
substitute toward the other two PCI hospitals in Amsterdam. 
Chapter 6142
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6.8 Conclusion
In this paper we examine whether Dutch patients in the market for angioplasty respond 
to publicly available information about hospital quality and what implications their 
choice behaviour may have for quality competition using detailed claims data from the 
year 2006. The market for angioplasty in the Netherlands provides a unique opportunity 
to empirically assess quality competition in a regulated hospital market: patient choice 
is affected by observed quality and geographic location only, hospital prices are fixed, 
and entry is restricted. The most important findings of the paper can be summarised 
as follows. First, publicly available consumer information about hospital quality in the 
Netherlands is incomplete and inconsistent. Even when measuring the same type of 
performance, hospitals ranked first by one indicator are generally ranked much lower 
by another indicator and vice versa. Second, observed quality nevertheless significantly 
affects patient hospital choice though willingness to travel for a lower readmission rate 
is found to significantly differ between patient groups. Third, simulation results suggest 
that unilateral changes in observed quality (readmission rate after heart failure) induce 
many patients to substitute toward alternative hospitals but hospital substitutability is 
Table 6.8: Effect of unilateral increase in readmission rate
Hospital name
Predicted 
patients
Standardised increase readmission rate: 
change in predicted patients
UMC St. Radboud 49 -23 -48% (0.0259)
LUMC 40 -18 -46% (0.0378)
AMC 495 -221 -45% (0.0599)
VUmc 224 -93 -42% (0.0943)
UMC Utrecht 271 -113 -42% (0.0414)
Alysis Zorggroep 71 -30 -41% (0.0438)
St. Antonius Ziekenhuis 635 -217 -34% (0.0277)
MC Rijnmond-Zuid 12 -4 -34% (0.0509)
Zorggroep Noorderbreedte 44 -14 -32% (0.0270)
UMC Groningen 19 -6 -30% (0.0228)
Amphia Ziekenhuis 13 -4 -29% (0.0351)
Medisch Spectrum Twente 10 -3 -28% (0.0281)
OLVG 545 -147 -27% (0.0665)
MC Alkmaar 22 -6 -27% (0.0392)
Isala Klinieken 181 -45 -25% (0.0244)
Erasmus MC 12 -3 -24% (0.1082)
Catharina Ziekenhuis 10 -2 -19% (0.0255)
HaGaZiekenhuis 17 -2 -13% (0.0319)
Sum 2,670
Note: standard deviations in parentheses are obtained by a parametric bootstrap (n = 1,000).
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found to be restricted to a few neighbouring hospitals. Fourth, since patients are found 
to respond to changes in a hospital outcome measure that is not adjusted for differences 
in the case-mix of hospitals, increased competition may encourage hospitals to select 
risks in order to improve measured quality and avoid a loss of market share. Risk selec-
tion can take many different forms. For instance, hospitals could implement changes in 
marketing to attract healthy patients and/or delay treatment for sick patients.
From a policy perspective, these findings suggest that a sudden repeal of entry regula-
tion in the Dutch market for angioplasty, as initially proposed by the Minister of Health, 
may have serious adverse effects. If more hospitals start to perform PCIs, this may 
increase financial incentives for improving measured and observed performances (e.g. 
readmission rate) at the expense of unmeasured and unobserved quality (e.g. accessibil-
ity). The policy decision from September 2009 to maintain the current entry regulation 
until the market for angioplasty becomes more transparent is therefore sensible. Public 
disclosure of reliable and detailed hospital quality indicators that are adjusted to dif-
ferences in the case-mix of hospitals should be the first step toward more competition 
and higher quality in this market. In the short run, increased competition in the Dutch 
market for angioplasty by permitting entry of new PCI hospitals is less welcome than it 
may appear.
Although this paper analyses patients’ responsiveness to publicly available information 
about hospital quality in one particular submarket, its policy implication is generally 
applicable. That is, increased competition in regulated markets where hospitals com-
pete for patients on non-price dimensions is only likely to increase quality when it is 
combined with public disclosure of hospital quality indicators that are comprehensive 
and adjusted for differences in the case-mix of hospitals. 
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Appendix 6.A: Descriptive statistics patient groups
Patient 
group
Age 
≥75
Major 
city
Female
Open 
heart 
surgery
Inpatient
Heart 
attack
Freq. Perc.
Actual 
travel
time
WTTi
1 yes yes yes yes yes yes 6 0.2% 7 3
2 yes yes yes yes yes 14 0.5% 10 4 *
3 yes yes yes yes 29 1.1% 15 6 *
4 yes yes yes yes yes 48 1.8% 12 2
5 yes yes yes yes 39 1.5% 10 4 *
6 yes yes yes 21 0.8% 13 6 *
7 yes yes yes yes yes 7 0.3% 10 5 *
8 yes yes yes yes 14 0.5% 15 6 *
9 yes yes yes 26 1.0% 13 8 *
10 yes yes yes yes 23 0.9% 11 4 *
11 yes yes yes 46 1.7% 11 6 *
12 yes yes 17 0.6% 12 8 *
13 yes yes yes yes yes 18 0.7% 34 8 *
14 yes yes yes yes 35 1.3% 31 10 *
15 yes yes yes 20 0.7% 30 12 *
16 yes yes yes yes 31 1.2% 29 9 *
17 yes yes yes 37 1.4% 25 11 *
18 yes yes 18 0.7% 37 14 *
19 yes yes yes yes 12 0.4% 31 10 *
20 yes yes yes 43 1.6% 32 12 *
21 yes yes 27 1.0% 27 14 *
22 yes yes yes 34 1.3% 31 11 *
23 yes yes 40 1.5% 26 13 *
24 yes 27 1.0% 35 16 *
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Appendix 6.A: Descriptive statistics patient groups (continued)
Patient 
group
Age 
≥75
Major 
city
Female
Open 
heart 
surgery
Inpatient
Heart 
attack
Freq. Perc.
Actual 
travel
time
WTTi
25 yes yes yes yes yes 11 0.4% 12 -1
26 yes yes yes yes 28 1.0% 16 1
27 yes yes yes 73 2.7% 16 3
28 yes yes yes yes 43 1.6% 11 -2
29 yes yes yes 65 2.4% 11 0
30 yes yes 30 1.1% 14 2
31 yes yes yes yes 33 1.2% 14 1
32 yes yes yes 50 1.9% 13 3
33 yes yes 143 5.4% 14 5 *
34 yes yes yes 124 4.6% 12 0
35 yes yes 162 6.1% 11 2
36 yes 87 3.3% 13 4 *
37 yes yes yes yes 24 0.9% 36 4 *
38 yes yes yes 50 1.9% 30 5 *
39 yes yes 44 1.6% 28 8 *
40 yes yes yes 59 2.2% 27 3 *
41 yes yes yes 119 4.5% 23 5 *
42 yes 52 1.9% 34 8 *
43 yes yes yes 61 2.3% 28 6 *
44 yes yes 130 4.9% 28 7 *
45 yes 136 5.1% 27 10 *
46 yes yes 151 5.7% 28 6 *
47 yes 234 8.8% 25 8 *
48 129 4.8% 34 11 *
Total 632 1,139 914 1,034 1,791 685 2,670 100% 22 6
24% 43% 34% 39% 67% 26%
Note: * Significance at 5% (standard deviation obtained by a parametric bootstrap: n = 1,000). Travel time 
represents the average time (in minutes) travelled for PCI by the patients included in that group. WTTi is 
the patient group’s willingness to travel (in extra minutes) for a one-standard-deviation (4.4%-point) lower 
readmission rate.
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Appendix 6.B: Where do patients go if their first-best hospital would close?
OLVG 100% St. Antonius Ziekenhuis 100%
AMC 11 km. 56% UMC Utrecht 19 km. 52%
VUmc 10 km. 32% AMC 36 km. 26%
St. Antonius Ziekenhuis 42 km. 6% OLVG 42 km. 8%
UMC Utrecht 49 km. 2% VUmc 45 km. 3%
LUMC 47 km. 2% UMC St. Radboud 82 km. 3%
MC Alkmaar 54 km. 1% Amphia Ziekenhuis 62 km. 2%
Isala Klinieken 101 km. 2%
Erasmus MC 58 km. 1%
MC Rijnmond-Zuid 59 km. 1%
Alysis Zorggroep 69 km. 1%
LUMC 57 km. 1%
AMC 100% VUmc 100%
OLVG 11 km. 45% AMC 12 km. 46%
VUmc 12 km. 27% OLVG 10 km. 44%
St. Antonius Ziekenhuis 36 km. 17% St. Antonius Ziekenhuis 45 km. 4%
UMC Utrecht 43 km. 6% LUMC 40 km. 3%
LUMC 49 km. 3% MC Alkmaar 47 km. 1%
MC Alkmaar 56 km. 1% UMC Utrecht 52 km. 1%
Isala Klinieken 108 km. 1%
UMC Utrecht 100% Isala Klinieken 100%
St. Antonius Ziekenhuis 19 km. 76% Alysis Zorggroep 65 km. 44%
AMC 43 km. 11% Medisch Spectrum Twente 109 km. 12%
OLVG 49 km. 5% St. Antonius Ziekenhuis 101 km. 12%
Alysis Zorggroep 65 km. 2% UMC Utrecht 87 km. 9%
VUmc 52 km. 2% Zorggroep Noorderbreedte 92 km. 8%
Isala Klinieken 87 km. 2% AMC 108 km. 7%
UMC St. Radboud 90 km. 1% UMC St. Radboud 88 km. 7%
UMC Groningen 106 km. 1%
OLVG 110 km. 1%
VUmc 115 km. 1%
Zorggroep Noorderbreedte 100% Alysis Zorggroep 100%
UMC Groningen 62 km. 59% UMC St. Radboud 24 km. 56%
Isala Klinieken 92 km. 41% Isala Klinieken 65 km. 27%
UMC Utrecht 65 km. 9%
St. Antonius Ziekenhuis 69 km. 5%
AMC 95 km. 1%
Medisch Spectrum Twente 93 km. 1%
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Appendix 6.B: Where do patients go if their first-best hospital would close? (continued)
Medisch Spectrum Twente 100% UMC Groningen 100%
Isala Klinieken 109 km. 66% Zorggroep Noorderbreedte 62 km. 94%
Alysis Zorggroep 93 km. 33% Isala Klinieken 106 km. 6%
UMC St. Radboud 116 km. 1%
UMC St. Radboud 100% MC Alkmaar 100%
Alysis Zorggroep 24 km. 55% AMC 56 km. 35%
St. Antonius Ziekenhuis 82 km. 24% VUmc 47 km. 28%
Isala Klinieken 88 km. 12% OLVG 54 km. 27%
Catharina Ziekenhuis 68 km. 4% LUMC 70 km. 7%
UMC Utrecht 90 km. 4% St. Antonius Ziekenhuis 85 km. 2%
Amphia Ziekenhuis 98 km. 1%
LUMC 100% HaGaZiekenhuis 100%
AMC 49 km. 31% LUMC 28 km. 42%
OLVG 47 km. 21% Erasmus MC 26 km. 32%
VUmc 40 km. 18% MC Rijnmond-Zuid 38 km. 18%
St. Antonius Ziekenhuis 57 km. 13% St. Antonius Ziekenhuis 68 km. 3%
HaGaZiekenhuis 28 km. 6% AMC 69 km. 2%
Erasmus MC 39 km. 5% VUmc 60 km. 1%
UMC Utrecht 64 km. 3% OLVG 67 km. 1%
MC Alkmaar 70 km. 2%
MC Rijnmond-Zuid 50 km. 1%
MC Rijnmond-Zuid 100% Catharina Ziekenhuis 100%
Erasmus MC 7 km. 56% Amphia Ziekenhuis 60 km. 63%
Amphia Ziekenhuis 47 km. 17% St. Antonius Ziekenhuis 80 km. 24%
St. Antonius Ziekenhuis 59 km. 12% UMC St. Radboud 68 km. 8%
HaGaZiekenhuis 38 km. 6% UMC Utrecht 90 km. 4%
LUMC 50 km. 6% Alysis Zorggroep 84 km. 1%
UMC Utrecht 66 km. 2%
AMC 84 km. 1%
Amphia Ziekenhuis 100% Erasmus MC 100%
St. Antonius Ziekenhuis 62 km. 50% MC Rijnmond-Zuid 7 km. 41%
MC Rijnmond-Zuid 47 km. 28% St. Antonius Ziekenhuis 58 km. 22%
Catharina Ziekenhuis 60 km. 7% HaGaZiekenhuis 26 km. 15%
Erasmus MC 53 km. 6% LUMC 39 km. 11%
UMC Utrecht 72 km. 6% UMC Utrecht 65 km. 5%
UMC St. Radboud 98 km. 1% Amphia Ziekenhuis 53 km. 2%
AMC 97 km. 1% AMC 78 km. 2%
OLVG 76 km. 2%
VUmc 70 km. 1%
Note: AZM not included, because there are no Agis enrolees for whom it is the first-best PCI hospital.
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The final chapter of this thesis first answers the central research questions formulated 
in the general introduction. Next, some policy recommendations and suggestions for 
further research are offered, based on the main findings of the preceding chapters.
7.1 Research questions
As stated in Chapter 1, this thesis aims to improve the understanding of patient choice, 
competition, and antitrust enforcement in Dutch hospital markets by addressing four 
central research questions. In this section each of these questions is answered.
7.1.1 What lessons can be learned from experiences with hospital merger 
control in countries with a competitive hospital sector?
From the examination of the experiences with preventive hospital merger control in the 
United States, Germany, and the Netherlands, as discussed in Chapter 2, three major 
findings stand out. 
First, more than in any other industry, geographic market definition is the Achilles’ heel 
of antitrust enforcement in hospital markets. Due to the presence of health insurance a 
hospital’s price elasticity of demand is not useful for defining geographic markets. How-
ever, European antitrust enforcement agencies do not necessarily have to struggle with 
this issue as much as their counterparts in the US. In a typical European setting, hospitals 
compete directly for patients and prices are not relevant for them when making hospital 
choices. Under these conditions hospitals’ substitutability crucially depends on patients’ 
willingness to travel. As shown by experiences with hospital merger control in Germany, 
commonly available patient flow data are then useful for defining geographic hospital 
markets. 
Second, recent court decisions in the US and Germany confirm that geographic hospital 
markets are rather small. In the US managed care setting people prefer health plans 
that include at least one nearby hospital suggesting geographic hospital markets are 
essentially local. In the German setting, where patients do not commit to restricted 
provider networks when buying health insurance, patient flow data show that most 
patients prefer hospitals nearby. Hence, hospital markets seem to be geographically 
limited regardless of the prevailing institutions and market structure.
Third, the German Bundeskartellamt (BKA) and the Netherlands Competition Authority 
(NMa) have different attitudes towards proposed hospital mergers, though national 
antitrust laws in EU member states to a large extent resemble the same features as 
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supranational European competition policy. In Germany the emphasis is on avoiding 
Type II errors (allowing a proposed hospital merger that restricts actual hospital compe-
tition), whereas in the Netherlands the emphasis is on avoiding Type I errors (blocking a 
proposed hospital merger that does not restrict actual hospital competition). 
7.1.2 What is the appropriate approach for defining geographic hospital 
markets in the Netherlands?
The standard method for market definition (SSNIP test) is difficult to implement in hos-
pital markets and the methods historically employed (Elzinga/Hogarty approach and 
critical loss analysis) have proven inaccurate. Some new approaches to hospital market 
definition are therefore suggested in the recent economic literature. Chapter 3 discusses 
both the general strengths and weaknesses of the time-elasticity approach, the com-
petitor share approach, and the option demand approach as well as their applicability to 
Dutch hospital markets. From this discussion it follows that the appropriateness of each 
of these approaches depends crucially on (i) how health insurers contract with hospitals 
and (ii) how patients choose their hospital. 
Despite the gradual introduction of managed competition in the Dutch health care sys-
tem, most hospital prices are still fixed, out-of-pocket payments are absent, and patients 
do not face restricted hospital networks. The competitor share approach (assuming that 
prices set by hospitals are a function of the underlying service-level demand elasticities) 
and the option demand approach (assuming that patients commit to a potentially re-
stricted network of hospitals prior to knowing their medical needs) do therefore not ac-
curately depict Dutch hospital markets. Since the introduction of managed competition 
in the Dutch health care system is still work-in-progress, the option demand approach 
may become more appropriate in the future. That is, if hospital prices in the Netherlands 
are further deregulated and insurer-hospital negotiations over network participation 
and composition increase.
Currently, Dutch hospitals compete directly for patients on non-price dimensions (geo-
graphic location and observed quality). In this context, the time-elasticity approach is 
the appropriate approach to defining geographic hospital markets in the Netherlands. 
This approach is an attempt to indirectly estimate the demand elasticity faced by hos-
pitals using the notion that when the decisions of patients are not affected by money 
prices, travel time functions as a price. The substitutability among (merging) hospitals 
can then be assessed by estimating a patient choice model and simulating the demand 
effects of an artificial increase in travel time from every patient to a particular hospital 
by a certain percentage, holding all other hospital attributes constant. Hospitals that 
are predicted to loose only a few patients after a (simultaneous) percentage increase in 
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travel time do not seem to have close substitutes. Using this approach for geographic 
market definition requires identifying the smallest set of hospitals such that a simultane-
ous travel time increase to all hospitals in the set would lead to relatively little substitu-
tion to outside hospitals. 
7.1.3 How to assess the substitutability of Dutch hospitals taking both patient 
and hospital heterogeneity into account?
When patients are insensitive to prices, hospital substitutability that underlies the inten-
sity of provider competition is determined by patients’ willingness to travel for quality 
differences. If patients do not consider alternative providers and automatically visit the 
nearest hospital when seeking care, effective hospital competition is not feasible. The 
empirical analysis in Chapter 4 shows that, even in the absence of financial incentives 
and adequate consumer information, numerous Dutch patients in 2003 bypassed the 
nearest hospital alternative capable of treating their disease for orthopaedic care (38 
percent) and neurosurgery (54 percent). This finding suggests the feasibility of hospital 
competition. In addition to travel time and hospital attributes (type, size, waiting time), 
patient characteristics (age and social status) are also found to significantly affect hospi-
tal bypass decisions. This illustrates the relevance of taking both patient heterogeneity 
as well as hospital differentiation into account when assessing hospital substitutability. 
To analyse the feasibility of effective competition among Dutch hospitals in more detail, 
Chapter 5 applies the time-elasticity approach. More specifically, time-elasticities are 
estimated to assess hospitals’ relative bargaining power in the market for neurosurgery. 
This analysis, using a large health insurer’s claims data from 2003, shows that patients 
are generally averse to travel. Nevertheless, the most important hospitals in the study 
sample (located in Amsterdam, Utrecht, and surrounding areas) all seem to have at 
least some close substitutes. The point estimates of hospitals’ time-elasticities suggest 
that overall hospital demand is rather time-elastic, implying the feasibility of effective 
hospital competition in the neurosurgery market. However, estimated time-elasticities 
differ significantly across individual hospitals. Though the empirical analysis in Chapter 
5 consists of one particular submarket, defined as an insurer-hospital service pair, it 
shows how the time-elasticity approach can be a useful instrument to assess hospital 
substitutability. This is not only relevant for assessing the feasibility of selective contract-
ing by health insurers, but also for assessing proposed hospital mergers by antitrust 
enforcement agencies. 
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7.1.4 Do patients respond to publicly available information about hospital 
quality and how may this affect competition in Dutch hospital markets?
In markets where hospitals compete for patients on dimensions other than price, com-
petition is expected to increase quality. This positive relation, however, requires market 
transparency, patient responsiveness to quality differences and a sufficient number of 
hospital substitutes to choose from. Chapter 6 examines whether in the Dutch market 
for angioplasty, or percutaneous coronary intervention (PCI), patients respond to 
consumer information about hospital quality. This regulated market provides a unique 
opportunity for empirically assessing the impact of consumer information on patient 
choice and hospital competition: patient choice is affected by observed quality and geo-
graphic location only, hospital prices are fixed, and entry is restricted. The analysis first 
reveals that publicly available information about hospital quality does not adequately 
inform patients and even provides them with conflicting signals. Even when measur-
ing the same type of performance, hospitals ranked first by one indicator are generally 
ranked much lower by another indicator and vice versa. Using detailed claims data for 
analysing patient hospital choice in 2006, it is found that most patients are nevertheless 
responding to differences in observed quality. However, hospital substitutability in this 
market is found to be restricted to a few neighbouring hospitals. Particularly because 
publicly available hospital outcome measures are not adjusted for differences in the 
case-mix of hospitals, competition in this market may induce both incumbent as well 
as new PCI hospitals to improve on an observed inadequate performance indicator (e.g. 
readmission rate) by avoiding sick patients and/or seeking healthy patients. If such risk 
selection occurs, increasing the room for competition by reducing current regulatory 
entry barriers may reduce patient welfare rather than improve it.
7.2 Policy recommendations and research suggestions
Based on the research presented in this thesis the following policy recommendations 
and research suggestions are offered:
1.  From a welfare perspective and similar to antitrust enforcement agencies in Germany 
and the United States, the NMa should be more restrictive when assessing proposed 
hospital mergers. Since Dutch hospitals on average already seem to face diseconomies 
of scale (Blank and Merkies, 2004), hospital mergers in the Netherlands are unlikely to 
result in cost savings. Additionally, empirical evidence suggests that higher outcome 
quality is associated with the concentration of complex surgical procedures rather 
than with the consolidation of hospitals through mergers (Ho et al., 2008). Combined 
with empirical evidence that hospital mergers may have serious anticompetitive ef-
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fects (Vogt and Town, 2006; Dafny, 2009), the reduction in social welfare caused by a 
Type II error (not blocking a merger that is anticompetitive) is therefore expected to be 
greater than the reduction in social welfare caused by a Type I error (blocking a merger 
that is not anticompetitive). Being overly permissive also prevents the development 
of industry-specific jurisprudence, as the current situation in the Netherlands clearly 
illustrates. Without deeper understanding of how courts tend to deal with the unique 
attributes of Dutch hospital markets, the effectiveness of antitrust enforcement in 
future hospital merger cases may be hampered. The evidence required to prevail 
in court is currently unknown. The NMa should therefore litigate proposed hospital 
mergers that are potentially anticompetitive more aggressively, thereby accepting the 
risk of losing some of the cases then initiated (see also Varkevisser and Schut, 2008).
2.  To accurately define the geographic market in hospital merger cases, the NMa should 
more carefully investigate the particular reasons why some patients travel while oth-
ers do not. Supplemented by an empirical analysis of patient hospital choice using 
revealed preference data, these insights should be used to substantiate conclusions 
about other hospitals (not) taken into account as feasible alternatives for merging 
hospitals. As shown by experiences from the US, new methods for geographic market 
definition provides antitrust enforcement agencies with powerful evidence that hos-
pitals may possess far more market power than previously acknowledged (Dranove 
and Sfekas, 2009). Since in the current context the time-elasticity approach is the 
appropriate approach to defining Dutch hospital markets, the NMa should apply 
this new approach when assessing proposed hospital mergers. The same holds for 
the Dutch Healthcare Authority (NZa) when assessing whether individual hospitals 
have significant market power. The benefit of estimated time-elasticities for antitrust 
enforcement is twofold. First, they can be used for ruling out hospitals as close substi-
tutes allowing for instance for quick review of mergers not involving close substitutes. 
Second, they can be used for ranking hospital substitutes so that antitrust analysis 
can focus on a particular set of hospitals that are identified as closest substitutes.
3.  To increase the efficiency of health care provision by means of provider competition, 
Dutch hospital markets should become more transparent. In addition to the presence 
of a sufficient number of hospital alternatives, the public availability of reliable and 
comprehensive information about hospital quality is another important precondition 
for effective hospital competition. In Dutch hospital markets, however, hospital qual-
ity information is currently incomplete and often provides patients (as well as health 
insurers) with conflicting information. Additionally, the hospital outcome measures 
developed by the Dutch Healthcare Inspectorate (IGZ) and published on the internet 
(www.KiesBeter.nl) are not adjusted for differences in the case-mix of hospitals. As 
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a result of these deficiencies, expanding the room for competition may provide 
hospitals with an incentive to focus on what is (incorrectly) measured rather than 
what is important. Public disclosure of reliable, sufficiently detailed, and risk-adjusted 
hospital quality indicators is therefore a necessary step before further liberalising 
Dutch hospital markets.
4.  To better understand competition in Dutch hospital markets and the effects of hos-
pital mergers, the NZa in close cooperation with the NMa should initiate a research 
programme focusing on how consolidation affects price, cost and quality of care in 
Dutch hospital markets. Within this programme a number of consummated hospital 
mergers needs to be selected for intensive study, similar to the Hospital Merger 
Retrospectives Project of the US Federal Trade Commission (FTC).1 To stimulate the 
development of in-depth analyses, the data required for empirical work in this area 
should be made accessible to academic researchers. 
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161Samenvatting
Samenvatting
Het Nederlandse zorgstelsel verandert. Na decennia van strikte aanbodregulering is de 
nadruk de afgelopen jaren steeds meer op de introductie van marktprikkels komen te 
liggen. De invoering van de Zorgverzekeringswet per 1 januari 2006 vormt in dit opzicht 
een mijlpaal. Binnen de door de overheid vastgestelde randvoorwaarden krijgen zowel 
zorgverzekeraars als zorgaanbieders geleidelijk meer vrijheden. Om zorgaanbieders te 
prikkelen hun prijs-kwaliteitverhouding (verder) te verbeteren, is een belangrijke rol 
weggelegd voor onderlinge concurrentie. Ten eerste worden verzekeraars gestimuleerd 
om zich namens hun verzekerden als kritische zorginkopers op te stellen. Met (voor-
keurs)aanbieders dienen zij goede afspraken te maken over de prijs en kwaliteit van 
zorg. Ten tweede worden consumenten (patiënten) aangemoedigd om wanneer zij zorg 
nodig hebben verschillende aanbieders met elkaar te vergelijken om zodoende een 
weloverwogen keuze te maken.
Dit proefschrift richt zich op de kansen en bedreigingen voor concurrentie tussen Ne-
derlandse ziekenhuizen. Voor effectieve concurrentie is vereist dat ziekenhuismarkten 
aan bepaalde voorwaarden voldoen. Allereerst moeten verzekeraars en patiënten uit 
voldoende ziekenhuizen kunnen kiezen. Daarnaast moet informatie over de kwaliteit 
van ziekenhuizen betrouwbaar, veelomvattend en openbaar zijn. Bovendien moeten 
patiënten gevoelig zijn voor waarneembare verschillen in kwaliteit en de beschikbare 
informatie ook gebruiken. 
Uit hoofdstuk 1 blijkt dat in Nederland aan deze voorwaarden momenteel niet zonder 
meer wordt voldaan. In de eerste plaats is het aantal ziekenhuisorganisaties als gevolg 
van fusies afgenomen van 162 in 1985 tot 93 in 2009. Aangezien nieuwe ziekenhuisfusies 
het aantal keuzemogelijkheden verder doen afnemen, is het cruciaal dat voorgenomen 
fusies door de Nederlandse Mededingingsautoriteit (NMa) streng worden getoetst. 
Als een fusie de onderlinge concurrentie sterk vermindert, dient deze door de NMa in 
beginsel te worden verboden. De bijzondere kenmerken van ziekenhuiszorg zorgen bij 
dit belangrijke onderdeel van het mededingingsbeleid echter voor problemen. Vooral 
de afbakening van geografische ziekenhuismarkten is lastig, omdat moeilijk is vast te 
stellen welke ziekenhuizen in de ogen van patiënten onderling uitwisselbaar (substi-
tueerbaar) zijn en dus met elkaar concurreren. In de tweede plaats staat de informa-
tievoorziening over de kwaliteit van ziekenhuizen ondanks enkele recente en op zich 
veelbelovende initiatieven in Nederland eigenlijk nog in de kinderschoenen. Bovendien 
is onduidelijk of openbare kwaliteitsinformatie, zoals die bijvoorbeeld via de website 
www.KiesBeter.nl beschikbaar is, van invloed is op de ziekenhuiskeuzen van patiënten. 
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Kwantitatief onderzoek naar het gebleken keuzegedrag van patiënten is tot op heden 
namelijk uitsluitend uitgevoerd in buitenlandse ziekenhuismarkten. 
Om het keuzegedrag van patiënten, concurrentie en mededingingsbeleid in Nederland-
se ziekenhuismarkten beter te begrijpen, staan in dit proefschrift vier onderzoeksvragen 
centraal:
1.  Welke lessen kunnen worden getrokken uit ervaringen met het toetsen van zieken-
huisfusies in landen met concurrentie tussen ziekenhuizen?
2.  Wat is de meest geschikte methode om de geografische omvang van ziekenhuis-
markten in Nederland te bepalen?
3.  Hoe kan, met inachtneming van waarneembare verschillen tussen ziekenhuizen en 
patiënten, worden bepaald welke Nederlandse ziekenhuizen substituten van elkaar 
zijn?
4.  Reageren patiënten op openbare informatie over de kwaliteit van Nederlandse zie-
kenhuizen en welke gevolgen kan hun keuzegedrag hebben voor de wijze waarop 
ziekenhuizen met elkaar concurreren?
De eerste onderzoeksvraag wordt beantwoord door in hoofdstuk 2 de praktijkerva-
ringen met ziekenhuisfusies van mededingingsautoriteiten in de Verenigde Staten, 
Duitsland en Nederland met elkaar te vergelijken. Deze analyse levert drie concrete 
lessen op. De eerste les luidt dat, meer dan in andere sectoren, afbakening van de 
geografische markt de achilleshiel vormt bij de mededingingsrechtelijke beoordeling 
van voorgenomen ziekenhuisfusies. Als gevolg van de aanwezigheid van zorgverze-
keringen is voor individuele ziekenhuizen namelijk geen prijselasticiteit van de vraag 
bekend. Hierdoor kunnen ziekenhuismarkten niet op de gebruikelijke manier worden 
afgebakend. De tweede les is dat, onafhankelijk van de precieze (institutionele) omstan-
digheden, ziekenhuismarkten in geografisch opzicht over het algemeen beperkt van 
omvang lijken te zijn. De derde les luidt dat, hoewel de nationale mededingingswetten 
van Duitsland en Nederland zijn gebaseerd op dezelfde Europese wet- en regelgeving, 
de toepassing ervan bij het toetsen van ziekenhuisfusies aanzienlijk verschilt. De Duitse 
mededingingsautoriteit (Bundeskartellamt) wil vooral voorkomen dat een voorgeno-
men ziekenhuisfusie onterecht wordt goedgekeurd, terwijl in Nederland de NMa vooral 
wil voorkomen dat een voorgenomen ziekenhuisfusie onterecht wordt verboden. 
163Samenvatting
Om de tweede onderzoeksvraag te beantwoorden zijn in hoofdstuk 3 traditionele en 
nieuwe methoden om ziekenhuismarkten af te bakenen geanalyseerd. Naast de sterke 
en zwakke punten van deze methoden, is vooral ook aandacht besteed aan de toepas-
baarheid van de nieuwe methoden in de Nederlandse context. Uit dit deel van de ana-
lyse volgt dat het berekenen van zogeheten (reis)tijdelasticiteiten momenteel de meest 
geschikte methode is om de geografische omvang van ziekenhuismarkten in Nederland 
af te bakenen. Als patiënten een ziekenhuis kiezen spelen prijsoverwegingen namelijk 
geen rol. Iedereen is verplicht verzekerd voor ziekenhuiszorg en het eigen risico is (zeer) 
beperkt, zodat men geen prijsverschillen ervaart. Onder dergelijke omstandigheden is 
reistijd feitelijk de enige prijs die patiënten betalen voor een bezoek aan een ziekenhuis. 
Door de reistijd naar een ziekenhuis voor alle patiënten denkbeeldig met een bepaald 
percentage te verhogen wordt het betreffende ziekenhuis onaantrekkelijker gemaakt. 
Vervolgens kan met behulp van modelsimulaties worden berekend hoeveel patiënten 
als gevolg van deze denkbeeldige ‘prijsverhoging’ naar andere ziekenhuizen zullen 
uitwijken. Ziekenhuizen die naar verwachting slechts een beperkt percentage patiënten 
kwijtraken, ondervinden (vrijwel) geen concurrentie van andere ziekenhuizen. Laatstge-
noemde ziekenhuizen behoren in dat geval tot een andere geografische markt. Wanneer 
zorgverzekeraars in de toekomst meer selectief zouden gaan contracteren neemt de 
bruikbaarheid van tijdelasticiteiten af. Voor de afbakening van geografische ziekenhuis-
markten kan dan gebruikt worden gemaakt van de meerprijs die verzekerden bereid 
zijn aan een verzekeraar te betalen als deze een bepaald ziekenhuis in het netwerk van 
gecontracteerde zorgaanbieders opneemt.
Voor de beantwoording van de derde onderzoeksvraag zijn twee kwantitatieve analyses 
uitgevoerd. Allereerst is in hoofdstuk 4 met behulp van declaratiegegevens uit 2003 
van een grote Nederlandse zorgverzekeraar onderzoek gedaan naar de keuzen van 
patiënten om het dichtstbijzijnde ziekenhuis al dan niet over te slaan en dus wel of 
niet verder te reizen dan strikt noodzakelijk. Om rekening te houden met de hetero-
geniteit van ziekenhuiszorg zijn de eerstepolikliniekbezoeken van twee verschillende 
medisch specialismen geanalyseerd, te weten orthopedie (aanwezig in alle Nederlandse 
ziekenhuizen) en neurochirurgie (aanwezig in circa tweederde van de Nederlandse 
ziekenhuizen). Uit de analyse volgt dat, ondanks de afwezigheid van financiële prikkels 
en adequate kwaliteitsinformatie, veel patiënten niet automatisch naar het dichtstbij-
zijnde ziekenhuis gaan. Om de substitueerbaarheid van Nederlandse ziekenhuizen in 
meer detail te onderzoeken zijn in hoofdstuk 5 voor dertien ziekenhuizen vervolgens 
tijdelasticiteiten berekend. Hiervoor is opnieuw gebruikt gemaakt van gedetailleerde 
gegevens uit 2003 die inzicht verschaffen in de achtergrondkenmerken van verzekerden 
en de ziekenhuizen die zij voor hun eerste bezoek aan de polikliniek neurochirurgie heb-
ben bezocht. Zoals vooraf kon worden verwacht laten de schattingsresultaten zien dat 
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patiënten reistijd sterk negatief waarderen. Dat wil zeggen, dichterbij gelegen zieken-
huizen zijn voor hen in principe aantrekkelijker dan verder weg gelegen ziekenhuizen. 
Naast reistijd hebben echter ook andere ziekenhuiskenmerken een meetbaar effect op 
het keuzegedrag van patiënten. In de markt voor neurochirurgie neemt de kans dat 
een patiënt een bepaald ziekenhuis kiest niet alleen toe als de reistijd korter is, maar 
ook als dat ziekenhuis vergeleken met andere ziekenhuizen een relatief korte wachtlijst 
en/of een goede reputatie heeft. Voor alle ziekenhuizen waarvoor een tijdelasticiteit is 
berekend, geldt dat deze redelijk hoog is. Als de reistijd met 10% zou toenemen, wijken 
relatief veel patiënten uit naar een ander ziekenhuis. Ondanks de gebleken vrij sterke 
afkeer van extra reistijd, impliceert dit resultaat dat mensen momenteel veelal nog uit 
voldoende nabijgelegen ziekenhuizen kunnen kiezen. Hoewel de analyse betrekking 
heeft op één specifieke deelmarkt, laat hoofdstuk 5 zien dat het berekenen van tijdelas-
ticiteiten in Nederland een bruikbare methode is om de vraag te kunnen beantwoorden 
welke ziekenhuizen door patiënten als substituten worden gezien en daarom met elkaar 
concurreren. 
De vierde onderzoeksvraag komt aan bod in hoofdstuk 6. In dit hoofdstuk wordt, 
opnieuw met behulp van declaratiegegevens van een grote Nederlandse zorgverzeke-
raar, het keuzegedrag van patiënten geanalyseerd die in 2006 een niet-spoedeisende 
dotterbehandeling hebben ondergaan. Hierbij is vooral gekeken naar het effect van 
openbare kwaliteitsinformatie op het keuzegedrag van patiënten. Op grond van de 
Wet op Bijzondere Medische Verrichtingen (WBMV) hadden dat jaar negentien zieken-
huizen een vergunning om patiënten te dotteren. Alvorens na te gaan of de openbare 
informatie over de kwaliteit van Nederlandse ziekenhuizen met een dottervergunning 
een meetbaar effect heeft gehad op de keuzen van patiënten, is eerst de beschikbare 
kwaliteitsinformatie zelf geanalyseerd. De publieksinformatie, afkomstig uit twee ver-
schillende bronnen, blijkt incompleet en inconsistent. Zelfs wanneer twee indicatoren 
dezelfde prestatie claimen te meten, is het eerder regel dan uitzondering dat een 
ziekenhuis op grond van de ene indicator tot de beste ziekenhuizen wordt gerekend 
terwijl het op grond van de andere indicator veel lager wordt gerangschikt. Ondanks 
deze tekortkomingen laten de schattingsresultaten zien dat de openbare kwaliteitsin-
dicatoren wel degelijk van invloed zijn geweest op het keuzegedrag van patiënten. Zo 
blijken de meeste patiënten bereid verder te reizen dan noodzakelijk om een ziekenhuis 
te kunnen bezoeken met een lager percentage heropnames. Uit modelsimulaties blijkt 
vervolgens dat een stijging van het aantal heropnames op de afdeling cardiologie voor 
veel ziekenhuizen een flinke daling van de vraag naar hun dotterbehandelingen zal 
betekenen. De onderlinge concurrentie in deze deelmarkt wordt echter sterk beperkt 
door de relatief grote afstanden tussen ziekenhuizen met een dottervergunning. Voor 
de meeste ziekenhuizen is het aantal (potentiële) concurrenten beperkt tot twee à drie 
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relatief nabijgelegen ziekenhuizen. Op het eerste gezicht lijkt het dus verstandig om 
de huidige toetredingsdrempels op deze markt te verlagen dan wel af te schaffen om 
zodoende de kwaliteitsconcurrentie te stimuleren. Een toename van de concurrentie 
brengt echter ook risico’s met zich mee. Zo is het percentage heropnames niet gecorri-
geerd voor verschillen in zorgzwaarte. Ziekenhuizen die veel ernstig zieke patiënten be-
handelen kunnen daardoor slechter scoren dan ziekenhuizen die vooral minder ernstig 
zieke patiënten behandelen. Deze tekortkoming zou ziekenhuizen bij een toename van 
de onderlinge concurrentie kunnen aanzetten tot maatschappelijk ongewenst gedrag. 
Gezien de grote financiële belangen zouden ziekenhuizen om een verlies aan marktaan-
deel te voorkomen zich dan namelijk vooral kunnen gaan richten op de behandeling 
van de meeste gezonde hartpatiënten.
Op grond van de bevindingen zoals gepresenteerd in dit proefschrift worden in hoofd-
stuk 7 de volgende vier beleidsaanbevelingen en suggesties voor verder onderzoek 
gedaan:
1.  Vanuit welvaartsperspectief bezien zou de NMa, net als de mededingingsautoritei-
ten in Duitsland en de Verenigde Staten, strenger moeten zijn bij het beoordelen 
van ziekenhuisfusies. Allereerst zijn alle Nederlandse ziekenhuizen nu al zo groot 
dat verdere schaalvergroting waarschijnlijk geen kostenvoordelen zal opleveren. 
Daarnaast zijn, gelet op de huidige omvang van Nederlandse ziekenhuizen, fusies 
niet noodzakelijk om kwaliteitsverbeteringen te realiseren. Gecombineerd met het 
feit dat ziekenhuisfusies aanzienlijke negatieve gevolgen kunnen hebben, is het 
welvaartsverlies van een Type II fout (een concurrentiebeperkende fusie wordt onte-
recht goedgekeurd) naar verwachting groter dan het welvaartsverlies van een Type I 
fout (een niet-concurrentiebeperkende fusie wordt onterecht tegengehouden). Een 
ander nadeel van een te weinig strenge houding bij het beoordelen van voorgeno-
men ziekenhuisfusies is dat geen nuttige sectorspecifieke jurisprudentie ontstaat. 
Zolang onduidelijk is hoe rechters omgaan met de specifieke kenmerken van zieken-
huismarkten in Nederland, blijft ook onduidelijk welke bewijsvoering nodig is om 
in voorkomende gevallen ziekenhuisfusies die de onderlinge concurrentie te sterk 
doen afnemen daadwerkelijk te kunnen tegenhouden.
2.  Om bij de beoordeling van voorgenomen ziekenhuisfusies de geografische markt 
nauwkeuriger te kunnen afbakenen dient de NMa meer gedetailleerd in kaart te 
brengen waarom sommige patiënten wel en andere niet naar verder weg gelegen 
ziekenhuizen reizen. Aangevuld met empirisch onderzoek op het gebied van het 
gebleken keuzegedrag ontstaat zo een beter beeld van de substitueerbaarheid en 
onderlinge concurrentie van ziekenhuizen. In de huidige context is het berekenen 
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van (reis)tijdelasticiteiten momenteel de meest geschikte methode om de geografi-
sche omvang van ziekenhuismarkten af te bakenen. Deze nieuwe methode zou dan 
ook door de NMa moeten worden toegepast. De methode is ook van toegevoegde 
waarde voor de Nederlandse Zorgautoriteit (NZa) wanneer zij antwoord moet geven 
op de vraag of individuele ziekenhuizen al dan niet over aanmerkelijke marktmacht 
beschikken.
3.  Om de voordelen van concurrentie tussen ziekenhuizen te kunnen realiseren is 
het noodzakelijk dat meer en betere kwaliteitsinformatie beschikbaar komt. Mede 
omdat de huidige prestatie-indicatoren van de Inspectie voor de Gezondheidszorg 
(IGZ) geen rekening houden met verschillen in zorgzwaarte, kan een toename van de 
onderlinge concurrentie ziekenhuizen onder de huidige omstandigheden aanzetten 
tot maatschappelijk ongewenst gedrag, zoals risicoselectie.
4.  Om beter inzicht te krijgen in de werking van markten voor ziekenhuiszorg en de 
effecten van ziekenhuisfusies in het bijzonder, verdient het aanbeveling dat de NMa 
in nauwe samenwerking met de NZa een onderzoeksprogramma opstart naar het 
voorbeeld van een programma van de Amerikaanse FTC (Federal Trade Commission). 
Ten einde de ontwikkeling van innovatief onderzoek op dit gebied te stimuleren, is 
het van belang de hiervoor benodigde kwantitatieve gegevens beschikbaar te stel-
len voor wetenschappelijk onderzoek. 
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antitrust enforcement in Dutch hospital markets. 
Marco Varkevisser is an assistant professor of Health 
Economics at the institute of Health Policy and Management 
(iBMG), Erasmus University Rotterdam. After graduating 
from the Erasmus School of Economics in 1998, his research 
focused on competition and regulation issues in various 
industries. Over the years he has specialised in competition 
and antitrust enforcement in health care markets.
Patien
t ch
oice, com
p
etition
 an
d
 an
titru
st en
forcem
en
t in
 D
u
tch
 h
osp
ital m
arkets  
—
 M
arco Varkevisser
